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ABSTRACT 
 
Clostridium difficile infection is the primary cause of nosocomial diarrhoea in developed 
countries and the cost to healthcare providers is substantial. C. difficile is an opportunistic 
pathogen, with disease occurring when the normal colonic flora is disrupted. Dysbiosis of 
the intestinal microbiota, usually associated with antibiotic use, allows ingested spores of 
C. difficile to germinate and proliferate. Clinical symptoms are mediated by production of 
two major exotoxins, toxin A and toxin B. Clinical manifestations of infection can range 
from a non-symptomatic carrier state to diarrhoea and inflammation of the gut. Severe 
infections have potential to be fatal. Current treatment strategies for this infection rely 
heavily on just a few available antibiotics, as strains display multiple antibiotic resistances. 
 
This thesis investigates the use of alternative treatment strategies, using Bacillus subtilis 
spores as a basis. One aspect of this assesses the use of B. subtilis spores as a mucosal 
vaccine delivery system. Delivery of a spore based vaccine by both oral and sublingual 
routes demonstrates these mucosal routes as promising strategies for generating 
protection against CDI. This thesis also uses B. subtilis spores as an oral probiotic 
treatment. The application of B. subtilis probiotics in a murine model of CDI is investigated 
and it is shown through optimisation of dose regimens that suppression of CDI symptoms 
can be achieved. Both use of vaccines and alternative treatments such as probiotics have 
the potential to reduce reliance on antibiotic treatment methods.  
 
 IV 
 
The role of C. difficile spores in infection was also investigated. Genetic manipulation was 
used to produce specific mutations in the spore coat and the resulting mutant phenotypes 
were analysed. This work demonstrated that the spore coat protein BclA1 plays a key role 
in colonisation of the host. This finding contributes to understanding how C. difficile can 
establish infection. 
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Chapter 1   
Introduction 
 
1.1.  Bacillus subtilis 
 
Bacillus subtilis belongs to the genus Bacillus, a diverse group of endospore forming, Gram 
positive organisms. The group also contains B. anthracis, the causative agent of anthrax 
and is also considered a potential biological weapon. B. cereus is also a member of the 
group and is linked to occurrences of food poisoning. B. subtilis has been reported 
occasionally to cause opportunistic infections in immunocompromised patients (Oggioni et 
al. 1998), but on the whole is not considered pathogenic. Other species of Bacillus have 
important roles in industrial production of both antibiotics and enzymes (Schallmey et al. 
2004). Examples of members of the Bacillus group include B. amyloliquefaciens H, which 
produces the BamH.1 restriction endonuclease commonly used in molecular biology. B. 
thuringiensis also has significant importance to the agricultural industry, producing crystal 
proteins known as delta endotoxins that have insecticidal action. B. thuringiensis is widely 
used as a natural method of pest control. Genes from this species have been used to 
develop several varieties of successful pest resistant GM crops (Tu et al. 2000). The group 
of Bacillus is well studied, with several members having genome sequences published 
(Takami et al. 2000; Read et al. 2003; Rey et al. 2004).  
 A wealth of information is available regarding B. subtilis, as it has been studied extensively 
as a model for cell differentiation and for applications in the biotechnology industry. The 
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genome sequence for this species was published in 1997 (Kunst et al. 1997). Current 
understanding of sporulation in Gram positive spore formers is due to studies on B. subtilis, 
the use of genetic tools allowing in depth study of the role of specific genes and proteins. B. 
subtilis is used as a model organism for Gram positive spore formers, enabling parallels to 
be drawn between this and other species. Much of the information known about the 
pathogen B. anthracis also comes from studies based on knowledge from the study of B. 
subtilis, highlighting its importance as model organism.  
 
1.1.1. Spore formation 
Spores are metabolically dormant, partially dehydrated structures produced to enable 
survival of bacteria when adverse conditions prevent vegetative growth. In more 
favourable conditions, spores germinate and vegetative growth can occur. The length of 
time that spores can lie dormant and then be revived is difficult to put an upper limit on. 
There are reports of spores being recovered from rocks millions of years old (Kennedy et al. 
1994) although the potential for these spores being more recent contaminants from the 
environment is high in such cases. Describing accurate ages of dormant spores is difficult in 
such studies, but the scale of protection the spore structures give to the bacterium is 
highlighted. A study using soil from tree root samples stored since 1640 also demonstrated 
recovery of spores (Sneath 1962), which due to specific storing of the samples gives a more 
credible time scale to spore recovery. Spore formation is beneficial to the bacterium in 
terms of long term survival, but also represents a risk as there is no guarantee that the 
spore will ever be exposed to conditions that allow germination and regrowth.   
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The Bacillaceae and Clostridia diverged 2.3 billion years ago (Paredes et al. 2005), but 
produce spores via an evolutionarily conserved mechanism. These two groups are not the 
only bacterial spore forming genera, but the process is less well understood in other 
species.   
In laboratory cultures of B. subtilis, sporulation (Figure 1.1) starts at the beginning of 
stationary phase, when nutrient depletion occurs. The process of sporulation begins with 
asymmetric cell division, creating a structure called the sporangium which provides a vessel 
for the formation of spores. This structure contains two compartments, a large mother cell 
and a forespore, which will eventually become the spore. A single spore is produced from 
each cell and contains genetic material from the cell division. The mother cell engulfs the 
forespore, in a process similar to phagocytosis, forming a double membrane around the 
forespore. In coordination with the formation of this double membrane, two external 
protective structures are formed. The cortex is made of peptidoglycan (Popham 2002) and 
assembles between the inner and outer spore membranes. At the same time as the cortex 
assembles, the proteinaceous coat that comprises the outermost layer of the spore 
accumulates (Driks et al. 1994). The spore structure is a series of concentric layers, first 
visualised using high powered electron microscopy (Bulla et al. 1969). At the centre is the 
partially dehydrated core, where most of the water is replaced by Ca2+-dipicolinic acid, 
which contains the genetic material. The core is surrounded by the inner forespore 
membrane and then a germ cell wall. The next layer is the peptidoglycan cortex, which is 
covered by the outer forespore membrane and contributes to the resistance of the spore. 
The outer layers of the spore are the spore coat, and a recently identified layer known as 
the spore ‘crust’ (McKenney et al. 2010). In B. subtilis, the spore coat is made of two layers,  
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the lamellar-like inner coat and an electron dense coat. In some species of spore formers, a 
sac like layer known as the exosporium is the final layer of the structure, although this is 
not present in B. subtilis.  
The spore coat can vary greatly between species, with little conservation of proteins 
present in the spore coat between species (Abhyankar et al. 2013). Spore forming bacteria 
inhabit a diverse range of habitats, and this is reflected by the variation in proteins forming 
the spore coats. The spore coat is the bacterium’s only contact with the environment while 
in the dormant form, so this structure needs to be adapted to the specific species and the 
ecological niche it occupies. A generic protein coat with a similar composition in all spore 
formers would not provide specific interactions required for survival of the bacterium. For 
example, the spore coat can contain enzymes used in detoxification of the surrounding 
environment, or for roles in germination (Driks 2002). In C. difficile spores, the spore coat 
protein CotE has been identified as a bifunctional enzyme with peroxiredoxin and chitinase 
activity (Permpoonpattana et al. 2013), proposed to aid access to nutrients for newly 
germinated cells. Proteins with enzymatic activity could contribute to virulence by causing 
inflammatory responses within the GI tract, or aid survival by making nutrients available to 
vegetative cells. Variation in the content of the spore coat means that proteins from this 
layer can also serve as important tools in the detection of specific species of spores, 
especially important for spore formers that could potentially be used as bioweapons such 
as B. anthracis (Swiecki et al. 2006). 
B. subtilis spores have the ability to resist extreme conditions, including ultraviolet (UV) 
radiation, chemicals, heat and other environmental stresses (Setlow 2006), with the goal of 
protecting the genetic material of the bacterium. Use of genetics, biochemistry studies and 
molecular biology has led to greater understanding of mechanisms behind such resistance 
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(Nicholson et al. 2000). Such work includes investigating the role of α/β-type small acid 
soluble proteins (SASPs) in protection of spore DNA and the heat resistance provided by 
thick layers of peptidoglycan (Henriques & Moran 2007). Survival of spores also occurs 
through the mammalian GI-tract, with spores displaying resistance to digestive enzymes 
and extremes of pH (Hoa et al. 2001). B. subtilis is generally regarded as a soil dwelling 
organism, although it has been shown to have a reduced metabolic level when grown at 
low temperatures (15°C) (Budde et al. 2006). This decreased activity indicates that the soil 
is not the primary environment that the vegetative stage of the B. subtilis life cycle is 
adapted to. The presence of spores in soil suggests that the environment acts as a reservoir 
for spores, but their detection in both animal and human GI tracts (Hong et al. 2009; 
Schyns et al. 2013) implies successful colonisation of alternative environments. The high 
number of spores found in the soil could accumulate over time as spores are excreted in 
animal faeces, rather than soil being the predominant habitat of B. subtilis.  
 
1.1.2. Applications of B. subtilis 
Extensive study of B. subtilis as a model organism and the resulting wealth of information 
now available have led to the exploitation of this bacterium.  
In the Cutting laboratory, B. subtilis spores have been used as antigen delivery systems in 
vaccine design. Two methods are used for the display of antigens, one using the physical 
properties of the spore coat to absorb antigens and an alternative approach using genetic 
manipulation to express antigens fused to spore coat proteins  (Mauriello et al. 2004; Duc 
et al. 2007). B. subtilis spores have been shown to have immunogenic properties (Duc et al. 
2004; Huang et al. 2010) and can therefore act as an adjuvant in the vaccine formulation. 
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The intrinsic resistance properties of the spores make them excellent candidates for use in 
oral delivery. In an approach similar to use of spores as vaccines, B. subtilis spores are also 
being experimented with as drug delivery agents. A recent study successfully expressed 
streptavidin as a fusion protein with the spore coat protein CotB and used these 
recombinant spores to target cancer cells (Nguyen et al. 2013). The findings of this study 
suggest that spores of B. subtilis show great potential as universal drug carriers to target 
specific biomarkers on cells.  
B. subtilis spores are commonly found in soil, often in association with the roots of a variety 
of plant types (Pandey & Palni, 1997; Cazorla et al. 2007). These interactions have been 
investigated, and properties of the strains involved have been exploited for use in 
commercial biocontrol agents (Nagórska et al. 2007; Ongena & Jacques 2008). Specific 
mechanisms behind B. subtilis biocontrol were studied using a model of tomato wilt caused 
by Ralstonia solanacearum (Chen et al. 2012, 2013). Results of these studies showed that 
biocontrol efficacy was strongly linked to biofilm formation. Identification of genes involved 
in biofilm formation allowed the generation of relevant mutations in B. subtilis that were 
deficient at biofilm formation. These mutant strains also demonstrated weak biocontrol 
efficacy, linking the two factors.  
 
1.1.3. B. subtilis summary 
The ability for simple genetic manipulation of B. subtilis has significantly contributed to 
understanding how this species functions. Increased understanding of the species has 
enabled exploitation of useful properties associated with B. subtilis such as in the 
biocontrol of plant pathogens and potential drug delivery agents. Parallels from studies can 
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also be drawn with other species that are less amiable to genetic manipulation, benefiting 
the study of further species.  
 
1.2. Clostridium difficile 
 
Clostridium species are a group of anaerobic, Gram positive bacteria with the ability to 
form endospores. They are ancient in evolutionary terms, occupying and well adapted to a 
range of environmental niches. Several species within this genus are well known human 
pathogens, whilst others have industrial applications in processes such as solvent 
production. Clostridium acetobutylicum and C. beijerinckii are both used in acetone, 
butanol and ethanol (ABE) fermentation processes (Jones & Woods 1986; Qureshi & 
Blaschek 2001; Lee et al. 2012). Use of these species contributes towards commercial 
production of solvents and also development of biofuel production.  
Pathogenic members of this group are the causative agents of several well-known diseases.  
C. botulinum produces a neurotoxin that is one of the most lethal naturally occurring 
toxins. Production of toxins by this species causes botulism, a paralytic disease that can be 
fatal in humans. Disease occurrence is rare, but has severe economic implications as it is 
most commonly associated with foodborne poisoning (Cherington 1998). Toxins from C. 
botulinum are also used to decrease muscle movement for both therapeutic and cosmetic 
practices (Arnon 2001). C. perfringens produces many toxins with five toxinotypes (A, B, C, 
D and E) described based on the production of four major toxins (Petit et al. 1999). Types A 
and C are associated with human disease, with a range of clinical manifestations depending 
on infection site. For example, Type A strains produce the alpha (α) toxin and are 
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associated with gangrene and gastrointestinal disease. Ingested spores can cause 
gastrointestinal diseases and are linked with food poisoning from contaminated foods 
(Brynestad & Granum 2002). Wound infections also occur and the production of toxins in 
the wound site causes gangrene. C. perfringens is also a significant zoonotic pathogen, 
causing enterotoxaemias in a range of animals. C. tetani is another member of the group 
that mediates disease through production of toxins. Infections occur through open wounds 
where C. tetani can then proliferate and produce toxin. The neurotoxin interferes with the 
central nervous system (CNS) causing muscle contractions and spasms that are classic 
symptoms of tetanus, also known as ‘Lockjaw’ (Bruggemann et al. 2003). 
Clostridial pathogens do not generally display host specificity, causing disease in both 
humans and animals. Preventing disease from these infections represents a key area of 
interest within animal husbandry and farming in order to reduce economic losses (Songer 
et al. 2006;  Songer 2010). 
 
1.2.1. Clostridium difficile disease 
Clostridium difficile is a further example of a clostridial pathogen and will be the topic of 
this thesis. C. difficile is the primary cause of nosocomial antibiotic associated diarrhoea 
(AAD) in developed countries and is the etiological agent of pseudomembranous colitis. 
Ingested spores are able to germinate and colonise the human gastrointestinal (GI) tract, 
taking advantage of dysbiosis of the gut flora normally caused by antibiotic treatment to 
proliferate and induce a toxin mediated disease (Figure 1.2). Symptoms of infection range 
from asymptomatic colonisation to mild diarrhoea, progressing to more severe infections 
causing colitis, inflammation and in extreme cases, toxic megacolon (Rupnik et al. 2009). 
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Severe infections can result in death. Spores are shed in the faeces of infected individuals 
facilitating further spread of the disease. Infections are not just limited to humans, but also 
occur in animals, demonstrating that this bacterium is capable of inflicting costs far beyond 
the human disease burden. C. difficile presents a significant economic cost to the farming 
industry, with infections in both cattle and swine reducing output (Songer & Uzal 2005; 
Songer 2010) 
  
Figure 1.2. CDI in response to antibiotic treatment. The effects of antibiotic usage on the 
human microflora resident in the GI-tract. In the presence of antibiotics (B) the gut flora 
declines and C. difficile present in the gut that is resistant to the antibiotic can proliferate. 
When antibiotic treatment stops (C), the normal gut microflora recovers but a certain delay 
exists depending upon the antibiotic regimen used. It is at this point (C) that there is a risk of 
CDI, whether by resistant or susceptible strains of C. difficile (modified from Rupnik et al. 2009). 
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C. difficile was first reported as Bacillus difficilis by Hall and O’Toole (Hall & O’Toole 1935) 
as a component of neonatal microflora. In the 1960’s a study of extra-intestinal C. difficile 
infections concluded that this species did not represent a hazard to human health, but was 
more likely to be an opportunistic resident of the infection sites investigated by the study 
(Smith & King 1962). It was not until the 1970’s however, that this bacterium was 
associated with the gastrointestinal pathogenicity that it is well known for today. Studies 
found C. difficile to be the principle causative agent for pseudomembranous colitis and also 
noted it’s frequent isolation in patients undergoing antibiotic treatment involving 
clindamycin (Tedesco et al. 1974; Gurwith et al. 1977; Lusk et al. 1977). A strong 
association was also observed between colitis and the depletion of the normal microflora 
during antibiotic treatment (Marr et al. 1975), introducing the link between antibiotic use 
and GI tract disorders.  Information from studies in the late 1970’s and early 1980’s 
contributed to increased diagnosis and development of treatments for C. difficile infection. 
Key risk factors such as hospitalisation, old age and antibiotic use were also identified 
(Bartlett 2008). Observations of a correlation between the use of specific antibiotics and 
the prevalence of C. difficile infections prompted the identification of antibiotic use as a key 
risk factor. Clindamycin was the first antibiotic associated with risk of C. difficile infection 
(CDI), but was quickly followed by cephalosporins and broad spectrum penicillins as use of 
these classes of drugs increased. Wide scale use of fluoroquinolones has now been linked 
with occurrence of CDI, particularly with the emergence of the 027 ribotype, which displays 
resistance to this class of antibiotic through a mutation in the gyrA gene (Drudy et al. 
2007). Increasing reliance on antibiotics and aging populations in developed countries have 
contributed to the current prevalence of this pathogen. In order to manage the incidence 
and development of this pathogen, better antimicrobial stewardship must be employed by 
Chapter 1  Introduction 
 
12 
 
healthcare providers. As an example, development of fluoroquinolone resistance in C. 
difficile has been observed to be associated with several different fluoroquinolone 
antibiotics. This suggests that rather than switching between different drugs within a class, 
use of that entire class should be restricted to control development  of resistance (Drudy et 
al. 2007). Strict measures such as this are necessary as rates of antibiotic resistance 
increase.   
The predominance of this nosocomial pathogen has made it the subject of popular media 
and news, not just the focus of scientific reporting. In 2007, mandatory reporting of cases 
was introduced, and the Health Protection Authority (HPA, now Public Heath England, PHE) 
has collated data on number of instances of infection since that point. In 2007, there were 
over 50,000 cases reported (HPA) (Figure 1.3A). Numbers of cases have declined since, due 
to increased awareness and implementation of better cleaning and disinfection regimens. 
However, reduction in the number of cases is now plateauing, as new treatments are 
required to achieve superior rates for eradication of infection. In addition to the health 
burden caused by this infection, monetary cost to the healthcare industry is estimated at 
over $1 billion in the USA annually (Kyne et al. 2002). This cost is due to additional 
treatment and prolonged hospital stays required once patients develop the infection. 
Implementation of disinfection and isolation regimens is also costly. Traditionally, C. 
difficile is associated with nosocomial infection, spread between patients in hospitals and 
healthcare centres. However, recently there has been an increasing trend in community 
associated infections (CAIs) (Wilcox et al. 2008; Khanna et al. 2012), with individuals who 
have no recent history of hospital stays or antibiotic usage developing infections. This is 
reflected in epidemiology data collected by the HPA, showing a decrease in the proportion 
of cases that are attributed to specific NHS Trust hospitals, implying that the disease is 
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becoming increasingly prevalent in the community (Figure 1.3B). This change in 
epidemiology highlights the need for further study and new treatments.  
 
  
Figure 1.3. HPA C. difficile epidemiological data from the mandatory reporting scheme 
introduced in 2007.  A) Total reported cases of CDI over the last 5 years. B) % of total 
reported cases that are categorised specifically as Trust apportioned. ‘Trust apportioned’ 
is defined as a positive case of C. difficile infection in a patient at an Acute NHS Trust 
where the infection occurs on the fourth day or later post admission.  
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Managing C. difficile infection is a difficult task, especially given the persistent and resistant 
nature of the spores produced by this bacterium. Colonisation with C. difficile can result in 
asymptomatic carriage, rates of which appear to depend on the population being studied. 
Screening of long term care patients found 51% of subjects were asymptomatically 
colonised with C. difficile (Riggs et al. 2007), with 37% of the isolates identified as epidemic 
strains. In a different population, screening of healthy adults over a nine month period 
showed transient colonisation also occurred in this group, with persistent colonisation by 
the same PCR ribotype found only in several individuals (Ozaki et al. 2004). While 
detectable colonisation will vary depending on the health status of the host, it has been 
reported that around 60% of the population has antibodies present against C. difficile 
toxins (Viscidi et al. 1983). This figure supports the hypothesis that a larger number of the 
population experiences some level of transient colonisation. Alternatively, the presence of 
antibodies could be a legacy of exposure to C. difficile in infancy, with much higher 
colonisation rates reported in children under 2 years old (Brazier 1998). Asymptomatic 
carriers of C. difficile act as potential reservoirs of infection, enabling the pathogen to 
spread to further hosts. Shedding of C. difficile spores also occurs in patients that have 
recovered from infection, even after resolution of symptoms. Spores shed by individuals 
can be transmitted by direct contact, but evidence also suggests that spores can be 
aerosolised (Best et al. 2010), increasing potential for wider dissemination and spread of 
spores into the environment. 
Additionally, farm animals have been reported to be a potential reservoir of infection, 
further increasing potential for exposure to this pathogen. Investigation into prevalence of 
particular ribotypes (Rodriguez-Palacios et al. 2006) and toxinotypes (Jhung et al. 2008) 
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found that similar strains of C. difficile are present in both human and animal infections, 
with clades showing no specificity to a particular host (Stabler et al. 2006).   
 
1.2.2. Virulence factors 
C. difficile produces two main toxins; TcdA and TcdB, which belong to the large clostridial 
cytotoxin (LCT) family. Other toxins in this family include C. sordellii haemorrhagic and 
lethal toxins as well as C. novyi alpha toxin (Voth & Ballard 2005). Toxins of the LCT family 
display a number of common characteristics including high molecular weight and similar 
protein domain structure (von Eichel-Streiber et al. 1996). Domains of the toxins include an 
amino terminal enzymatic domain, a central hydrophobic region and a carboxy terminal 
domain with carbohydrate recognition sequence repeats. TcdA and TcdB fulfil the high 
molecular weight requirement, being 308kDa and 270kDa respectively. These toxins are 
encoded by a region of the genome known as the pathogenicity locus (PaLoc), a 19.6kb 
section that contains five open reading frames (Figure 1.4). TcdA and TcdB are expressed in 
late log and stationary phases of growth (Hundsberger et al. 1997). A distinct homology 
exists between the two toxins, suggesting that they may have been the subject of a 
duplication event. Like other members of the LCT family, TcdA and TcdB are organised as 
modular domains, each domain specific to a function (Davies et al. 2011) (Figure 1.4A). The 
N-terminus is enzymatic, the glucosyltransferase domain. This domain is the section 
translocated into host cells causing damage through intracellular processes. The 
hydrophobic domain in the centre of the toxin structure is thought to be involved in 
translocation of the N terminus, but this mechanism is not well understood. The C terminus 
contains polypeptide repeats that facilitate binding to the target host cells.  
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The two C. difficile toxins behave similarly to others in the LCT family, causing damage by 
modulation of cell physiology and altering the host environment (Aronoff 2013). The host 
environment is altered by targeting the Ras superfamily of small GTPases for modification 
by glycosylation. This action inactivates these small regulatory proteins, causing the 
disruption of signalling within the target cell. In seminal studies by Just and colleagues in 
the mid 1990’s, the mechanistic action of these toxins was described (Just et al. 1995a; Just 
et al. 1995b). These studies demonstrated the ability of TcdB to glycosylate RhoA via 
transfer of a sugar moiety to Thr-37 of the GTPase, using UDP-glucose as a substrate. Rac 
and Cdc42 were also shown to be glycosylated by TcdB. Rho proteins are primary 
regulators of the actin cytoskeleton and are found ubiquitously in mammalian cells (Hall, 
1990). Inactivation of these proteins within a cell leads to actin condensation, cell rounding 
and membrane blebbing, finally leading to apoptosis and cell death. Effects of TcdA include 
neutrophil infiltration (Castagliuolo et al. 1998), cytokine and chemokine production 
(Pothoulakis & Lamont 2001). TcdA and TcdB both contribute to disruption of tight 
junctions and apoptosis (Hecht et al. 1988). One or more of these effects leads to fluid 
accumulation within the host environment and inflammatory responses, which causes the 
signature diarrhoea and inflammatory symptoms of CDI.  
In order to affect damage, the toxins need to be able to gain access to the cells, and a 
potential receptor has been described for TcdA. Galβ1-4GlcNac has been reported to 
enable translocation of TcdA (Tucker & Wilkins 1991), although it should be noted that this 
receptor is not present in all cells that TcdA has cytotoxic effects in. TcdB has toxic effects 
on a broad range of cells, but as yet no receptor has been described, suggesting a 
ubiquitous receptor for this toxin. 
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The importance of the two toxins has been the cause of some debate. TcdA- TcdB+ strains 
have been isolated from clinical cases (Drudy et al. 2007), but no naturally occurring TcdA+ 
TcdB- strains have been reported. This suggests that TcdA is not necessary for causing the 
disease, although this does not rule out its importance. Development of genetic tools has 
allowed further study of the toxins, through generation of strains with disrupted toxin 
genes (Lyras et al. 2009; Kuehne et al. 2010). These studies showed that fatal disease could 
be induced in a hamster model of infection with strains producing just one of the toxins. 
Complexity of toxin involvement in disease is highlighted by a recent study (Buckley et al. 
2013) in which damage to the intestinal tract of hamsters was seen after infection with a 
non-toxigenic strain. Clearly, this is a complex disease with multiple mechanisms for 
causing damage to the host that are still to be fully understood.  
As mentioned above, the PaLoc has five ORFs (Figure 1.4A), only two of which have been 
addressed. The remaining reading frames encode proteins that have regulatory roles. TcdC 
acts as a modulator in toxin production, and deletions in this gene have been identified in 
027 strains (Spigaglia & Mastrantonio 2002), suggesting that regulation of toxin production 
is altered in ‘hypervirulent’ strains. TcdR (also named as TcdD) is the activator for toxin 
production. TcdE bears structural resemblance to holins, so has a predicted role in release 
of toxin from the bacterial cell. A comparison of toxin production between different 
ribotypes found increased expression of TcdE in 027 strains (Vohra & Poxton 2011). This 
suggests a role in increased release of toxin from cells, linking to reported increased toxin 
production in the 027 ribotype (Warny et al. 2005). It should be noted that not all studies 
have found an increase in toxin production in the 027 ribotype, so variation is likely to exist 
even within ribotypes (Merrigan et al. 2010).  
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The presence of the binary ADP-ribosyltransferase toxin, CDT (Clostridium difficile 
transferase) (Popoff et al. 1988), has also been reported in 027 ribotype strains. This is not 
encoded within the PaLoc (Figure 1.4B). The binary actin-ADP-ribosylating family of toxins 
are produced by pathogenic members of the Clostridia and Bacillus, including the C. 
perfringens iota toxin and the B. cereus vegetative insecticidal proteins. The CDT toxin from 
C. difficile acts on microtubules, causing disruption of the actin cytoskeleton resulting in 
microtubule based protrusions in epithelial cells (Schwan et al. 2009). It is proposed that 
these protrusions aid adherence of C. difficile in the GI tract, enabling the toxin to have a 
two-fold contribution to pathogenicity, facilitating increased damage to tissues lining the GI 
tract and allowing increased persistence of the infection. 
The toxins of C. difficile are the predominant virulence factors in C. difficile disease, but 
other factors also contribute to pathogenicity. Various proteins associated with the 
vegetative cell act as accessory virulence factors, facilitating the initial colonisation phase of 
infection through interactions with host tissues. Adhesins, including surface layer proteins 
(SLPs), have been shown to bind to gastrointestinal tissues (Calabi et al. 2002) and also 
generate immune responses (Wright et al. 2008). Specifically, proteins such as cell surface 
protein Cwp66, flagellal proteins FliC and FliD and fibronectin binding protein Fbp68 have 
all been defined as having adhesin-like properties. Adhesins enable binding interactions 
between the C. difficile cell and epithelial cells in the host (Péchiné et al. 2005). Proteolytic 
enzymes such as the cysteine protease Cwp84 have also been identified as having roles in 
initial colonisation of the infection (Denève et al. 2009; Bien et al. 2013).   
Spores of C. difficile also contribute to the spread and persistence of disease. ClosTron 
technology (Heap et al. 2007) has been used to inactivate the spo0A gene which acts as a 
transcriptional master regulator in the sporulation process of both Bacillus and Clostridium 
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species (Deakin et al. 2012). With this gene inactivated spores were not formed, which 
severely affected the ability of the strain to persist in infection and spread between 
individuals. Spore coat proteins should also be considered as potential virulence factors, as 
specific proteins enable interaction of the spore with its environment. Analysis of the spore 
coat has identified 54 proteins (Abhyankar et al. 2013) that make up the C. difficile spore 
coat. The protein make-up of spore coats varies between species, as it is adapted for 
specific functions. Study of specific spore coat proteins in C. difficile has demonstrated 
enzymatic properties present on the spore, suggesting a contribution to inflammatory 
responses during infection (Permpoonpattana et al. 2013). Further interest in spore 
proteins has led to an interest in the exosporial BclA protein (Pizarro-Guajardo et al. 2013), 
previously identified as a key protein in the B. anthracis exosporium. Studies identified the 
BclA protein as an immunodominant component of the exosporium (Steichen et al. 2003; 
Brahmbhatt et al. 2007a). While this protein is not required for virulence in B. anthracis, it 
does have some involvement in binding interactions (Bozue et al. 2007a). Comparisons 
drawn between the two spore forming species make this a potentially important protein in 
C. difficile interactions. 
 
1.2.3. Hypervirulence 
The appearance of the 027 ribotype led to an observed increase in severity of associated 
infections (Pépin et al. 2004), resulting in use of the term ‘hypervirulent strains’ to describe 
strains causing outbreaks in hospitals. There has been some debate about the definition of 
this term and the properties and characteristics of a strain that contribute to an increase in 
virulence. Many studies have generalised the 027 ribotype as presenting similar properties, 
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but variation exists within ribotypes, so specific properties of ‘hypervirulence’ are difficult 
to define. Separate studies have shown 027 strains to produce higher levels of toxin (Vohra 
& Poxton 2011) and also have a higher sporulation rate (Merrigan et al. 2010) both of 
which could contribute to an increase in virulence and incidence. Using a large number of 
isolates to assess sporulation rates however, a further study has demonstrated that 
differences exist within the 027 ribotype (Burns et al. 2011). This highlights the case for not 
attributing general characteristics to certain ribotypes.  
Detailed study of 027 ribotype C. difficile strains has led to variations in toxin structure 
being identified. 027 strains, which belong to toxinotype III, show variation in the 3’ end of 
the TcdB sequence in comparison to the reference sequence in toxinotype 0. This variation 
has been implicated in increasing severity by altering the binding ability of the toxin and 
potentiating cytotoxic ability (Denève et al. 2009). TcdB from ‘hypervirulent’ strains has 
also been demonstrated to have increased toxicity based on the ability to enter cells more 
rapidly than non ‘hypervirulent’ toxins (Lanis et al. 2010). Genetic analysis of the PaLoc has 
shown that 027 strains can be characterised and detected by a specific mutation in the tcdC 
gene (Wolff et al. 2009). An in frame, non-specific, 18bp deletion and a specific point 
mutation at position 117 of the PaLoc results in a frame shift mutation. This results in a 
truncated, inactive TcdC protein in 027 strains. TcdC is a negative regulator of toxin 
production in C. difficile (Dupuy et al. 2008) therefore an inactive version of this protein 
could contribute to the reported increase in toxin production from 027 strains (Curry et al. 
2007). Mutations in other genes may also contribute to hypervirulence. Mutations have 
been identified in the gyrA and gyrB genes of 027 strains that result in antibiotic resistance 
against fluoroquinolones and erythromycin. Increased antibiotic resistance increases the 
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risk factor associated with antibiotic usage, giving the 027 strains a significant advantage in 
causing outbreaks of disease. 
 
1.2.4. Analysis of strains and genetic tools 
Molecular biology provides several methods for identifying and distinguishing between 
strains of C. difficile (Janezic & Rupnik 2010), including PCR ribotyping, restriction 
endonuclease analysis (REA) and pulsed field gel electrophoresis (PFGE). These methods 
work on the principle of creating a genetic profile or fingerprint of a strain. This allows for 
grouping of isolates with varying degrees of sensitivity. Strains involved in outbreaks can 
then be identified and spread of particular groups can be tracked. Use of microarray data 
has also contributed to understanding of the pathogen through increasing the power of 
genetic studies (Stabler et al. 2006). 
The toxins of C. difficile serve not just as virulence factors but also provide a means of 
detection and typing of strains. Positive cases of CDI are confirmed by the presence of 
toxins through a cell culture rounding assay and culture of C. difficile from a stool sample. 
These methods represent the gold standard for detection and confirmation of infection. 
ELISA detection kits are used more frequently for rapid detection although this results in a 
compromise between speed and reliability. Typing of strains is achieved by genetic analysis 
of the PaLoc, analysing variations that occur within this sequence. A reference strain, 
VPI10463, is classed as toxinotype 0 and strains displaying variability from this are grouped 
into toxinotypes denoted I to XXVII. 27 toxinotypes have been described at present (Rupnik 
et al. 1998; Rupnik 2010).  
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The advent of a method of genetic manipulation of the Clostridia has greatly improved the 
ability to work with and understand C. difficile (Heap et al. 2007). ClosTron is a method of 
creating stable mutations in the genome of Clostridium species. The system uses group II 
intron based technology to allow knockouts of specific genes to be created, broadening the 
scope of research possible with this group of bacteria. B. subtilis is used as a model 
organism for Gram positive spore formers, due to the ease with which genetic studies 
could be conducted. This has led to a wealth of information being available on the species 
which can be applied to similar organisms. The use of genetic tools could potentially 
achieve the same for the study of C. difficile, with the information all the more valuable 
given its standing as a human pathogen.  
 
1.3. C. difficile as a human pathogen 
 
C. difficile infection can present at a variety of clinical levels, ranging in severity from mild 
diarrhoea to serious inflammatory conditions such as pseudomembranous colitis. The most 
severe cases can result in toxic megacolon and perforation of the gut, which can lead to 
fatalities. Data collated by the Office for National Statistics (ONS) shows that C. difficile was 
listed as a cause or contribution to death in 0.8% of all hospital deaths between 2010 and 
2012 (ONS 2013), with 1646 deaths in 2012 involving C. difficile infection. 
The disease caused by C. difficile is primarily mediated by the release of toxins from 
vegetative cells that are able to proliferate in the gut following disruption of the microflora. 
As this organism is a strict anaerobe, transmission of disease is facilitated by the spread of 
highly resistant spores, which generally enter the body through ingestion and then can 
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reside in the GI tract. Bile salts secreted by the liver pass through the GI-tract and are 
reabsorbed in transit. Levels of the bile salt taurocholate are optimum to serve as 
germination agents for the spores in the colon, allowing germination, outgrowth and 
proliferation of C. difficile (Sorg & Sonenshein 2008). The bile salt chenodeoxycholate acts 
as a germination inhibitor (Sorg & Sonenshein 2009), but is only present in low levels in the 
colon. Studies using 027 strains have also suggested that the presence of antibiotics in the 
gut could promote germination of spores (Saxton et al. 2009). 
Various risk factors have been identified in the study of C. difficile, with the clearest 
correlations for disease shown between old age and antibiotic usage (Carroll & Bartlett 
2011). The elderly are more at risk from infection for a number of reasons; 
immunosenescence means a reduced ability to mount an effective immune response, and 
advanced age also leads to changes in the microflora. Use of treatments such as antibiotics 
and proton pump inhibitors (PPIs) affect the microflora of the gut in patients,  creating 
niches that allow colonisation of C. difficile (Garey et al. 2008; Loo et al. 2011). 
Immunosuppressant treatment and other under-lying conditions also contribute to 
increased susceptibility to C. difficile infection. There is also a suggestion of genetic 
susceptibility to the disease, with the identification of a polymorphism in the human IL-8 
gene that renders individuals more susceptible to infection (Jiang et al. 2006). With the 
evolution of virulence in strains, prevalence of C. difficile in groups previously thought to be 
at low risk is increasing. This includes an increase in cases of CDI in peripartum women, a 
group that previously had a low association with C. difficile (Garey et al. 2008). Cases of 
community associated infections are also increasing (Wilcox et al. 2008; Chitnis et al. 2013; 
Heslop et al. 2013), creating a more complex field of disease for monitoring.   
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Adding to the complexity of this disease, around 20% of CDI patients will experience a 
relapse of infection (Barbut et al. 2000; Johnson 2009). Recurrent infections are attributed 
to either residual spores in the GI tract, reinfection from original source, or infection with a 
new strain. Higher relapse rates have been reported for infections involving 027 strains 
(Figueroa et al. 2012). Once patients have experienced a relapse of infection, continued 
recurrent disease is much more likely to occur. Recurrent episodes of disease tend to occur 
in those who have mounted ineffective immune responses during in primary infection 
(Garey et al. 2008). Failure of the gut microflora to recolonise post antibiotic treatment or 
illness is also a common factor in relapse. The costs of relapsing infection are not only 
financial but are also substantial in terms of personal health. Preventing recurrent infection 
is a key issue in the control of C. difficile.  
 
1.3.1. Transmission of infection 
Current control methods for preventing the spread of C. difficile are based on transmission 
occurring between infected patients, normally on hospital wards. Infected individuals are 
isolated and strict cleaning regimens are implemented to avoid further spread of infection 
(Vonberg et al. 2008). A key issue related to the control of C. difficile is the highly resistant 
spores that remain in the environment, and can be transmitted on inanimate objects or 
even by airborne transmission (Best et al. 2010). However, genetic tools and molecular 
typing systems are now being used to track the spread of individual infections. In a hospital 
based study, cases of symptomatic C. difficile infection were analysed using molecular 
typing. Using these data, it was shown that around 20% of cases in hospitals have obvious 
sources within the hospital itself, a figure much lower than expected. The study did not 
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screen all patients and visitors, so does not account for asymptomatic carriers being 
sources of infection within hospitals. Data from the study also suggests that a minority of 
symptomatic patients (<10%) could remain infectious for up to 8 weeks, far beyond the 
infectious period anticipated by control measures employed in hospitals. This study could 
be improved by screening asymptomatic patients for potential sources of infection, but it 
does address an important issue for C. difficile infection in that not all cases can be 
accounted for by transmission from an obviously infectious source. A more recent study 
also addressing the issue of ward based transmission found that isolates from 45% of those 
cases studied were genetically diverse from existing cases in a hospital (Eyre et al. 2013). 
This highlights how C. difficile infection is not just transmitted patient to patient, but 
infection can come from diverse sources. The complex epidemiology of CDI means that 
control measures need to be extended beyond the hospital setting. Nosocomial infections 
have been reduced by increasing awareness of C. difficile so it is plausible that increasing 
awareness outside of the hospital setting could aid control. 
Use of genomics to track the spread of C. difficile strains (Stabler et al. 2006) shows how 
easily infections and virulent strains can spread in our ‘hyper-connected’ world. Global 
transmission highlights the need for widely used control measures, for example, improved 
antimicrobial stewardship should be global, not simply a localised effort.  
 
1.3.2. Epidemiology 
Classically, C. difficile is associated with nosocomial infection and is limited to vulnerable 
individuals who are exposed to risk factors for the infection. However, the prevalence of 
community associated (CA) C. difficile infection is increasing and reported cases of 
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community acquired infections are increasing in severity (Heslop et al. 2013). Warny and 
colleagues (Warny et al. 2005) have also reported isolating strains of the ‘hypervirulent’ 
027 ribotype from community associated cases. Studies on CDI tend to focus on hospital 
cases and populations, so a bias exists in location reports of CDI. More recent studies are 
starting to address this imbalance in information however. In an epidemiological study 
(Khanna et al. 2012), a cohort population displayed a significant number of cases (41%) 
occurring in the community, rather than being associated with a hospital stay. These cases 
occurred in a younger age group than normally associated with nosocomial C. difficile and 
were generally less severe. This implies that the burden of disease caused by this pathogen 
is likely to be underestimated, although more severe cases remain associated with hospital 
infections. Attention needs to be focused on the reservoir of infection in the community 
that has potential to increase in severity, just as has occurred with hospital associated cases 
of infection.   
It is difficult at some points to distinguish between community associated and health care 
associated infections, especially when this requires investigating the medical history of 
patients for exposure to risk factors for C. difficile infection. Reports on the risk of 
community acquired CDI state that it is an issue to be considered alongside hospital 
acquired cases (Wilcox et al. 2008; Brown et al. 2013; Chitnis et al. 2013). The increased 
geographical distribution of cases makes monitoring the overall occurrence of disease more 
complex, but such monitoring would enable better awareness of where the risk of CDI is 
greatest. This information would allow more comprehensive control measures to be 
implemented, not just in hospitals.  
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1.4. Treatment of Clostridium difficile infection 
 
1.4.1. Antibiotics 
Antibiotic use is a key risk factor for CDI but despite this, antibiotics are still the main 
treatment for this infection. Vancomycin and metronidazole are the two main antibiotics 
used in treatment. However, approximately 20% of initial cases will experience a relapse 
following this treatment (Johnson 2009), highlighting the need for more effective antibiotic 
agents or alternative treatments. Fidaxomycin is a recently developed antibiotic that is 
reported to have increased efficacy against C. difficile (Goldstein et al. 2012). It is a narrow 
spectrum antibiotic, having little effect against other groups in the microflora such as Gram 
negative aerobes, anaerobes and yeasts so causes less disruption to the microflora than 
broader spectrum antibiotics. This could be a factor that contributes to the lower relapse 
rate reported with use of fidaxomycin compared to vancomycin (Louie et al. 2011). 
Reducing relapse rate is an important step in the treatment of CDI, but it is dangerous to 
rely on a single antibiotic. Further development of new antibiotics is required in order to 
avoid issues with antibiotic resistance developing. This is especially relevant with C. difficile 
where increased virulence has been associated with development of resistance to 
antibiotics. 
 
1.4.2. Toxin binding 
A diverse range of alternative treatments have been investigated in an attempt to reduce 
reliance on antibiotics. One such treatment is the development of ‘Tolevamer’, a novel 
toxin binding polymer. This works on the basis of neutralising toxins by binding to them in 
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order to prevent toxin mediated damage to the host in disease (Braunlin et al. 2004; 
Hinkson et al. 2008). When tested in a human gut model however, the polymer did not 
perform well (Baines et al. 2009), suggesting that this method would need to be refined for 
successful use in a clinical setting. 
 
1.4.3. Probiotics 
Antibiotic use is key risk factor in development of CDI as it can cause dysbiosis of the gut 
microflora. Several treatment strategies address the depletion of the microflora as a factor 
in disease. An example of this is the use of probiotics; studies have been carried out using 
various species and strains of bacteria to assess the potential for treatment of C. difficile 
with some success (McFarland 2006; Islam et al. 2012). The current state of available 
information contributes to a lack of clear conclusions regarding probiotics as a potential 
treatment. Studies are often carried out using small sample sizes or are unclear as to the 
regimen used in treatment, making results difficult to replicate. As probiotic effects are 
likely to be species or even strain specific, clear identification of the probiotic agent is also a 
necessity. Improved design and communication of results is needed if probiotics are going 
to be considered seriously, especially when doubts exist within the scientific community 
(Miller 2009). 
 
1.4.4. Faecal therapy 
Building on the idea of probiotics supplementing the gut flora leads to one of the most 
successful alternative treatments to antibiotics. Faecal transplants use stool samples from a 
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healthy ‘donor’ which are then implanted into the colon of a C. difficile patient. The 
microbiota in the donor stool recolonises the gut and enables clearance of the infection, 
restoring the gut environment to a normal state This treatment is reported to have 
excellent efficacy in resolving infection (Gough et al. 2011), especially in cases where 
relapse of disease has been a significant issue. This treatment is now being refined, with 
the development of ‘synthetic stools’. This involves identifying and isolating key species 
within the faecal microflora and using these to create a treatment that delivers a 
restorative microflora to the infected gut. This eliminates the risk of transplanting further 
pathogens into the patient and results in a more attractive treatment option (Lawley et al. 
2012; Petrof et al. 2013). 
Increasing knowledge regarding how C. difficile causes and behaves during progression of 
disease is useful in the design of new treatments. For example, a recent paper reported the 
identification of a germination receptor that interacts with bile salts present in the gut to 
initiate germination (Francis et al. 2013). This receptor could be used in drug design in 
order to prevent germination of ingested spores, eliminating the threat of disease, or as a 
potential antigen in vaccine design. 
 
1.4.5. Vaccines 
There is as yet no available vaccine for prevention of C. difficile infection. Development of a 
preventative vaccine would reduce the use of antibiotics in treatment of this infection, 
addressing a key issue in finding alternative treatments. The majority of potential C. difficile 
vaccines use parenteral delivery of toxin based antigens to generate systemic immune 
responses against C. difficile toxins. This method produces antibodies that have neutralising 
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activity against the toxins produced in disease, so protects against the damage caused 
during infection. The correlation between antibody response against toxins and protection 
from disease is well established (Torres et al. 1995). This response can be achieved by 
immunising subjects with inactivated toxins, or toxin fragments. Several studies have used 
chimeric proteins which use fusions of toxin A and toxin B in vaccine formulations (Tian et 
al. 2012; Wang et al. 2012). Sanofi Pasteur currently is the most advanced company in trials 
for a candidate vaccine, having announced entry into Phase III of testing for their vaccine 
candidate in the summer of 2013. This vaccine consists of formalin inactivated toxins A and 
B from C. difficile reference strain VPI 10463, delivered in an intra-muscular (IM) injection 
(Alkan et al. 2012).  
Vaccine strategies focus on production of systemic responses to C. difficile. However it is 
possible that alternative approaches need to be considered. Study of interactions between 
C. difficile and the host has indicated the involvement of a mucosal response to infection 
(Johnson et al. 1992), which may represent an alternative option for vaccination strategies. 
Previous studies have addressed the use of an alternative route for immunisations, 
including use of cellular antigens delivered mucosally in an attempt to prevent colonisation 
of C. difficile (Pechine et al. 2007). The development of a B. subtilis spore based vaccine for 
CDI was based around mucosal delivery of toxin antigens (Permpoonpattana et al. 2011a). 
This approach used oral immunisation of spores expressing a toxin A antigen to produce 
protection against C. difficile infection in the hamster model. The route of dosing and use of 
the bacterial spore effectively as an adjuvant for the vaccine are important factors in this 
study. The delivery strategy of an antigen can alter the patterns of immune response 
produced (Lima et al. 2004) so the choice of adjuvant and delivery strategy can be vital to 
identifying a successful candidate vaccine. In the generation of mucosal responses, an 
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entity that interacts with the innate immune system to boost responses could be important 
(Kaisho & Akira 2002; Rhee et al. 2012; Woodrow et al. 2012). B. subtilis spores have been 
shown to interact with aspects of the innate immune system (Huang et al. 2010) and 
results from use of the B. subtilis vaccine show that it is capable of inducing both cellular 
and humoral responses to support protection against symptoms (Permpoonpattana et al. 
2011a). Manipulation of multiple aspects of the immune system to evoke a more complete 
response is presented as an avenue worth investigation. Understanding the immune 
response required for protection will aid the development of more efficacious vaccines. For 
example, a connection between the mounting of an initial immune response to infection 
and protection from relapse has been established (Kink & Williams 1998). Analysis of 
immune responses in relapsing and non-relapsing patients could provide important 
information about what is required to protect against an initial infection. 
 
1.4.6. Passive immunotherapy 
Passive immunotherapy involves a similar idea to vaccination for treatment of C. difficile, 
using antibodies against toxins directly as a treatment. This avoids relying on a vaccine to 
induce production of antibodies within the host to neutralise toxins (Salcedo et al. 1997; 
Wilcox 2004). High production costs of antibodies make this treatment less commercially 
feasible than others however.  
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1.4.7. C. difficile summary 
C. difficile is a relatively new pathogen and represents a significant challenge to healthcare 
providers for several reasons. Firstly, control of the disease is difficult with highly resistant 
spores contributing to spread and persistence of infections. Secondly, the ability of the 
pathogen to evolve has resulted in altered virulence properties such as increased antibiotic 
resistances and more robust toxin production. This leaves both research and treatment 
options playing catch up with the pathogen. Thirdly, the epidemiology of this infection is 
also evolving. Previously C. difficile infections were associated with hospitals and elderly 
patients, but it is now becoming more prevalent in younger individuals and in community 
settings away from associations with common risk factors. 
Research investigating all facets of the infection is useful to understand further how this 
pathogen causes disease. As more information becomes available, it can be exploited in the 
generation of novel treatments to aid control of this pathogen. 
 
1.5. The Gastrointestinal tract 
 
The gastrointestinal (GI) tract is essentially a tube, split into specialised sections enabling 
digestion of ingested food, to obtain nutrients required by the body and then dispose of 
the remaining waste. The histology throughout the digestive system varies, reflecting the 
differences in speciality of functional anatomy. For example, villi in the small intestine 
increase surface area for absorption of nutrients. Concentric layers of tissue form the gut, 
the mucosa being the innermost of these layers. This layer is important as it creates a 
barrier between the contents of the gut and the tissue layers. The mucosa is itself in three 
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layers; the epithelium which is responsible for most of the digestive, absorptive and 
secretory processes. The lamina propria provides a layer of connective tissue, and this is 
encased by the thin muscular layer of the muscularis mucosae. In the lumen of the GI tract, 
especially in the lower colonic regions, a large number of microbial inhabitants are present. 
Relevant to this thesis, the colon is also where C. difficile infection is localised to.  
 
1.5.1. Microbiome of the gut 
A commonly cited figure is that humans are 10% human cells and 90% microbial cells, 
demonstrating the large number of microbes that colonise the human body. The majority 
of these colonising microbes inhabit the gastrointestinal tract (Savage 1977). The 
microflora of the gut is of vast importance to human health and our ability to digest many 
foods. In 2007, the Human Microbiome Project was initiated with funding from the NIH. 
This mammoth project built on the success of the Human Genome Project, using advancing 
sequencing technology to screen the microbial flora of over 200 individuals (Yatsunenko et 
al. 2012). This included samples from 15 sites, including skin, mouth, nose and stools. The 
aim was to develop a set of reference microbial genome sequences and perform a 
preliminary characterisation of the human microbiome. This information would be used 
then as a base to understand the role of microbes from the human body in health and 
disease. The project confirmed that the number of microbial cells in our bodies far 
outnumbers the amount of human cells, by over a magnitude. The human genome contains 
over 22,000 protein coding genes, but the microbiome contributes a further 8 million 
unique protein coding genes (Human Microbiome Project Consortium, 2012; Li et al. 2012). 
The presence of the microflora provides access to a vast wealth of genes that are not 
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available within just the human genome. In the GI tract, the microflora aid digestion, help 
regulate homeostasis and synthesise vitamins and enzymes otherwise absent from the 
environment. The metabolic activity performed by the microflora has led to it being termed 
the ‘forgotten organ’ (O’Hara & Shanahan 2006). Much of the capability of the gut is due to 
its microbial residents and when the complex composition of this flora is altered, it can 
have significant effects.  
A wealth of information is now available surrounding the composition of the gut microflora 
and developments in genetic tools enable huge amounts of data to be analysed. A study in 
2011 proposed three main ‘enterotypes’ of gut flora, based on analysis of gut microbial 
communities, that were  independent of sex, nationality, age and body mass index (BMI) 
(Arumugam et al. 2011). Despite not attributing specific factors to definitions which would 
describe each enterotype, this study opens up the possibility of using biomarkers from the 
flora to identify microbial signatures of factors such as age, or disease susceptibility. 
Studies comparing the composition of healthy or diseased subjects can demonstrate clear 
differences in the microflora of individuals. For example, microbial signatures of irritable 
bowel syndrome (IBS) have been identified (Saulnier et al. 2011). Significant differences 
between the flora of obese and lean individuals can also be seen (Turnbaugh et al. 2009) in 
a comparison of microflora.  
The microbiota of the GI-tract is of key importance to C. difficile infection, as dysbiosis in 
this environment is a key risk factor for development of disease. In a healthy individual, 
with a robust microflora, C. difficile carriage presents little problem and is normally 
asymptomatic. However, when dysbiosis of the gut microflora occurs, the shift in microbial 
composition allows C. difficile to proliferate and disease mediated by production of toxins 
occurs. Dysbiosis is commonly caused by antibiotic treatment, but other factors can also 
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have a disruptive effect. The state of the microflora of an individual is therefore very 
important to study of CDI. As the disease is a product of dysbiosis, the obvious solution is to 
counter this, leading to the use of microbial therapy in treatment of the disease (Petrof et 
al. 2013). The effect of treatments on the existing microflora is also a key factor in 
development of new drugs. Fidaxomycin, a recently licenced antibiotic for treatment of 
CDI, has been successful as it reduces the rate of relapse of infection. This is due to its 
narrow spectrum antimicrobial action, reducing the effect on the remaining microflora and 
encouraging return of the microflora and the GI tract environment to a healthy state. 
Having identified the significant role that the microflora plays in the human body, it is 
important that this is taken into consideration when developing new medical treatments. 
 
1.5.2. The Gut Associated Lymphoid Tissue (GALT) 
The microbiota of the GI tract also plays a key role in development of the immune system. 
The intestine contains the largest mass of mucosa associated lymphoid tissue (MALT) in the 
body and commensal microbiota significantly contributes to the development of the gut 
associated lymphoid tissue (GALT). Lymphoid tissue plays a role in protecting the body from 
invasion by pathogens, by facilitating recognition of pathogens and initiating responses to 
clear infections. In animal studies, germfree mice showed low densities of lymphoid tissue 
(Guarner & Malagelada 2003) and whilst colonisation with specific strains of commensal 
flora helped reinstate expected immune responses, administration of complete normal 
flora is required to restore the full spectrum of immune responses (Cebra 1999). In 
humans, colonisation of the GI tract begins just hours after birth, with studies showing that 
the method of birth and subsequent feeding method affects the composition of an infant’s 
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microflora (Grönlund et al. 1999; Jarvis 1996). In a study from Finland, researchers 
investigated if the effect linked with the method of birth was evident in the long term. The 
composition of microflora from seven year olds who had been delivered either naturally or 
by caesarean section was compared. This found that bacterial composition levels were 
similar between groups apart from the Clostridia, which were higher in the group of 
children that had been naturally delivered. Interestingly, all children included in the study 
that had a history of asthma had lower levels of Clostridia present (Salminen et al. 2004). 
The link between microflora composition and allergy related illness is interesting. The 
development of the intestinal immune system is due to exposure to antigens presented 
through the colonisation of the GI tract. A popular theory connecting increased cleanliness 
with increase in allergic conditions such as eczema and asthma is known as the ‘Hygiene 
hypothesis’ (Strachan 1989). The hypothesis implies that with less exposure to microbial 
antigens, the immune system develops differently, with a T-cell response (TH2) bias that is 
associated with allergic reactions. Several studies have provided supporting evidence to 
this; in the comparison of infants from Sweden and Estonia, lower levels of enterococci and 
bifidobacteria were found in children with allergic conditions. The differences in the 
composition of flora were seen from the first month of life, highlighting that colonisation 
from the very beginning of life is important (Björkstén et al. 2001). This study also noted 
that bifidobacteria, common in probiotic applications, are known to elicit TH1 responses, 
which would counter development of allergy associated TH2 responses. The development 
of the microflora from the neonatal to the adult composition is important with respect to 
the development of the intestinal mucosal immune system. The mature immune system 
should have the ability to discriminate between pathogenic microorganisms and the vast 
array of antigens to which it is exposed over a lifetime. Where such development has not 
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occurred to the proper extent, such discriminations cannot be made effectively, leading to 
conditions such as IBS and colitis.  
The link between the microbiome and the GALT has a two-fold importance. Firstly, the 
development and presence of the gut microflora stimulates the development of the 
lymphoid tissue. This interaction from an early age contributes to development of a mature 
and protective immune system. Secondly, the location of the lymphoid tissue allows the 
microflora to interact with immune receptors in the gut, enabling maintenance of 
homeostasis within this system. When this regulation is disrupted, a range of effects can 
follow, from acute infections by gastrointestinal pathogens to chronic inflammatory 
conditions. When the structure or composition of the microflora is altered, so is the ability 
to suppress potential pathogens. 
The link between the GI tract microflora and the development of a mature immune system 
highlights the importance of the intestinal immune system. When investigating infections 
that occur within this environment, interactions with the local immune tissues should be a 
consideration. This is especially important when developing a vaccine or treatment for such 
an infection. In the case of C. difficile, which as yet does not have a commercially available 
vaccine, antibiotics are relied on for control of infections. Perhaps an approach including 
consideration of interactions within the gut would bring a more effective treatment.  
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1.6. Thesis objectives 
 
The work of this thesis centres on strategies for treatment of CDI that avoid the use of 
antibiotics. Part of developing new treatments requires information about how infections 
work and behave in order to find novel targets for treatments. Based on this, the thesis 
falls into two sections; Firstly, the investigation of how B. subtilis spores can be 
incorporated into alternative treatments that can be employed in the management of C. 
difficile infections. Secondly, identification of spore coat specific functions during infection, 
focusing particularly on the role of the BclA proteins on the C. difficile spore coat. 
 
1.6.1. B. subtilis based treatments 
A B. subtilis spore based vaccine candidate will be evaluated using oral and sublingual 
delivery routes. Activation of a mucosal immune response by this potential vaccine rather 
than parenteral delivery of antigens has previously been shown to be successful in 
preventing disease (Permpoonpattana et al. 2011a). Evaluating alternative delivery routes 
for this vaccine will aid understanding of the role of the mucosal response in protecting 
against CDI. 
B. subtilis spores also display great potential for their use as probiotics, with a history of 
safe human consumption. The use of spores provides a treatment that is simple to produce 
and store, which can be delivered through simple oral doses. Spores of B. subtilis will be 
trialled as a probiotic treatment for CDI using animal models to replicate the in vivo human 
infection. 
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1.6.2. BclA proteins on the C. difficile spore coat 
 
The spore of C. difficile is the infectious agent, so plays a pivotal role in development of 
disease. By use of strains with mutations in bclA genes, spores lacking these proteins can be 
investigated for any anomalies in infectious behaviour. Both in vitro and in vivo 
characteristics of the bclA- spores will be investigated in order to ascertain whether these 
proteins contribute to significant processes associated with infection. 
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Chapter 2 
Materials and Methods 
 
2.1. General Methods 
 
2.1.1. Bacillus subtilis  
General methods for working with B. subtilis are described elsewhere (Harwood & Cutting 
1990).  
 
2.1.2. Clostridium difficile strains 
630 is a toxigenic (tcdA+ tcdB+) strain of C. difficile isolated from a patient with 
pseudomembranous colitis during an outbreak of C. difficile infection (CDI). For ClosTron 
mutagenesis and mutant analysis an erythromycin-sensitive derivative 630Δerm was used 
(provided by N. Minton, Univ. Nottingham, UK). R20291 is an epidemic strain of ribotype 
027 isolated from Stoke Mandeville Hospital in 2006 and was obtained from T. Lawley 
(Wellcome Trust Sanger Institute, UK). VPI10463 (provided by B. Wren, London School of 
Hygiene and Tropical Medicine, UK) was originally isolated in the USA in 1980 and has since 
been used as a reference strain.  
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2.1.3. Growth of C. difficile and preparation of spores 
C. difficile was routinely grown in vegetative culture by overnight growth in TGY- medium. 
Spores of C. difficile were prepared by growth on SMC agar plates using an anaerobic 
incubator (Don Whitley, UK) as described previously (Permpoonpattana et al. 2011b). After 
growth for seven days at 37oC spores were harvested from agar plates and purified using 
HistoDenz as follows. Crude spore suspensions were washed five times with ice-cold sterile 
water, then aliquots were re-suspended in 500µl of 20% HistoDenz (Sigma, MO, USA) and 
layered over 1ml of 50% HistoDenz in a 1.5ml tube. Tubes were centrifuged at 10,000 x g 
for 15 min. The spore pellet was recovered and washed three times with ice-cold sterile 
water. Spore purity was assessed by phase contrast microscopy and spore yields in 
individual preparations were estimated by counting colony forming units (CFU) of heat-
treated (60°C, 20min) aliquots on BHIS agar plates (Brain heart infusion supplemented with 
0.1% L-cysteine and 5 mg ml-1 yeast extract) supplemented with 0.1% sodium taurocholate 
(BHISS).  
 
2.1.4. Toxin detection 
Faecal samples were collected fresh and kept at -20oC until assay. Caecal samples were 
treated in the same manner as faecal samples for extraction of toxins. Toxins  were 
extracted using a protease inhibitor buffer as described previously (Permpoonpattana et al. 
2011a) and detected by a capture ELISA method as follows. ELISA plates (Greiner, high 
binding) were coated with rabbit polyclonal antibodies against toxin A or toxin B (Meridian 
Life Science; 1Pg ml-1 in PBS buffer).  After blocking plates with 2% BSA (1h at 30oC), 
samples (10μl) and reference toxin A or toxin B (AbD Serotec) were added to plates. 
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Incubation was made at 30oC for 3h. For detection, monoclonal antibodies (AbD Serotec) 
against toxin A (1/500) and toxin B (1/500) were used. Plates were incubated for 1h at 
30oC. After washing, the secondary antibody, HRP-conjugated anti-mouse IgG was added 
with incubation at RT for 1h. Colour was developed with the TMB substrate and 
measurement at OD450nm. The titres of toxin in samples were calculated against a serial 
dilution of commercial reference toxins A or B. The sensitivity of the assays for toxin A and 
B were 7ng ml-1 for both toxins.  
 
2.1.5. Spore enumeration 
Post treatment for toxin extraction, faecal and caecal samples were resuspended in ethanol 
(100%) and then incubated for 20 minutes at RT to kill all vegetative forms in samples. 
Samples were pelleted by centrifugation at 10,000 x g for 5 minutes and ethanol was 
removed from the sample. Pellets of faecal/caecal matter were resuspended in 1ml sterile 
H2O, and serially diluted. Dilutions were plated on BHIS agar supplemented with 0.1% 
sodium taurocholate, before incubation in anaerobic conditions at 37°C for 48hrs. Colonies 
were counted and number of spores/g calculated based on the original weight of the 
sample. A detection limit of 102 spores/g was applied to prevent over estimation of spore 
content. 
 
2.1.6. Animal studies 
All animal work was carried out under Home Office Project License 70/7025.  
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2.2. Chapter 3 – PP108 sublingual immunisation 
 
2.2.1. PP108 spore preparation 
PP108 is derived from B. subtilis PY79 and expresses a C.  difficile toxin A antigen on spore 
coat proteins CotB and CotC. The original construction is described elsewhere 
(Permpoonpattana et al. 2011a). Growth and sporulation protocols for B. subtilis are 
described in detail elsewhere (Harwood & Cutting 1990). Briefly, spores were produced as 
follows; single colonies grown on antibiotic resistance selective plates were used to 
inoculate DSM broth liquid cultures. Once cultures had reached OD600 0.5-0.8, each culture 
was diluted to an OD600 of 0.1 and spread on DSM agar. Trays of agar were incubated at 
30°C for 48 hours. Spores were harvested using ice cold sterile H2O washed over agar and 
sterile loops to mix bacterial overlay into a suspension. This suspension was removed from 
trays of agar and stored in falcon tubes at 4°C. Following harvesting, spores were purified 
as follows. Spores were washed three times in sterile H2O prior to suspension in lysozyme 
buffer (Tris HCl 1.5M, EDTA 0.5M, lysozyme 50mg/ml). Spores were incubated with 
lysozyme buffer for 1hr at 37 °C with agitation. Lysozyme buffer was removed by washing 
three times with sterile H2O. This was followed by salt washes (1x 1M NaCl, 1x 1M KCl). The 
spore pellet was recovered and washed three times with ice-cold sterile water. Spore purity 
was assessed by phase contrast microscopy and spore yields in individual preparations 
were estimated by counting colony forming units (CFU) from serial dilutions made on DSM 
agar plates.  
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2.2.2. Formaldehyde inactivation of spores  
Formaldehyde solution (1% and 4%) was made by dilution of 37% formaldehyde (Sigma, 
MO, USA) with sterile H2O. Spore pellets were suspended in formaldehyde solutions and 
incubated at 37°C for between 2 and 24 hours in Protein LoBind tubes (Eppendorf) for 
preliminary assessment of inactivation. Spore suspensions were washed three times to 
remove traces of formaldehyde and then checked for residual levels using a titration based 
formaldehyde quantification kit (Hach, Düsseldorf, Germany). Efficacy of inactivation was 
tested by plating spore suspensions on DSM agar to ascertain if colony formation would 
occur. Inactivated spores were stored in sterile H2O at 4°C over 7 days to assess longevity of 
inactivation. Spores used for immunisations were incubated with 4% formaldehyde for 
4hours at 37°C. After washing, these spores were used immediately for immunisation.  
 
2.2.3. Immunisation schedule 
Groups of 6-8 week C57/Bl6 mice (Charles River) received oral or sublingual immunisations 
on days 1, 15, 36, 64 and 85. Oral doses of spores were 4x1010 /dose and were delivered by 
oral gavage with mice under light sedation. To receive sublingual doses, mice were briefly 
immobilised using a 0.1μl intraperitoneal (i.p.) dose of hypnorm/hypnovel mix (1:1:2 
hypnorm:hypnovel:H2O). 10μl containing 2 x 109 spores was placed under the tongue of 
individual mice. Due to volume restrictions of this dosing method, the total sublingual dose 
was delivered over three days, with mice receiving 2 x 109 spores per day. To account for 
this disparity in dose regimen, control oral dosed groups were included that received the 
oral dose over three days, with one dose of 1.3 x 1010 given per day. Groups received live or 
formaldehyde inactivated PP108 spores, with the wild type B. subtilis PY79 strain used as 
 
 
Chapter 2  Materials and methods 
 
 
46 
 
control for immunised groups. Mice were weighed regularly to ensure immunisation doses 
or use of anaesthesia had no ill effects.   
 
2.2.4. Determination of mouse antibody titres by indirect ELISA  
For analysis of responses, serum was collected on days -1, 20, 34, 63, 79 and 108, and 
stored at -20°C. Faeces were collected on days -1, 10, 35, 43, 71 and 99 and kept at -20°C. 
Faecal sample extractions were made at 1/5 (weight/vol) dilution in extraction buffer (2% 
foetal bovine serum (FBS) in Dulbecco’s modified eagles medium (DMEM) plus protease 
inhibitor cocktails; trypsin 0.1mg/ml, leupeptin 1μg/ml, benzamide 1μg/ml, aprotinin 10 
μg/ml, phenylmethylsulphonyl fluoride 1mM and ethylenediaminetetraacetic acid (EDTA) 
0.05 mg/ml). Samples were gently shaken for 30 min at 4°C to disrupt solid material and 
then centrifuged (14,500 g 15 min). Supernatants were filtered (0.45 μM) before analysis. 
Antibodies from serum (IgG) and faeces (IgA) were determined by indirect ELISA. Greiner 
96 well plates (Maxisorp) were coated with purified 1μg/ml rA26-39 (CDTA14) proteins 
(50μl/well) in PBS buffer, overnight at RT. After blocking for 1h at 30°C with 2% bovine 
serum albumin (BSA) two-fold serially diluted samples were added, starting at 1/50 (IgG) or 
1/5 (IgA) in diluent buffer (0.01 M PBS [pH7.4], 0.5% (w/v) BSA, %5 (v/v) FBS, 0.1% (v/v) 
triton X-100, 0.5% (v/v) tween 20). Replicate samples were used together with a negative 
control (pre-immune serum or faecal extraction). Plates were incubated for 2 h at RT 
before addition of appropriate horseradish peroxidase conjugated anti-mouse antibodies in 
conjugate buffer (5% FBS (v/v), 1% BSA (w/v) 0.05% tween-20 in 0.01 M PBS). Plates were 
incubated for 1 h at RT and then developed using tetramethyl benzidine (TMB) substrate 
(0.1 mg/ml 3.3’, 5.5’-tetramethylbenzidine in 0.1 M sodium acetate buffer (pH 5.5) in 
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distilled water). Reactions were stopped using 2 M H2SO4 and absorbance was measured at 
450nm. Dilution curves were created for each sample and end-point titres for each specific 
antibody were estimated at the maximum dilution of serum giving an absorbance reading 
of 0.1 units over the absorbance of naïve samples. 
 
2.2.5. Cytokine flow cytometry 
Immunised mice were culled 14 days post the last immunisation and splenocytes were 
recovered. 5x105 splenocytes were seeded per well in 96 well plates (Corning) and 
stimulated with the following antigens: rA26-39 (CDTA14) protein 1μg/ml with ConA 
1μg/ml as a positive control for stimulation. Supernatants were removed after 96h of 
incubation (37°C, 5% CO2) and stored at -20°C. A Cytometric Bead Array (CBA) mouse 
TH1/TH2/TH17 cytokine kit (BD Bioscience, Oxford, UK) was used to evaluate cytokine levels 
in supernatant samples according to manufacturer’s instructions. Briefly, 50μl of sample 
was added to mixed capture beads. PE detection reagent (BD) was added to all tubes and 
then incubated for 2h at RT in the dark. After incubation, 1ml of wash buffer was added to 
each reaction tube then tubes were centrifuged to pellet beads. The supernatant was 
removed and pellets suspended in 300μl of wash buffer. Fluorescence characteristics of 
samples were acquired and recorded using a BD Accuri C6 flow cytometer. Levels of each 
cytokine (IL-2, IL-4, IL-6, IFN-γ, TNF, IL-17A, and IL-10) were evaluated based on production 
of a standard curve for each cytokine included in the assay.  
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2.2.6. Challenge studies 
After the final immunisation, mice were given oral antibiotic doses as described elsewhere 
(Chen et al. 2008) but with minor alterations. Mice received antibiotic doses via orogastric 
(o.g.) gavage rather than in drinking water. Doses on days 1, 2 and 3 were antibiotic 
cocktails (kanamycin, gentamycin, colistin, metronidazole and vancomycin). A single oral 
dose of clindamycin (30mg/kg) was given on day 5, followed by orogastric challenge with 
104 C. difficile R20291 spores. Animals were then monitored for the appearance of 
symptoms including diarrhoea, lethargy, pilo-erection and weight loss. Symptoms were 
scored on a numeric scale, where 0 represented no symptoms (no diarrhoea, active and no 
weight loss), and 3 represented severe disease (diarrhoea, weight loss, reduced activity and 
obvious lethargy). Animals were caged in IV-C units (Tecniplast UK), with sterilised bedding 
and ad libitum access to food and water. All handling of infected animals was carried out in 
a biosafety cabinet.  
 
2.3. Chapter 4 – B. subtilis probiotics 
 
2.3.1. Strain preparation 
B. subtilis PXN21 is one of 14 strains in the commercial product BioKult (Probiotics 
International Ltd). The strain was obtained from NCIMB (www.ncimb.com) where it is 
registered as NCIMB strain 30223. Spores of this strain were prepared as described 
previously (Harwood & Cutting 1990). Pure suspensions of spores were obtained using 
lysozyme treatment to remove vegetative cells. Phase bright microscopy was then used to 
visually assess spore suspension for presence of vegetative cells or debris. If debris 
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remained in suspension, spores were washed in sterile H2O until suspension only contained 
spores as seen under the microscope. Counts of spores were made using serial dilutions on 
solid DSM agar. Spore stocks were stored at -20°C until use. 
 
2.3.2. Probiotic dose regimen 
Mice: Assessment of probiotic treatment in animals used female C57Bl/6 mice (Charles 
River, UK) aged 6-8 weeks. Probiotic doses were delivered via orogastric gavage as 
stipulated by treatment group (Table 2.1). One dose was delivered per animal per day. 
 
Table 2.1. Study groups for probiotic treatments 
Study Regimen 
Pre vs. post infection treatment Daily dose of 1x109 spores. Pre infection 
treatment for 7 days prior to infection. Post 
infection treatment for 7 days post infection. 
Dose response Daily dose of either 1x107 or 1x109 spores for 
7 days post infection. 
Viability Daily dose of either 1x109 live spores, heat 
killed spores or vegetative cells for 7 days 
post infection. 
 
Susceptibility to infection was induced by antibiotic treatment. In colonisation experiments, 
a single o.g. dose of clindamycin (30mg/kg) was used one day prior to o.g. infection with 
104 R20291 spores. To achieve required severity of infection, C. difficile strain VPI10463 was 
used in probiotic treatment studies. Antibiotic treatment as described by Chen and 
colleagues (Chen et al. 2008) was delivered via o.g. dosing followed by infection with 104 
VPI 10463 spores. Animals were monitored for appearance of symptoms, with faecal 
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samples and weights recorded daily. Animals were culled at the clinical end point of 
disease, which was considered when animals lost 20% of original body weight.  
 
2.3.3. Hamster challenge 
Golden Syrian hamsters weighing approximately 100g were obtained from Charles River. 
Animals were housed individually in IVC units with sterilised bedding and had ad libitum 
access to sterilised food and water. A single oral dose of clindamycin (30mg/kg) was used 
to induce susceptibility to C. difficile infection. 24 hours after clindamycin treatment, 
animals were infected using 100 spores of C. difficile 630. Pre-treatment with B. subtilis 
PXN spores consisted of 5x oral daily doses of 1 x 109. Post treatment doses were delivered 
every 12 hours after infection. Animals were monitored for appearance of symptoms, and 
culled as clinical end point of infection was reached, based on severity of symptoms.  
 
2.3.4. Cytokine ELISAs 
Murine macrophage cell line RAW264.7 were grown to 70% confluence in 12 well plates 
(Corning, NY, USA) in DMEM (Sigma, MO, USA) growth medium supplemented with 10% 
foetal calf serum (FCS), incubated at 37°C, 5% CO2. Wells were washed twice with fresh 
growth medium and then medium containing 107 spores per ml was added to cell 
monolayers. Cells were incubated with spores for 24hrs before growth medium was 
removed for use in assays. Detection of cytokines in the medium was carried out using 
commercial ELISA kits (eBioscience) for IL-6 and TNFα according to manufacturer’s 
instructions.  
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2.3.5. Histology 
C57Bl/6 mice (Charles River) were culled three days post infection with C. difficile. Colon 
and caecum were removed from animals that had received probiotic treatment either pre 
or post infection, using non-treated animals as control for apparent tissue damage. Tissue 
was also taken from non-infected mice. Contents of the tissue were carefully washed out 
and tissues were fixed using 4% paraformaldehyde (PFA). Tissues were then sectioned, 
fixed on slides and stained with hemotoxylin and eosin (H&E) (TUPI manufacturing, 
Woodbridge, UK). Appearance of tissue was assessed under the microscope once stained 
and images were taken using associated camera and software (GT Vision, Haverhill, UK).  
 
2.3.6. Toxin binding assay 
1x109 B. subtilis PXN21 spores were washed with 0.1M PBS (pH7) and then pelleted by 
centrifugation in Protein LoBind tubes (Eppendorf). The supernatant was removed and 
pellet was resuspended with PBS containing commercially purified C. difficile toxins (AbD 
Serotec) to a total volume of 500μl. The spore suspension was incubated with gentle 
agitation for 12hrs at 4°C. Spores were pelleted by centrifugation and washed three times 
in PBS to remove unbound toxin. Spore coats were then extracted using an SDS-DTT buffer 
described elsewhere (Harwood & Cutting 1990). Spore coat extracts were run on a 7% SDS-
PAGE gel then were transferred to a nitrocellulose membrane for detection of toxins by 
western blot.  
 
 
Chapter 2  Materials and methods 
 
 
52 
 
2.3.7. DotBlot assay 
Female C57Bl/6 mice were infected with 104 C. difficile VPI spores following treatment with 
an antibiotic cocktail as used previously. Daily o.g. doses of 1x109 B. subtilis PXN spores 
were given to mice post infection, totalling two doses before tissue was harvested. Mice 
were culled 48hrs after infection and the caecum removed intact with contents. The 
caecum was then split open longitudinally and the contents washed out carefully with 1ml 
PBS. The contents were placed in a Protein Lobind tube (Eppendorf), pelleted by 
centrifugation and washed 3x in PBS to remove unbound toxin. The resuspended pellet was 
washed through a cell strainer (Corning, NY, USA) to remove solid caecal matter but allow 
spores to remain in suspension. Spores were pelleted and spore coats were extracted as 
described elsewhere (Harwood & Cutting 1990). BioDot apparatus (BioRad, Hemel 
Hempstead, UK) was then used to transfer proteins in samples to a nitrocellulose 
membrane as per equipment instructions. Briefly, 3 layers of Whatman filter paper and the 
membrane were pre-soaked in TBS and layered onto the BioDot base. The equipment was 
screwed together and a vacuum applied. Wells were washed with 100μl TBS before 
samples were added to wells. Once samples had run through the membrane, wells were 
washed 2x using TBS. The membrane was then removed from the apparatus and toxins 
were detected using western blot.  
 
2.3.8. Detection of toxins by western blotting 
The membrane was blocked in 5% skim milk TBS for 1hr at RT. Monoclonal α-mouse 
primary antibody (AdB Serotec) for toxin detection was added, either α-toxin A or α-toxin B 
at 1/500 dilution for 1 hr. The membrane was then washed 3x in TBS + 0.05% tween. The 
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secondary antibody, HRP labelled α-mouse IgG was incubated for 1hr at RT. Following 
incubation with antibodies, the membrane was washed 3x in TBS + 0.05% Tween and 
developed using a chemiluminesence developer.  
 
2.3.9. TLR2 expression 
RAW264.7 macrophage cells were seeded to 6 well plates (3 x 105) in antibiotic free media 
(DMEM supplemented with 10% foetal bovine serum) and incubated for two days until 
around 70% confluent. Cells were washed twice with fresh growth medium, then media 
containing infecting agent (spores or vegetative cells of B. subtilis PXN21 1 x 107/ml) were 
added to the wells. Cells were incubated with these media for 4 hours before washing two 
times more with sterile PBS. Macrophages were then lysed in situ and homogenised by 
passing cell lysate through a 20 –gauge needle five times. Total RNAs were then extracted 
using RNeasy kit (Qiagen, Netherlands) as per manufacturer’s instructions.  Purified RNA 
samples were stored at -80°C. 
 
RNA samples from RAW264.7 macrophages were reversed transcribed to cDNA using  
Precision qScript Reverse Transcriptase kit (PrimerDesign, Southampton, UK) using  
reaction conditions as follows: annealing step 65°C for 5mins, extension step 55°C for 
20mins, 75°C for 15 mins and stop at 4°C. qPCR was carried out using primers targeted at 
the TLR2 gene (Table 2), with β-actin used as a reference gene. A three step PCR cycle was 
used with following conditions: 95°C for 15secs, 55°C for 30 secs, 72°C for 10 secs. Cycle 
was repeated 50 times. Melt curves were produced at the end of each PCR to check primer 
efficiency. Rotor-Gene 6000 series software was used for analysis of real time data, and 
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relative gene expression was calculated using relative standard curve method, with β-actin 
as a reference gene.  
Table 2.2. Primer sequences 
Gene Forward 5'-3' Reverse 5'-3' 
TLR2 AAGAGGAAGCCCAAGAAAGC CAATGGGAATCCTGCTCACT 
β-actin AGAGGCAAATCGTGCCTGAC CAATAGTGATCATCACCTGGCCCT 
 
2.3.10. Antibiotic resistance 
Six hour cultures of Bacillus strains were diluted in Muller-Hinton broth to an OD600 of 0.15, 
which gives a concentration of approximately 107 cells/ml. This was used as inoculating 
culture for the assay. In a 96 well plate (Corning, NY, USA) 150µl of Muller-Hinton broth 
was added to each well. Antibiotics were diluted in the plate, in 2 fold dilutions from 
64µg/ml to 0.03µg/ml. Control wells contained 150µl Muller-Hinton broth without 
antibiotics. 10µl of inoculating culture was added to each well and plates were then 
incubated overnight on a shaking platform at 37°C. After overnight incubation, OD600 of 
each well was read using a spectrophotometer (Molecular Devices). Wells that showed an 
increase in OD600 were considered positive for bacterial growth. Wells with no increase in 
OD600 were considered negative for bacterial growth, and so were recorded as inhibitory 
concentrations. Assay was carried out with duplicates, and was run three times in total. 
Values for minimum inhibitory concentration (MIC) were compared with those published in 
guidelines from the European Food Safety Authority (EFSA) and the Clinical Laboratory 
Standards Institute (CLSI). 
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2.4. Chapter 5 – BclA spore coat proteins 
 
2.4.1. Growth and sporulation curves 
BHI broth was inoculated with a single colony from an overnight streak plate. For growth 
curves, a 1ml aliquot was taken from the culture every hour. OD600 was recorded using a 
spectrophotometer. Sporulation samples were taken every 24 hours. Total bacterial counts 
were produced using serial dilutions of culture plated on BHIS agar supplemented with 
0.1% sodium taurocholate. For spore counts, samples were heated at 60°C for 30 minutes 
to kill vegetative forms before plating on sodium taurocholate supplemented BHIS agar.  
 
2.4.2. Germination Assays 
Spore germination was carried out in a 96-well plate (Greiner Bio-One) and germination of 
spores was measured by the percentage change in OD600. HistoDenz-purified spores at an 
OD600 of ~0.8–1.0 (~1 X 108 ml-1) were pelleted by centrifugation (10,000g, 1min) and 
suspended in 1ml of BHIS supplemented with 0.1% sodium taurocholate (germinant) or 
0.1% sodium chenodeoxycholate (inhibitor). The initial OD600 was recorded and then 
measured at 1 minute intervals over 30 minutes using a microplate reader (Molecular 
Devices, Spectramax plus). Plates were shaken in between readings to keep spores in 
suspension. % fall in OD was determined as (recorded OD600 at time interval/initial OD600) X 
100. The experiment was performed three times. For preparations of sonicated spores ten 
cycles of sonication were used as described elsewhere (Permpoonpattana et al 2011b). 
Using phase contrast microscopy a plateau in optical density readings was confirmed to 
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correspond to 100% of spores losing phase brightness after incubation with the germinant. 
Loss of phase brightness indicates initiation of the germination process.  
 
2.4.3. Spore adhesion to hydrocarbon (SATH) assay 
This method is described elsewhere (Huang et al. 2010), with minor alterations.  HistoDenz-
purified spores were washed in 1M NaCl and then suspended in 0.1M NaCl for assay. 500μl 
of spore suspension was added to 800μl n-hexadecane (Sigma, MO, USA) and vortexed for 
1min. Samples were then incubated for 10 min at 37°C with mild agitation, vortexed (30s) 
and optical density (OD) (OD600nm) recorded. % hydrophobicity was determined from the 
OD of the original spore suspension (A1) and the OD of the aqueous phase after incubation 
with hydrocarbon (A2) using the equation: %H = [(A1 - A2)/A1]. 
 
2.4.4. Mouse colonisation experiments  
Groups of C57LB/6 mice (6-8 weeks old; female) were given a single o.g. dose of 
clindamycin (30mg/kg in 0.1ml of sterile water). Groups of animals were kept in IV-C units 
(with sterilized food, bedding and water). Animals were infected with different doses of 
R20291, 630Δerm or bclA1- mutant spores five days later since the 630Δerm and bclA1 
mutant strains are sensitive to clindamycin. Spore counts in freshly voided faeces were 
determined by ethanol treatment (20 min incubation of homogenate in 100% ethanol) and 
plating on BHISS supplemented with supplemented with cefoxitin and cycloserine 
(Bioconnections, Knypersley, UK). 
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2.4.5. Hamster infections 
Golden Syrian Hamsters (female, ~100g; Charles River) were given doses of clindamycin 
(30mg/kg) by oral gavage, then infected 5 days later with C. difficile spores. Histodenz-
purified spores of wild type (630Δerm) and the bclA1 mutant were given by oral gavage, at 
doses of either 102, 103 or 104. Hamsters were then monitored for signs of disease 
progression and culled as individuals reached the clinical end point, based on severity of 
symptoms. Time to the clinical end point was recorded for each individual. Statistical 
significance between groups was calculated using a student’s t-test. Caecum samples were 
examined for toxin B by ELISA as described in general methods. To assess spore counts 
caeca were removed from euthanized animals and added to protease inhibitor buffer 
(Thermo Scientific). Tissue was roughly homogenized; aliquots ethanol treated (100%, 20 
minutes) and serially diluted on BHISS agar plates. Plates were incubated anaerobically for 
48 hours before counting colonies. Number of spores/gram was calculated based on the 
weight of the original sample.  
 
2.4.6. Resistances 
Spores purified using Histodenz (Sigma, MO, USA) were tested for resistance to heat, 
ethanol and lysozyme. 
Heat: 107 spores suspended in sterile water were incubated in a heat block at 60°C for 1hr 
and 24hrs. After incubation spores were placed on ice before serial dilutions were made. 
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Ethanol: 107 spores were suspended in 70% ethanol and incubated at room temperature 
with agitation for 1 or 24 hours. After incubation period, spores were washed once with 
sterile water and serially diluted for enumeration of surviving spores. 
Lysozyme: 107 spores were suspended in a lysozyme buffer (20mM Tris HCl (pH8.0) and 
300mM NaCl) and incubated with agitation at 37°C. One set of spores was incubated in a 
buffer containing 250µg/ml lysozyme for 10 minutes and a second set was incubated in a 
buffer containing 1mg/ml lysozyme for 20 minutes. Spores were washed once in ice cold 
sterile buffer before serial dilutions were made.  
Serial dilutions for enumeration of surviving spores were plated on BHI agar supplemented 
with 0.1% sodium taurocholate. Plates were incubated in anaerobic conditions at 37°C for 
48 hours before colonies were counted.  
Chapter 3  Mucosal immunisation with a spore vaccine 
59 
 
Chapter 3 
Mucosal Immunisation with a 
Spore Vaccine 
 
3.1. Introduction 
 
3.1.1. Clostridium difficile vaccines 
Current vaccine research is focused on the use of toxoids and recombinant proteins to elicit 
an immune response against C. difficile, via production of a systemic response. Injection of 
these proteins will initiate immune responses and in many reported cases results in 
production of toxin neutralising antibodies (Sougioultzis et al. 2005; Tian et al. 2012; Wang 
et al. 2012). Protection in animal models has been reported and there are several potential 
vaccine candidates at various stages of development. The most advanced of these is a 
toxoid based vaccine from Sanofi Pasteur (Alkan et al. 2012), which entered in to Phase III 
clinical trials in the summer of 2013 having been granted fast track designation by the 
American FDA in 2010. Currently, no product has yet come to market for human use.  
The appearance of so called hypervirulent strains (Pépin et al. 2004) highlights the 
complexity of treatment and control of C. difficile. Strain evolution (Stabler et al. 2009) and 
development of antibiotic resistance (He et al. 2012) have contributed to CDI becoming 
increasingly difficult to treat. Multiple virulence factors for the pathogen have been 
described (Voth & Ballard 2005; Janoir et al. 2007; Rupnik et al. 2009), including toxins and 
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cell associated proteins. The best described virulence factors are Toxins A and B, two major 
exo-toxins produced by C. difficile during vegetative growth. However, the importance of 
these two toxins has been a point of contention between some researchers (Lyras et al. 
2009; Kuehne et al. 2010). It should be noted that not all strains produce the two major 
toxins, as naturally occurring virulent strains of A-B+ C. difficile have been reported (Johnson 
et al. 2003; Drudy et al. 2007b). Understanding of CDI cases is further complicated as 
incidences independent of the hospital setting, including community associated CDI, are 
now more commonly reported (Warny et al. 2005; Khanna et al. 2012). It is necessary to 
find treatments that will resolve infections of the most tenacious nature, beyond the scope 
of the few antibiotics that are used currently. Development of a successful vaccine would 
significantly help in reducing the burden of disease caused by C. difficile and reduce the 
pressure of reliance on antibiotics.   
Previous work from the Cutting Laboratory resulted in the development of a vaccine 
candidate that focuses on production of a local mucosal response  (Permpoonpattana et al. 
2011a). This approach differs from the majority of current studies that use parentally 
delivered toxoids and focus on production of systemic immune responses (Giannasca & 
Warny 2004). Mucosal vaccination will be the focus of this thesis chapter, as the generation 
of immune responses and potential methods for use of a B. subtilis spore based vaccine are 
evaluated. The spore based vaccine candidate, referred to as PP108 (Permpoonpattana et 
al. 2011a), confers a 75% protection rate in a hamster model of infection. Furthermore, 
PP108 produces both mucosal and systemic neutralising antibodies against toxins. In the 
same study, it was demonstrated that antibodies against a C. difficile toxin A fragment also 
recognised toxin B and that antibodies against toxin A were able to provide protection 
against an A+B+ strain of C. difficile in challenge studies. 
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3.1.2. Stimulation of mucosal immune responses 
Classical vaccination using parenteral delivery of antigens aims to protect against C. difficile 
infection by systemic generation of toxin neutralising antibodies. The primary site of 
infection is the colon, where the pathogen can rapidly multiply and cause damage to the 
lining of the gut through production of toxins. The mucosal surface of the gastrointestinal 
tract is therefore the main site of contact with the developing infection. In order to 
produce an immune response local to the site of infection, alternative vaccination 
strategies need to be investigated. Use of mucosal routes of immunisation, for example, to 
produce localised immune responses could harness the powerful potential of the immune 
tissue in the G. I. tract – the Gut Associated Lymphoid Tissue (GALT). Specific to C. difficile, a 
localised immune response could increase protection of the gut during infection through 
neutralisation of toxins at the surface where damage is most likely to occur.  
While an important factor of vaccine development includes identifying immunogenic 
antigens, a significant component involves finding a safe and efficient way to deliver that 
antigen (Levine & Sztein 2004). By demonstrating the potential of a particular delivery 
approach with one successful vaccine, this could be applied in development of further 
vaccines. Specific to this, development of vaccines that exclude the use of needles 
represents an important step in producing vaccines for use in the developing world. Spread 
of infectious disease through misuse of needles could be prevented by development of an 
alternative delivery system for vaccinations.  A novel vaccine must also be relatively cheap 
if it is to be widely distributed and used. With C. difficile, groups with increased risk of 
developing the infection have been identified such as the elderly and patients receiving 
antimicrobial therapy (Loo et al. 2011), representing a considerable target market for a 
vaccine protecting against C. difficile.  
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Immunisation can result in stimulation of different responses – systemic and mucosal. 
Protection through systemic responses relies on production of circulating antibodies 
against the pathogen in question. Mucosal responses involve production of secreted 
antibodies at mucosal surfaces. Localised mucosal immunisation can lead to antigen 
specific IgA production at remote mucosal sites (Kunkel & Butcher 2003), allowing 
immunisations to be delivered at easily accessible surfaces to produce a response at an 
alternative site. This property of mucosal immunisation is limited however, in that specific 
routes will not produce responses at all mucosal sites. For example, oral dosing can 
produce immune responses in the gut, but the effect is limited when considering the 
mucosa of the respiratory system (Holmgren & Czerkinsky 2005). 
 Mucosal surfaces form a physical barrier against invading pathogens and IgA is the 
predominant immunoglobulin isotype in mucosal secretions (Fagarasan & Honjo 2003). 
When pathogens penetrate this layer it is potentially the first point of contact with the 
host’s immune system. Therefore a response local to the infection could aid in preventing 
colonisation by potential pathogens, rather than relying on the systemic response to be 
initiated once an infection has proliferated. If a vaccine can stimulate both mucosal and 
systemic responses the host is provided with two levels of protection, increasing the 
potential for success of the immunisation.   
The focus on mucosal immune responses stems from CDI occurring in proximity to the 
mucosal surfaces of the G.I. tract (Goulding et al. 2009). The mucosal surface is a prime 
target for stimulating a local immune response, with mucosal responses classically achieved 
through intra nasal (IN) or oral dosing (Neutra & Kozlowski 2006). 
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Oral dosing is a relatively simple process, requiring little equipment or specialist knowledge 
for delivery of doses, unless a patient is unable to swallow independently. This route does 
however require large amounts of the antigen in question to initiate a response, as dilution 
of the antigen can occur before contact with the appropriate site. Oral dosing is also often 
linked to tolerance mechanisms (Weiner et al. 1994; Azizi et al. 2010). Additionally, the oral 
route requires passage through the stomach and G.I. tract, which contain various extremes 
of pH plus exposure to enzymes that could cause degradation to antigens before reaching 
the target mucosal surface.  
Nasal dosing requires smaller amounts of antigen as delivery to mucosal surface is more 
direct, but use of this route has associated safety concerns. Reports of antigen and 
adjuvant trafficking to the central nervous system (CNS) have caused issues with regard to 
use of IN dosing as a delivery route for immunisations. Some adjuvants used in vaccines are 
able to bind to olfactory nerve fibres and can potentially reach the olfactory lobes of the 
brain (van Ginkel et al. 2000; van Ginkel et al. 2005). A review of an intranasal influenza 
vaccine used in Switzerland reports on occurrences of  Bell palsy cases associated with use 
of the vaccine (Mutsch et al. 2004). Currently an intranasal vaccine for influenza is licensed 
in the USA, but it is recommended only for individuals aged 2-49 years and it is advised that 
individuals with underlying health conditions do not receive the vaccine (CDC 2013c). 
Intranasal routes do, however, provide a reliable route for generation of mucosal immune 
responses in the respiratory tract (Kweon et al. 2002).  
A disadvantage of mucosal immunisation is the higher quantity of antigen required when 
compared to parenteral immunisation. (Holmgren 1991; Neutra & Kozlowski 2006). The 
potential cost of a vaccine is a significant consideration in vaccine development; increasing 
the amount of antigen used will escalate costs (Levine & Sztein 2004). Quantification of 
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antigen necessary for parental vaccination is relatively simple, but when using mucosal 
pathways to deliver antigens the process is more complex (Ogra et al. 2001). Increased 
amounts of antigen are required in mucosal immunisations for several reasons. Firstly, 
mucosal routes of immunisation can cause degradation to the antigen through harsh pH or 
presence of enzymes, the effects of which is difficult to quantify. Secondly, methods of 
antigen delivery for mucosal immunisation such as orogastric dosing do not deliver the 
antigen directly to the mucosal surface. The lack of direct delivery results in dilution of the 
antigen, so a higher dose of antigen is required to counteract the reduced amount of 
antigen reaching the final targeted mucosal site.  
 
3.1.3. Sublingual antigen delivery 
Sublingual (SL) comes from Latin – literally ‘under the tongue’. Sublingual immunotherapy 
(SLIT) has been used previously in allergy therapy as it has been shown to successfully 
modulate immune responses (Durham et al. 2006; Moingeon et al. 2006). Sublingual based 
therapies have also been reported in delivery of pain relief drugs and vitamin supplements 
(Zhang et al. 2002). Recently SLIT has been applied to use in vaccines as an alternative 
route of delivery for antigens. A group in Korea (Song et al. 2008) have developed a 
successful influenza vaccine based on sublingual delivery of antigens and induction of a 
mucosal immune response through this route. More recently, the same group have used B. 
subtilis spores as a mucosal adjuvant in a H5N1 vaccine study (Song et al. 2012), 
demonstrating the successful use of B. subtilis for invoking protective immune responses.  
Delivery of antigens to mucosal surfaces using orogastric and intranasal routes can result in 
both local and systemic responses (Permpoonpattana et al. 2011a; Song et al. 2012). 
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Sublingual (SL) dosing of antigens has also been demonstrated to produce both mucosal 
and systemic responses (Cuburu et al. 2007) and has several benefits over the orogastric 
and intranasal routes. SL dosing of antigens allows delivery straight to the mucosa in the 
oral cavity, bypassing the stomach and G.I tract where the antigen could be destroyed or 
damaged. SL dosing also enables a reduction in the amount of antigen used as the delivery 
of the dose to the mucosal surface is more precise. As yet, no safety concerns have been 
reported with this method of antigen delivery (Song et al. 2008). With regard to the 
mechanism behind sublingual immunisation, studies investigating the immune responses 
associated with sublingual delivery of antigens suggest the involvement of Langerhans cells 
and submucosal dendritic cells in uptake of the antigen (Noirey et al. 2000; Kweon 2011). 
The cervical draining lymph node has been identified in several studies as the primary site 
of antigen presentation in sublingual immunisations (Song et al. 2009; Kweon 2011).  
 
3.1.4. Bacillus as vaccines 
Bacillus subtilis spores have been used in studies by the Cutting group as vehicles for 
delivery of antigens to mucosal surfaces in order to elicit immune responses. Display of an 
antigen on the surface of these spores can be accomplished by either of two methods: the 
antigen can be absorbed on to the spore surface (Huang et al. 2010), or the strain can be 
genetically engineered to express the antigen fused to existing spore coat proteins (Isticato 
et al. 2001; Mauriello et al. 2004; Duc et al. 2007). Successful generation of systemic and 
local immune responses has been shown using several different spore bound or expressed 
antigens, including C. perfringens alpha toxin and the TTFC (tetanus toxin fragment C) 
antigen from C. tetani (Huang et al. 2010). 
Chapter 3  Mucosal immunisation with a spore vaccine 
66 
 
One of the most recently developed B. subtilis based vaccines is the PP108 spore vaccine 
for CDI (Permpoonpattana et al. 2011a). PP108 was produced using genetic modification to 
express a fragment of the C. difficile toxin A protein fused to coat proteins (cotB-A26-39 and 
cotC-A26-39), facilitating expression on the spore coat. The fragment A26-39 is taken from 
the carboxy-terminal repeat domain of toxin A that is involved in cell binding (Figure 3.1B). 
The spore vaccine candidate has previously been demonstrated to confer a 75% protection 
rate in a hamster model of infection (Permpoonpattana et al. 2011a). Furthermore, the 
study demonstrated that PP108 produces both mucosal and systemic neutralising 
antibodies against toxins.  
The advantages of using B. subtilis spores are that the spores are relatively simple to 
produce in large quantities and are also heat stable (Nicholson et al. 2000). The intrinsic 
heat stable nature of B. subtilis spores has been shown to extend to antigens expressed on 
the spore coat. Specifically, tetanus toxin fragment C (TTFC) expressed on the spore surface 
was shown to be effective at producing protection even after spores were lyophilised and 
stored for 12 months (Lee et al. 2010). B. subtilis also demonstrates a history of safe human 
consumption through use as a probiotic supplement (Hong et al. 2005). 
This thesis will investigate use of the PP108 vaccine in a murine model of infection. More 
detailed study of immune responses can be carried out using a murine model, as reagents 
for murine studies are more readily available than those for hamster studies. Results from 
previous work with the PP108 vaccine candidate have been used to argue for the 
importance of a mucosal response in protection against CDI (Permpoonpattana et al. 
2011a). Continuing on this track, investigation of alternative routes for stimulation of 
mucosal responses is of interest as the established oral route can be associated with 
development of tolerance to the antigen (Song et al. 2008). The work in this thesis will 
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compare two mucosal routes for immunisation: oral and sublingual. Nasal delivery of 
antigens will be avoided to rule out complications from potential infections that could 
occur with this method of delivery and the use of live bacteria.  
 
3.1.5. Experimental Objectives 
As yet, no vaccine is available to protect against C. difficile infection. Interactions of C. 
difficile with the immune system have yet to be fully elucidated; this makes understanding 
what is required for a successful vaccine candidate difficult to define.  This study will use 
mucosal delivery of a spore based vaccine, with the aim of investigating the role that 
mucosal responses play in protection from infection. This will address the hypothesis that a 
localised mucosal response is key in preventing the symptoms of C. difficile infection.  
The PP108 strain is genetically modified (GM) to express a C. difficile antigen. Use of GM 
organisms introduces a host of issues, including ethical and regulatory concerns. Therefore, 
the efficacy of the vaccine strain will be assessed when spores are inactivated with 
formaldehyde. Use of inactivated viruses and antigens is common practice in production of 
vaccines and also helps avoid the issue of using live GM organisms. Use of the inactivated 
spores will contribute to two aspects of this study. Firstly, non-viable spores serve as a 
control for viable spores that have potential to germinate during dosing and transit through 
animals. PP108 expresses the C. difficile antigen on its spore coat so when the spore 
germinates and enters a vegetative phase it will no longer display the antigen. This 
introduces the possibility that a potential response from the animal would be reduced if 
vaccinated with live spores. Germination of B. subtilis spores has been shown to occur in 
vivo (Hoa et al. 2001), but in this study did not attempt to quantify levels of germination 
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linked to the different immunisation routes. Secondly, excluding the possibility of 
germination allows responses to be attributed solely to the spore as a vaccine rather than 
implying some probiotic effect by use of live organisms. Inactivation of spores also enables 
the comparison of immunogenicity between live and inactivated spores.  
A murine model of infection will be used to quantify immune responses generated by oral 
and sublingual delivery of the PP108 spore vaccine. Mucosal IgA and systemic IgG titres will 
be measured alongside analysis of responses based on cytokine profiles from vaccinated 
animals. Levels of protection generated by immunisations will be assessed in a challenge 
experiment.  
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3.2. Results 
 
3.2.1 Production of PP108 spores 
PP108 spores for use in immunisations were prepared on solid media in batches. Each 
batch was tested for consistent expression of the antigen by extracting the spore coat and 
probing with αA26-39 after SDS-PAGE separation for presence of the antigen (Figure 3.1A).  
 
  
Figure  3.1. Display of antigen on spore coat: A) Western blot showing expression of A26-
39 on spores of PP108 (CotB-A
26-39
 and CotC-A
26-39
 ). Extracted spore coat proteins from 
PP108 were probed with antibodies to rA26-39. Lane1 is proteins extracted from PY79 
spore coat. Lanes 2-9 are spore coat proteins extracted from individual batches of B. 
subtilis PP108 spores. B) Functional domain of toxin A, including the glycotransferase 
(black), cysteine protease (grey), translocation  (white) domains and repetitive sequences 
involved in cell binding. The A26-39 region expressed on PP108 spores is shown in blue. 
(Figure adapted from Permpoonpattana et al. 2011) 
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Inactivation of spores in suspensions of 109 or 1010/ml was achieved with use of 4% 
formaldehyde solution at 37° (Figure 3.2). Viability of formaldehyde treated samples was 
tested by plating on DSM agar to produce colonies from any remaining viable spores. This 
inactivation is not 100% effective or permanent. When samples were tested after storage 
at 4°C for one week, a slight increase in spore recovery from inactivated samples was 
observed. In preliminary work two incubation periods were tested for inactivation 
efficiency (Figure 3.2A and 3.2B). The two hour spore incubation was more successful than 
the 24 hour time period. Considering success of inactivation and practicality of the 
protocol, a four hour inactivation period was used for preparation of the spores for 
immunisation doses (Figure 3.2C). Spores for use in immunisations were always used 
immediately after inactivation, but levels of viable spores were tested after seven days to 
assess the long term success of the protocol (Figure 3.2C).  
Groups of Balb/C mice were used to compare immunogenicity of PP108 spores in the live 
and inactivated state. Mice received two doses of the spores delivered via IP injection and 
then serum samples were tested for specific IgG responses (Figure 3.3).  Elevated levels of 
α-A26-39 specific IgG show that when PP108 spores were delivered via the I.P. route live 
spores produce the highest systemic response against the antigen. Formaldehyde 
inactivated spores produce a lower response after two doses compared with live spores. 
Gluteraldehyde inactivated spores (Russell 1990) were the least immunogenic although a 
low antigen specific response was detected. Formaldehyde inactivation is classically 
associated with vaccine production for antigen stabilisation (Rappuoli 1994) and spores 
inactivated by this method generated a detectable immune response so use of this method 
was continued in this study.  
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Figure 3.2. Recovery of PP108 spores following inactivation with A) 1% formaldehyde and B) 
4% formaldehyde. In preliminary inactivation studies, spores were incubated at 37°C for either 
2 or 24 hours, then washed 3x in cold sterile H
2
O then serial dilutions were plated on DSM agar 
to enumerate surviving spores (white bars). After 7 days of storage in H
2
O at 4°C, surviving 
spores were enumerated again on DSM agar (grey bars). PP108 spores used in immunisations 
were inactivated using C) 4% formaldehdye and 4 hours incubation at 37°C.  
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Figure 3.3. Immune response to PP108 spores in Balb/C mice, with spore doses (2x10
9
 PP108 
spores/dose) delivered via I.P injection. Doses were given at intervals of two weeks with 
αA26-39 specific IgG response measured by ELISA from serum samples taken ten days after 
delivery of each dose. F denotes inactivation of spores with a solution of formaldehyde, G 
denotes inactivation with gluteraldehyde. 
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3.2.2  Protection from CDI in immunised mice 
Groups of mice received doses of live or inactivated PP108 spores for assessment of oral 
and sublingual immunisation. After the final vaccine dose, mice were infected with C. 
difficile R20291 to evaluate levels of protection. Symptoms during infection were assessed 
(Figure 3.4) by ranking on a numerical scale (1-3) where a score of three represents the 
most severe symptoms, and one represents no symptoms. Weights were also recorded to 
monitor loss of body mass during infection (Figure 3.5).  
Mice immunised sublingually with inactivated spores were the best protected based on 
symptoms displayed during infection (Figure 3.4B). No severe symptoms were recorded 
over the seven day monitoring period of infection (Table 3.1). In terms of total symptoms 
(1 observation per day over 6 days) 14% were recorded as mild (symptoms recorded as two 
on the numerical scale) compared with a protection rate of 86% (Table 3.1) demonstrating 
that sublingual immunisation with inactivated spores was the most successful within the 
groups tested. Mice receiving PP108 live spores via the sublingual route also showed some 
protection against development of symptoms (Figure 3.4A) although not to the same level 
as mice receiving inactivated spores via the same route. The occurrence of symptoms 
scored as severe was 2.8%, and 38.9% of observed symptoms were recorded as mild giving 
a protection rate of 58.3% (Table 3.1). 
Live spores delivered orally demonstrated protection against CDI symptoms although not 
to the same extent as inactivated spores delivered via SL route (Figure 3.4C). Protection 
rate was similar to the sublingual live spore immunisation group at 55.7%, with 41.5% mild 
symptoms and 2.8% severe symptoms recorded (Table 3.1). Oral delivery of inactivated 
spores gave the lowest level of protection (Figure 3.4D) with 47.2% of recorded symptoms 
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at 1 on the numerical scale. Mild symptoms were recorded at 50.5% and severe symptoms 
2.8% (Table 3.1).  
In PY79 control groups (Figure 3.4E), 22.3% of symptoms recorded were severe. Mild 
symptoms were recorded at 36.2%, with 41.5% displaying no symptoms. 
All groups immunised with PP108 spores displayed protection from the severe symptoms 
of CDI.  
As the strain used in this study (R20291) does not cause fatal infection in the study model, 
body mass of the animals during the period of infection was used to provide a clear 
representation of the animal’s health status. Weight data (Figure 3.5) replicates the results 
from symptom profiles (Figure 3.4), with the group receiving inactivated PP108 spores 
sublingually displaying the least weight loss over the course of infection (Figure 3.5A). 
Groups immunised with live spores either via the oral or sublingual route show a similar 
profile, mirroring the results from the symptom profiles. The most loss of body mass over 
the course of infection was recorded in groups given oral doses of inactivated spores 
(Figure 3.5B), which also showed the lowest rate of protection. All immunised groups 
displayed higher percentage body mass over infection than the PY79 control groups, 
confirming symptom profile data that all animals receiving PP108 in any form showed 
greater protection against CDI symptoms than non-immunised animals.  
Analysis of faecal samples show that though mice appear protected against symptoms of 
CDI by immunisation (Figure 3.4) this only extends to the symptoms of the disease. 
Immunised groups did not display resistance to colonisation by C. difficile. When 
enumerating levels of C. difficile spores in faecal samples (Figure 3.6), there was no 
difference between spore content in samples from immunised mice when compared to 
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PY79 control groups (p>0.1). The presence of C. difficile in such high numbers in the faecal 
samples shows that although animals are not as susceptible to the disease, colonisation is 
not prevented and shedding of high numbers of spores still occurs.  
Table 3.1.  Severity of CDI symptoms in immunised mice: C57BL/6 mice were infected with 
CD R20291 spores following immunisation with PP108 spores. Symptoms of CDI were 
scored according to a numerical scale where 1 = healthy, 2 = mild disease symptoms and 3 = 
severe symptoms. % of symptoms displayed in each category is calculated over the 
monitoring period of 7 days demonstrating the frequency of each class of symptom within 
this time period. Symptoms were recorded on 6 days with 6 mice per group, so an 
occurrence of 2.8% represents one event.  Groups (n=6) are denoted by the route and 
spores used for immunisation, where F represents formaldehyde inactivated spores. No 
animals reached clinical end point in this study so group numbers remain constant. Refer 
also to Fig. 3.4.  
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Figure 3.5.  % Body mass over period of infection post A) sublingual or B) oral 
immunisation. Groups received live PP108 spores (○), inactivated PP108 spores 
(Δ) or PY79 spores (□). Animals treated with an antibiotic cocktail to induce 
susceptibility to C. difficile infection and then infected via o.g. gavage with 10
4
 CD 
R20291 spores. Body mass following infection was calculated as % of body mass 
at point of infection. 
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3.2.3 Immune response in immunised mice 
Mice received a total of five immunisation doses, with blood and faeces samples taken 
throughout the dose regimen to analyse immune response generated over time.  
αA26-39 specific secreted IgA was measured from faecal sample extracts. Both groups of 
sublingually immunised mice demonstrate increasing and comparable levels of IgA over the 
period of immunisation until the final dose where levels of specific IgA are higher in the 
group receiving inactivated spores (Figure 3.7A). The difference between viable and non-
viable spores is not statistically significant at any time point however (p>0.1). Levels of IgA 
from faecal samples in sublingually immunised groups are not significantly different from 
Figure 3.6. Average maximum C. difficile spore content in faecal samples from 
immunised mice. C57BL/6 mice were infected with CD R20291 spores following 
immunisation with PP108 spores. Daily faecal samples were taken and C. 
difficile spore content assessed by serial dilution on BHISS agar. Average 
maximum – faecal samples were taken daily, and the maximum faecal spore 
count from individuals within a group was recorded over the infection period (1 
week). The mean maximum count was then calculated for each group. 
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PY79 control groups until after the third dose of spores. After fourth and fifth doses in 
sublingual groups, the specific IgA response is significantly higher than respective control 
groups receiving PY79 spores (p<0.05). Mice receiving oral doses of live and inactivated 
PP108 spores also demonstrated presence of an antigen specific mucosal response (Figure 
7B). Faecal IgA levels are comparable between the oral PP108 immunisation groups and 
significantly higher (p<0.05) than PY79 control groups after the third immunisation dose. 
Levels of IgA are significantly higher (p<0.05) in immunised groups compared with 
respective PY79 control groups after fourth and fifth dose of PP108 spores. Both routes of 
spore delivery require the same number of doses to induce a significant mucosal IgA 
response.  
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Figure 3.7. A26-39 specific IgA measured from faecal sample extracts using an ELISA. 
Seroconversion is shown over the immunisation schedule time period in groups 
receiving A) sublingual or B) oral doses. Doses contained live PP108 (Δ), live PY79 (□), 
inactivated PP108 (○) or inactivated PY79 (X). * indicates where immunised groups are 
significantly different from PY79 control groups (p<0.05) 
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Immunisation via mucosal routes gives the potential for systemic responses to be 
generated concurrently with localised mucosal response. Therefore, antigen specific IgG in 
blood serum samples was measured throughout the immunisation period to ascertain if a 
systemic response was also generated. Results show that immunisation via both routes 
stimulated an antigen specific IgG response (Figure 3.8), although this is slightly higher in 
the sublingual groups (Figure 3.8). Mice immunised sublingually with live PP108 spores 
demonstrated the highest levels of specific IgG after the fourth dose of spores (Figure 
3.8A). Sublingual immunisation with inactivated spores generated a limited response and 
specific IgG level decreased after the fourth dose of spores. Despite this decrease, 
immunised groups displayed a significantly higher response than PY79 control groups from 
the third dose (p<0.05). Orally dosed groups also demonstrated an antigen specific IgG 
response. Similar to sublingual immunisation groups, groups immunised orally with 
inactivated spores also show a decrease in response at the final doses (Figure 3.8B). 
Following the pattern set by sublingual groups the lives spore doses generate the highest 
IgG responses. In both sublingual and oral groups an effect greater than in the PY79 control 
groups is not achieved until after the third immunisation dose. After the fourth and fifth 
dose of spores responses from immunised groups were higher than PY79 control groups 
(p<0.05), although this is an aspect of the vaccine that could be improved on as levels 
remain quite low. At the same time points (fourth and fifth dose) IgG titre from animals 
dosed with live PP108 spores was higher than those dosed with inactivated spores 
(p<0.05).  
The timing of immune response generation is similar between mucosal and systemic 
responses, both requiring at least three spore doses to generate a significant response.  
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Figure 3.8. A26-39 specific IgG from serum samples was measured using ELISA. 
Seroconversion is shown over  the immunisation schedule in groups receiving A) sublingual 
or B) oral doses. Doses contained live PP108 (○), live PY79 (□), inactivated PP108 (Δ) or 
inactivated PY79 (X).  Significance when immunised groups are significantly higher than PY79 
control groups * = p<0.05, ** p<0.01.  
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To ascertain immune responses at the point of challenge, responses at the end point of the 
immunisation schedule were analysed. In all immunised groups both sublingual and oral 
delivery of PP108 initiated a significant mucosal immune response (Figure 3.9) in 
comparison to PY79 control groups (p<0.001). In sublingually immunised groups inactivated 
PP108 generated a higher specific IgA response than live PP108 (Figure 3.9A), however this 
is not statistically significant at this sample size (p=0.09). In oral groups (Figure 3.9B) 
inactivated PP108 spores also generated only a marginally higher response than live spores 
(p=0.5). Immunisation with inactivated spores delivered sublingually resulted in the highest 
specific IgA response (Figure 3.9A). This result supports the theory that a mucosal response 
is required for protection against CDI. Levels were not significantly different between 
PP108 immunised groups, however, so it is likely that there are several mechanisms that 
contribute to generating protection against CDI. 
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Figure 3.9. A26-39 specific IgA measured from faecal sample extracts of A) sublingual and B) 
orally immunised mice at the end point of immunisation schedule (after 5th dose) using an 
ELISA. Groups were immunised with live spores (white bars) or formaldehyde inactivated 
spores (grey bars). Significance when immunised group response is significantly higher than 
respective PY79 control group, * = p<0.05. 
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Figure 3.10. A26-39 specific IgG levels in serum samples from A) sublingually and B) orally 
immunised mice at end point of the immunisation schedule (after 5th dose), measured with 
an ELISA. Groups of mice received either live spore doses (white bars) or formaldehyde 
inactivated spores (grey bars). Significance when immunised group response is significantly 
higher than respective PY79 control group, * = p<0.05, ** = p<0.01 
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Final IgG titres were assessed in immunised groups (Figure 3.10). In all immunised groups 
the specific IgG response was significantly higher than in PY79 controls (p<0.01 for all 
groups except inactivated oral doses, where p<0.05). While these results are significant, the 
levels of IgG reported could be an area of improvement for this vaccine candidate. In 
comparison of live and inactivated PP108 spore immunisations, live spores were 
responsible for higher levels of specific IgG with both delivery methods (sublingual p=0.004, 
oral p=0.03). This deviates from mucosal response data where the highest response was 
generated by sublingual dosing of inactivated spores (Figure 3.8A). The highest specific IgG 
titre was found in the group immunised sublingually with live spores (Figure 3.10A).  
To control for the difference in dose regimen between oral and sublingual groups, included 
in the study were groups that received the oral dose split over three doses (Figure 3.11). 
This enables detection of any changes in response due to dose regimen rather than the 
immunisation route. No significant difference was evident in mucosal IgA responses from 
these oral control groups (p>0.1). With the oral use of inactivated spores a slight overall 
decrease in IgA levels was observed in control groups (Figure 3.11B). This observation was 
not replicated in the live spore control group (Figure 3.11A).  
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Figure 3.11. Sublingual control groups; A26-39 specific IgA measured from faecal sample 
extracts of mice immunised with A) live and B) inactivated PP108 spores, at the end point 
of immunisation schedule using an ELISA. Sublingual doses were administered in three 
consecutive daily doses due to volume restrictions in dose method, so oral control groups 
received PP108 spores over three consecutive days (X3) in separate doses to replicate the 
sublingual delivery. No significant differences exist between groups.  
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Similarly to mucosal responses, IgG responses in sublingual dosing control groups, where 
the oral dose was split over three days, were assessed (Figure 3.12). In groups receiving live 
spores, specific IgG levels between groups were not significantly different (p>0.1). With the 
use of inactivated spores in immunisations, the sublingual control group receiving the oral 
dose as three consecutive daily doses showed higher specific IgG levels (p<0.05) than both 
sublingual and standard oral dosing (Figure 3.12B). Levels of antigen specific IgG were 
lower in groups immunised with inactivated spores than in groups immunised with live 
spores.   
IgG subclass ratio was calculated from IgG1 and IgG2a content of serum samples from 
immunised mice. This ratio is classically used to give an indication of whether an immune 
response demonstrates a TH1 or TH2 bias. 
According to the ratios calculated, neither delivery route displayed consistency towards a 
particular bias in response (Figure 3.13). Sublingual doses with live spores produced an IgG 
subclass ratio indicative of a TH2 response, while a decreasing ratio in the sublingual 
inactivated spore group represents a TH1 response (Figure 3.13A). Ratios from oral groups 
showed contrasting results, with live spores producing a lower subclass ratio indicative of a 
TH1 response, but inactivated spores producing a higher ratio (Figure 3.13B).  
  
Chapter 3  Mucosal immunisation with a spore vaccine 
89 
 
 
  
Figure 3.12. Sublingual control groups; A26-39 specific IgG levels in serum samples from mice 
immunised with A) live and B) inactivated PP108 spores at end point of immunisation schedule, 
detected via ELISA. Sublingual doses were administered in three consecutive daily doses due to 
volume restrictions in dose method, so oral control groups were used, with dose delivered over 
three consecutive days (X3) in separate doses to replicate the sublingual delivery.  * shows a 
significantly higher IgG response, p<0.05. 
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Figure 3.13. IgG1:IgG2a ratios in serum samples from A) sublingual and B) orally 
immunised mice.  Ratios are shown over time course of immunisations, at 63 (white bars) 
79 (hatched bars) and 108 (grey bars) days post first vaccine dose (dpv).  
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To further analyse the response to this vaccination, spleen cells were isolated from 
immunised animals and stimulated in vitro with rA26-39 protein over 96hrs. The 
supernatants from stimulated cells were then analysed for cytokine content (Figure 3.14) 
using a flow cytometry kit optimised for this application (CBA kit, BD Biosciences). The 
dominant cytokine in all samples was TNFα, primarily a TH1 associated cytokine. Levels of 
IL-6 were lower in two groups: animals dosed sublingually with inactivated spores and the 
group that were immunised orally with live PP108 spores. Both these groups also 
demonstrated low IgG subclass ratios.  
Interestingly, IL-10 was only present in the supernatant of cells from mice immunised with 
live PP108 spores (Figure 3.14A and 3.14C). IL-10 plays a role in regulation of inflammatory 
responses and control of the TH1 response. Of note, IL-6 is a cytokine involved in 
stimulation of IgA responses. Groups immunised sublingually showed the highest levels of 
this cytokine, in particular animals receiving inactivated PP108 spores (Figure 3.14B). The 
sublingual inactivated PP108 group also showed the highest level of protection (Table 3.1) 
lending support to the hypothesis that development of mucosal immunity is important in 
protecting against CDI. The lowest protection rate was seen in animals that received oral 
doses of inactivated PP108 spores. This group also produced few cytokines, with TNFα 
being the only one of note (Figure 3.14D).  
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3.3. Discussion 
 
This work has shown the successful use of a spore based vaccine in generating both 
mucosal and systemic immune responses, resulting in protection against severe symptoms 
of CDI in a murine model. Of particular interest was how the route of immunisation and 
viability of PP108 spores affected the generation of an immune response. This will be 
discussed alongside the implications for development of mucosal vaccines.  
 
3.3.1. Induction of mucosal responses 
Development of a successful vaccine presents many challenges, from finding an effective 
antigen to the use of the correct adjuvant and employing the best dose regimen. This study 
has shown that with both sublingual and oral dosing, robust mucosal responses can be 
seen through production of antigen specific IgA.   
Immunisation with the PP108 spore vaccine induces a response against C. difficile toxin A, 
which is sufficient to provide protection against a strain producing both toxin A and B. 
Previous studies with this vaccine have shown that antibodies against the toxin A fragment 
additionally recognised toxin B (Permpoonpattana et al. 2011a). In the same studies, oral 
spore doses were shown to be a successful route and method for antigen delivery, resulting 
in generation of protection. Oral immunisation with the spore vaccine was demonstrated 
to be superior to the protection generated by injection of the antigen without a supporting 
adjuvant. Oral delivery of a vaccine is a well-documented route for production of a mucosal 
response, the oral poliovirus (OVP) vaccine an excellent example of this (Sabin 1985; 
Holmgren & Czerkinsky 2005).  However, the use of the oral route for delivery of a vaccine 
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has many potential pitfalls, including exposure of the antigen to extremes of pH and 
degradative enzymes as well as inaccurate delivery to mucosal surface. Development of 
tolerance to the antigen delivered via this route is also a potential issue. Tolerance to 
specific antigens that are present as part of our bodies or everyday diets for example, is 
required to keep the normal state of homeostasis within the GI tract. However, this 
mechanism could also allow specific antigens delivered as a vaccine to be ignored by the 
immune system. Therefore this needs to be taken into account especially when designing a 
mucosal delivery system for a vaccine. Investigation of alternative routes of immunisation 
will contribute to development of the vaccine in order to provide the best possible 
response. The work in this study has shown that sublingual dosing of the spore vaccine is a 
viable and in some respects a superior method of vaccine delivery. Sublingual delivery 
provides a more direct method of antigen delivery and reduces the exposure of the antigen 
to the potential degradation that transit through the G.I. tract is associated with. 
Comparison of protection rates in the challenge study showed that sublingually immunised 
groups had fewer symptoms than their orally immunised counterparts. More detailed 
comparison of the dose routes show that sublingual immunisation produces a comparable 
level of IgA response but also a higher titre of systemic antigen specific IgG. Sublingual 
doses use fewer spores: the total sublingual dose uses 6x109 spores compared to the 
4x1010 spores in an oral dose. Therefore higher responses are produced from significantly 
less vaccine presenting sublingual delivery as a more economical route for use of this 
vaccine. In the comparison of the two delivery routes, the data of this study present 
sublingual as the superior delivery route. The focus of this study was mucosal immunisation 
routes, so there is no comparison with a systemic based vaccination. This comparison, 
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however, would be of interest when considering the broader scope of the immunisation 
process. 
 
The importance of developing a vaccine to incorporate a mucosal immune response is 
highlighted by the current situation in CDI management. Antibiotics are becoming less 
effective and a vaccine would aid the control of this disease. However, despite the focus on 
parenteral immunisation there is currently no commercial vaccine product available for 
use. Perhaps a change of perspective for the development of vaccines is required. In a 
review on mucosal immunity and vaccines, studies show that other pathogens such as HIV, 
Human Papillomavirus, Vibrio cholerae and Mycobacterium species require a mucosal 
response for effective protection (Holmgren & Czerkinsky 2005). A study using mice with 
specific defects in their immune system suggests that generation of a mucosal response is 
important to protection from CDI, although not essential (Johnston et al. 2013). The 
authors noted that immunocompetence of the host will play an important role in the 
mechanism of protection during infection. This is an important factor in the development 
of a vaccine to prevent CDI, where the target population is elderly and likely to have 
reduced immunocompetence (Grubeck-Loebenstein et al. 2009). Understanding how C. 
difficile interacts with the host, especially immune interactions during infection will 
contribute towards defining the required response from vaccination. Longevity of immune 
responses from specific vaccines will also be of interest. 
Protection generated by immunisation with PP108 spores was highest in animals that 
received inactivated, sublingual doses. This group also demonstrated the highest level of 
IgA production. However, in this study, the highest IgA producers are not the highest IgG 
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producers. Sublingual delivery of inactivated spores gave better protection and higher IgA 
levels in immunised mice, but sublingual, live spores induced a higher IgG response when 
the groups are compared. As the highest level of protection is provided by the inactive 
spores in the sublingually immunised groups, it could be argued in this case that the 
production of IgA is the primary protective factor.  
Comparison of the orally immunised groups shows that live spores produce higher levels of 
IgG than inactive spores, despite similar levels of IgA being produced. Live spores in this 
case produce a higher protection rate, so while IgA production is important for protection, 
the more robust systemic response from live spores gave this group a boost in protection. 
Increased protection from live, orally dosed spores could also be attributed to a probiotic 
effect, as B. subtilis spores can colonise the mammalian gut. 
This result implies that the balance of the response generated by immunisation is 
important in providing protection. The results of this study do not allow either the mucosal 
or systemic response to be solely attributed to generation of protection. However, this 
does highlight the necessity to consider multiple aspects of the immune response when 
considering the success or mechanisms of a vaccine.  
 
3.3.2. Improving the vaccine  
Mucosal immunity is important in generating a local response at the site of infection and 
providing a barrier to invading pathogens. Production of IgA and innate mucosal receptors 
contribute to protection from infection at the mucosal surface (Fagarasan & Honjo 2003). 
Both routes of immunisation used in this study were shown to induce production of specific 
IgA in the GI tract. Results from the challenge study using C. difficile R20291 show that the 
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response generated in PP108 immunisations gave protection from the symptoms of 
infection. However, analysis of stool samples from immunised mice revealed that high 
levels of spores were present.  The PP108 vaccine does not prevent the colonisation of C. 
difficile in the murine model, so dissemination of infectious spores from infected animals 
can still occur. Risk of spreading the infection is reduced when symptoms are prevented, 
but colonised asymptomatic individuals form a carrier population that acts as a reservoir 
for C. difficile infection. A more comprehensive solution is required to fully control this 
disease, preventing colonisation so that reservoirs of C. difficile can be eradicated. The 
PP108 candidate vaccine uses a toxin antigen as a basis for protection, but the spore based 
delivery system could be extended. The spore vaccine model is a flexible platform and 
could be engineered to express more than one antigen allowing for a multivalent approach. 
A multivalent vaccine that could produce toxin neutralising antibodies and be active against 
colonisation would fully address the problem presented by C. difficile infection (Pechine et 
al. 2007). To reduce colonisation, a cell or spore based antigen is required for generation of 
a targeted immune response. The benefit of creating an immune response against the 
spore, which is the infecting agent in this disease (Deakin et al. 2012), is that the infection 
can be curtailed before progression to fulminant disease. A vaccine focusing solely on 
neutralisation of toxins does not address the complex nature of this infection. For example, 
in a comparison of different C. difficile strains in a hamster model it was shown that 
infection with a non-toxigenic strain resulted in some gut pathology (Buckley et al. 2013). 
Gut injury in the absence of toxin production highlights the need to think of C. difficile 
infection in broader terms than just the ability to produce toxins.  
The mechanism of this vaccine platform uses fusion with the spore coat proteins CotB and 
CotC for display of antigens. However, the recent discovery of the crust layer, covering the 
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spore coat of B. subtilis may hinder the display of the antigens (McKenney et al. 2010). 
Therefore to improve the vaccine by increasing exposure of the antigen, a ΔcotXZY strain of 
B. subtilis could be used, as this mutation would prevent formation of the spore crust. 
 
3.3.3. Mechanisms of immune stimulation 
The highest rate of protection against CDI symptoms in this study was reported in animals 
that received sublingual doses of inactivated PP108 spores. This method of immunisation 
resulted in production of significant amounts of antigen specific mucosal IgA and systemic 
IgG as well as induction of TNFα and IL-6 cytokine responses. Activation of the mucosal 
immune system in the gut is key to the premise of this study. However, care needs to be 
taken with balance of immune responses as over stimulation of inflammatory responses 
across mucosal surface could occur (Cerutti et al. 2011). An inflammatory environment 
could aid CDI rather than preventing this infection.  
Using data analysing IgG subclasses and in vitro cytokine production a T cell response bias 
towards either a cellular (TH1) or humoral (TH2) response can be assigned. B. subtilis spores 
have previously been shown to produce a broad range of responses when dosed either 
intranasally or oro-gastrically (Barnes et al. 2007; Huang et al., 2010). No consensus in type 
of response is apparent between either routes of dosing or viability of the PP108 spores. 
This implies that mechanisms behind oral and sublingual routes for immunisation could use 
different pathways despite both having a mucosal basis. Alternatively, inactivation of the 
spores could also result in a variation in the mechanism employed in generating an immune 
response. A consistent pattern of IgG subclass ratio and cytokine expression would make 
identifying important mechanisms for protection more straight forward, but it is evident 
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from these data that generalisations between different mucosal routes cannot be made. It 
should also be pointed out that IgG levels, while significantly higher than the control 
groups, were quite low. It could be that low levels of IgG potentially confound results.  
Cytokine expression profiles of stimulated splenocytes from immunised mice were also 
included in the analysis of immune responses. In vitro experiments showed that only 
groups that had received live PP108 spore immunisations produced detectable levels of IL-
10. The group with the highest level of protection received inactivated spores, and 
demonstrated no production of IL-10. These observations suggest that this cytokine is 
unlikely to be required for protection but more likely to be associated with a probiotic 
effect (Hart et al. 2004; Di Giacinto et al. 2005). However, links between probiotics and 
immune modulation are likely to be strain specific so conclusions from other studies should 
be considered carefully. Links to a probiotic effect raises the question of whether the PP108 
strain can also colonise the murine gut during immunisation doses and exert effects 
through this means. Colonisation of the PP108 strain was not a focus of this study, but B. 
subtilis spores have previously been shown as able to germinate and reproduce in the 
murine G.I. tract (Hoa et al. 2001). The presence of IL-10 in the groups immunised with live 
spores is of interest, with particular reference to regulation of homeostasis. IL-10 is an anti-
inflammatory cytokine that is thought to be essential for immunoregulation in the GI tract. 
Indeed, IL-10 has been proposed as an option for treatment of dysregulatory bowel 
conditions such as Crohn’s Disease and IBD (Steidler et al. 2000; Braat et al. 2006). It should 
be noted that delivery of IL-10 to the required region is one of the issues in developing this 
as a treatment. Induction of IL-10 in treatment of colitis is also linked with use of some 
strains of probiotic or commensal bacteria (Di Giacinto et al. 2005; Pils et al. 2011). IL-10 is 
also noted for its ability to inhibit synthesis of pro inflammatory cytokines from regulatory 
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T cells, which in the context of C. difficile infection may be a property of the vaccine worth 
exploiting. The live spore groups did not display the highest levels of protection in the 
challenge study and only groups immunised with the live spore vaccine displayed 
production of IL-10 from stimulated splenocytes. However, a mechanism that has potential 
to reduce or control an inflammatory response should be a consideration in the delivery of 
this vaccine candidate.  
Detection of IL-6 was interesting as it is linked to IgA production (Ramsay et al. 1994). Mice 
immunised sublingually with inactivated PP108 spores showed both the highest level of 
protection and highest IL-6 production. This indicates that inducing production of IL-6 could 
be an important factor for this vaccine strategy, strengthening the argument for 
importance of a mucosal response (Johnson et al. 1995; Stubbe et al. 2000; 
Permpoonpattana et al. 2011a). TNFα was generated by all groups but was lower in 
sublingual inactivated spore group suggesting that increased levels of this pro inflammatory 
cytokine may hinder generation of protection.  
 
3.3.4. Immobilisation of antigen 
Interestingly, significant protection was demonstrated with the use of inactivated spores. 
Use of inactivated spores allows the vaccine strain to be used without issues associated 
with the use of genetically modified (GM) organisms (HSE 2007). In assessment of spore 
inactivation protocol, it was shown that formaldehyde is an effective agent for inactivation. 
Gluteraldehyde was investigated as an alternative sporicidal agent to formaldehyde (Power 
& Russell 1990; Tennen et al. 2000), but gluteraldehyde inactivation appeared to reduce 
immunogenicity of PP108 spores. The incubation time of spores in the formaldehyde 
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solution is linked to the success of inactivation. Treatment over 24 hours with 4% 
formaldehyde was less effective than shorter incubations, potentially due to the stability of 
formaldehyde in solution at 37°C. When inactivated spores were stored at 4°C and then 
tested for viability, it was shown that complete inactivation was not permanent, with an 
increase in spore recovery after a week. The increase in recovery was minimal but in a 
commercial product, this observation would need addressing to avoid a reduction in the 
amount of antigen present. As the spore vaccine is a GM organism, use in a commercial 
setting would require complete and permanent inactivation in order to avoid regulatory 
issues associated with GM organisms. It is also possible that the in vivo environment would 
encourage reversal of the inactivation and germination of spores could occur, although this 
was not studied in this work.  
Spores inactivated with formaldehyde are unlikely to germinate so it is unlikely that 
protection from the immunisation with inactivated PP108 spores relies on a probiotic 
mechanism. Orally delivered inactivated spores showed the lowest rate of protection in 
this study however, implying a benefit of live spores when utilising the oral route of 
delivery. Germinating spores may contribute to interactions with the microflora in the gut, 
increasing protection through a probiotic action. It is also possible that live spores 
germinate (Hoa et al. 2001) and could remain in the gut for a prolonged period going 
through vegetative growth cycles. This would allow for increased exposure to the antigen 
when spores are produced from vegetative growth. Persistence in the gut of the PP108 
strain was not investigated in this study, so prolonged exposure to the antigen is purely 
speculative. Sublingual delivery of the vaccine avoids swallowing so does not rely on 
probiotic mechanisms to aid protection and the increased protection rate suggests that 
inactivation with formaldehyde increases the immunogenicity of the PP108 spores. 
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Formaldehyde inactivation results in the stabilisation of antigens (Rappuoli 1994), 
potentially aiding interaction with immune cells and therefore the induction of an immune 
response. Use of non-viable spores has the added benefit of not interfering with existing 
microflora as spores will be unable to germinate and initiate vegetative growth. 
 
3.3.5. Vaccine delivery regimen 
The method of sublingual dosing used in this study lead to an interesting observation with 
regard to importance of dose regimen. In mice, small body size means that sublingual doses 
are limited by volume. This meant that sublingual immunisation doses were delivered in 
separate doses over three days (3 x 2x109 spores). A control group for oral dosing was 
added to the study, dividing delivery of the oral dose over three days (3 x 1.3x1010 spores). 
This alteration of the oral dose regimen resulted in an increased specific IgG response. This 
effect was significant with inactivated spores demonstrating that spores do not need to be 
viable, but that optimal dose regimens will be different for live and inactivated spores. The 
increase in IgG response with smaller, more frequent doses emphasises the importance of 
validating the dose regimen. More frequent exposure to smaller amounts of the antigen 
could be used as a method of boosting immune response in the case of this vaccine 
candidate. Timing of immunisation doses has been linked to the development of 
immunological memory (Bakke et al. 2004) and should be considered an important 
optimisation factor in vaccine development.  
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3.3.6. Use of a CDI vaccine 
This study has shown that the PP108 spore based vaccine can provide protection against 
symptoms of CDI. Use of mucosal delivery routes is a key aspect of the study and provides 
several benefits. Use of needles is avoided in the delivery of this vaccine and both systemic 
and mucosal aspects of the immune system are activated. The spore based delivery system 
serves as a stable and safe adjuvant for the antigen that avoids the use of traditional toxin 
based adjuvants can have associated safety issues (van Ginkel et al. 2000). 
Sublingual delivery of this vaccine has several benefits over the oral route. Firstly, fewer 
spores are used to create a similar or improved immune response. This reduces the cost of 
a potential product as the same amount of spores would be able to produce more doses of 
the vaccine. Secondly, the ease of dosing is increased. Oral dosing is a simple procedure, 
not requiring medical professionals for administration, but if patients have difficulty 
swallowing this could present a complication. Sublingual doses are placed under the tongue 
to be absorbed by the associated mucosa, eliminating the need for swallowing a tablet or 
liquid dose. The global scheme for the eradication of polio seems a grand comparison to 
make with the need for an effective C. difficile vaccine but it does highlight the importance 
of easy delivery of a vaccine. The eradication scheme has been so successful in part 
because of the minimal expertise required for delivery of a dose, to the point where 
vaccinations can be carried out by volunteers with little or no medical training (Koinange et 
al. 1973; Hull et al. 1997). Having more people able to give the vaccine means more people 
can be reached with the vaccine. The issues now faced in completing the eradication 
program are mostly political, although vaccine derived poliovirus outbreaks are a concern 
(Kew 2012). C. difficile will be difficult to eradicate as a human pathogen, as reservoirs of 
infection are currently poorly defined (Walker et al. 2012). However, definite risk factors 
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associated with the disease and vulnerable populations have been identified (Johnson 
2009; Loo et al. 2011), so those most in need of the vaccine can be focused on. The 
population most at risk of CDI are elderly, immune-compromised and often have other 
underlying health issues. CDI is most commonly associated with occurrence in hospitals. 
This presents a clear sub sect of individuals who would benefit from receiving a C. difficile 
vaccination. While a recent study suggests that transmission within hospitals is not as 
common as previously thought (Walker et al. 2012), C. difficile remains a key nosocomial 
pathogen even if the source of infection is not the hospital environment. Ideally, 
immunisation of individuals would be carried out before admission to hospital or a 
healthcare facility. This would aid prevention of CDI, whether the infection was contracted 
from the hospital or due to opportunistic infection by C. difficile carried asymptomatically 
prior to hospitalisation. Immunisation of the population on a larger scale would be 
expensive but could contribute to reducing reservoirs of carriers.  To facilitate 
immunisations prior to hospital stays, therefore enabling protection to be in place before 
entering a health care environment, patient out care facilities or even pharmacists could 
prescribe and deliver the vaccine.  
In summary, the results of this study show that both oral and sublingual routes of 
immunisation are promising options for use with the PP108 spore vaccine. Sublingual 
dosing presents an encouraging method for delivery of antigens. This study raises questions 
about the importance of different aspects of the generated immune response in protection 
against C. difficile. 
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3.4. Conclusion 
 
3.4.1. Generation of protection from symptoms of CDI 
The work presented in this chapter builds on a previous study, which focused on 
developing a vaccine candidate that produced mucosal responses against CDI 
(Permpoonpattana et al. 2011a). Results from immunisation of mice in this work have been 
used to demonstrate that both systemic and mucosal responses are generated when the 
PP108 spore based vaccine is employed. It should be noted however that while significant 
levels of IgG were produced in immunised animals, levels could be improved. Protection 
was also generated against symptoms of CDI in a murine model. Comparison of the two 
mucosal delivery routes showed that the two methods are similar in their ability to produce 
an immune response. Sublingual immunisation however, resulted in a greater level of 
protection in the murine model. The effect of inactivating the spore vaccine was especially 
interesting. When inactivated spores were delivered via the sublingual route a higher level 
of protection was generated than with use of live spores delivered by the same route. The 
effect, however, appears to be route specific as inactivated spores via the oral route gave a 
poor level of protection in comparison. This indicates that with live oral delivery, a certain 
aspect of the protection could be attributed to a probiotic mechanism. 
Analysis of immune responses generated by the PP108 spore vaccine show that the 
resulting protection is likely due to multifaceted interaction with the immune system. 
Interactions and results vary depending on the method of immunisation. Unravelling the 
complexities of the immune response required for protection against CDI is still an ongoing 
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process. This study however, highlighted the potential for development in mucosal vaccine 
research.  
 
3.4.2. Developing immunisation strategy 
The immune response produced by the PP108 vaccine is based on the toxins of C. difficile, 
but it should be noted that variations in toxin gene have been reported between different 
strains. Indeed, toxinotyping is one method of differentiating between strains (Rupnik et al. 
1998). Multiple strains need to be used in challenge studies to ensure no restrictions in 
protection exist based on variation in toxin sequence.  
This vaccine produces immune responses against the toxins of C. difficile and therefore 
protects against the clinical manifestation of infection. However, it does not address the 
issue of colonisation by this pathogen. Induction of localised responses at the mucosal 
surface where C. difficile will be present could be used to protect not only from disease 
symptoms but also against colonisation. This would aid in reducing infections further by 
eradicating carriers from vulnerable populations so preventing the opportunistic nature of 
the pathogen. The PP108 vaccine could, for example, facilitate this strategy by being 
further engineered to display an antigen from the C. difficile spore coat. The ability to 
produce an immune response in the GI tract has been demonstrated in this study. If the 
response generated by a vaccine enabled eradication of C. difficile spores from the gut a 
huge step could be taken in control of this pathogen. 
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Chapter 4 
Suppression of Clostridium 
difficile infection using Bacillus 
subtilis spores 
 
This work has been published in part:  
Use of Bacillus subtilis PXN21 spores for suppression of Clostridium difficile infection 
symptoms in a murine model. 
Colenutt and Cutting, 2014. FEMS Microbiology Letters ePub 29th May. 
 
4.1. Introduction 
 
4.1.1. Clostridium difficile infection and current treatments 
Cases of Clostridium difficile infection (CDI) have reduced since the introduction of  
mandatory reporting in 2007 (Public Health England 2013), mostly due to increased 
awareness of the disease and improved control measures. However, this reduction in cases 
has now plateaued and new methods of tackling the infection are needed. Current 
treatment regimens depend on use of the antibiotics vancomycin and metronidazole. Up to 
30% of patients treated with these antibiotics experience relapses in infection (Barbut et al. 
2000; McFarland 2002) and reduced antibiotic susceptibility has been reported in 
hypervirulent strains (Pépin et al. 2004; Valiente et al. 2012). New treatments are therefore 
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required that are more effective at controlling this pathogen. A newly developed antibiotic, 
fidaxomycin, has been shown to demonstrate a reduction in cases of relapse when 
compared to treatment with vancomycin (Louie et al. 2011). This represents an important 
step in improving treatment of CDI, but that antibiotic usage is a principal risk factor for 
contracting this disease should be kept at the forefront of research for novel treatments. 
Rising levels of antibiotic resistance are increasing pressure on medical resources so 
alternative options should be considered where possible in order to reduce both use and 
reliance on antibiotics.  
C. difficile is listed as an urgent threat by the CDC based on the risk posed to human health 
by antibiotic resistance (CDC 2013a). This highlights the importance of alternative 
treatments for CDI and reducing reliance on antibiotic usage. Measures such as good 
antimicrobial stewardship would aid in control of cases (Vonberg et al. 2008). The issue of 
antibiotic resistance has received wide coverage in both scientific papers and the popular 
press. It is not a recent issue; scientists and doctors have expressed concerns about 
overuse of antibiotics for many years (Neu 1992). Despite this long term awareness, 
antibiotic resistance is an increasing problem and has the ability to cripple our medical 
system if managed wrongly. Firstly, inappropriate use of antibiotics can cause a patient 
more harm than good. Broad spectrum antibiotics will affect a significant amount of an 
individual’s normal microbial flora, not just the pathogen causing disease. This dysbiosis of 
the microbial flora leaves the patient vulnerable to other infections, C. difficile being an 
excellent example here. Secondly, exposure to high levels of antibiotics has potential to 
drive evolution of resistance in bacteria. Most of the hospital ‘superbugs’ are considered as 
significant threats due to wide scale antibiotic resistance making effective treatment 
difficult (CDC 2013a). C. difficile is a textbook example of this, with only two antibiotics in 
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mainstream use for treatment of CDI and the appearance of ‘hypervirulent’ strains linked 
with increased antibiotic resistances (Drudy et al. 2007a). Methicillin resistant 
Staphylococcus aureus (MRSA) is another example superbug, still listed as a ‘serious’ threat 
to public health by the CDC despite falling numbers of infection, due to the limited 
treatment options for this infection once antibiotic resistances are taken into account (CDC 
2013a). Certain antibiotics can also act as a predisposing factor to other infections; 
treatment with oral metronidazole and vancomycin (both used in treatment of CDI) 
increase the risk of colonisation and infection with vancomycin resistant enterococci (VRE), 
another nosocomial pathogen (Bhorade et al. 1999; Fridkin et al. 2001). 
 
One of the more successful alternative treatments for CDI is stool transplantation, or 
bacterial therapy (Rohlke & Surawicz 2010; Gough et al. 2011). This involves reconstitution 
and implantation of faeces from a healthy donor into the gut of an infected patient. This 
treatment has been reported to have high long term success rates at resolving CDI (Brandt 
et al. 2012; van Nood et al. 2013), but comes with associated safety issues. Recently this 
process has been refined, with researchers creating ‘synthetic stools’ where a specific mix 
of bacterial strains is used in place of a donor stool (Lawley et al. 2012; Petrof et al. 2013). 
Bacteriotherapy based treatments could provide a therapy that avoids the use of 
antibiotics, or at least serves to restore the protective balance of the normal gut flora post 
antibiotic treatment. Identifying specific strains of bacteria that show efficacy in alleviation 
of particular symptoms is especially relevant to production of synthetic stool treatments. 
Alongside the commensal strains typically used in these treatments, it is plausible that 
probiotic strains found to have specific effects against disease symptoms could be 
incorporated in these treatments.  
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4.1.2. Use of probiotics 
Probiotics are widely used in treatments and dietary supplements for purported health 
benefits. Lactobacillus and Bifidobacteria species are common in probiotic products, 
especially yoghurt or dairy based drinks that are supplemented with bacteria. The 
probiotics market is large, estimated to be worth upwards of €1.4 billion in Western Europe 
alone (Saxelin 2008). This includes probiotics used in animal feed, aqua culture and 
functional food for human consumption. Probiotics are incorporated into a variety of foods, 
including dairy products, meat products and cereals (Sanders & Marco 2010). Research into 
health benefits of probiotics has mainly focused on gastrointestinal disorders, but also 
extends to potential probiotic effects on skin conditions such as eczema and dermatitis 
(Boyle et al. 2008; Lee et al. 2008).  
The World Health Organisation (WHO) and the Food and Agricultural Organisation of the 
United States (FAO) jointly published guidelines for the evaluation of probiotics (Araya et 
al.2002) which state that probiotics are ‘live microorganisms which when administered in 
adequate amounts confer a health benefit on the host.’ This report also addressed the 
need for clearer information regarding probiotic products, setting a list of minimum 
recommendations for information regarding a potential probiotic strain. Safety concerns 
such as risk of systemic infection, deleterious metabolic activities, excessive immune 
stimulation in susceptible individuals and gene transfer from the probiotic strain are all 
factors for consideration. Recommendations for products included: 
1) Determination of antibiotic resistance patterns. 
2) Assessment of certain metabolic activities. 
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3) Assessment of side effects during human studies. 
4) Epidemiological surveillance of adverse incidents in consumers. 
5) Toxin production tests, if the strain is from a species that produces known 
mammalian toxins. 
6) Determination of haemolytic potential, if any. 
7) Risk of infectivity in immunocompromised individuals. 
The report provides a framework for generating information about probiotic strains, 
highlighting the importance of correct identification of strains and avoiding generalisations 
in attributing specific characteristics to specific strains. Certain groups of bacteria can share 
a key characteristic, such as S. thermophilus and L. delbrueckii, where  production of β-
galactosidase for treatment of lactose intolerance is evident as a characteristic of the group 
rather than the specific strains (de Vrese et al. 2001). However, the guidelines are firm on 
describing specific strains rather than making generalisations in order to avoid misleading 
claims. There have been cases in the past where probiotic products have been either 
mislabelled or found to contain different strains than the product claims (Cutting 2011). 
The presence of such guidelines should benefit the probiotics industry as well as providing 
transparency for the consumer. Health claims that are corroborated with scientific 
evidence and standardised information regarding products will ensure standards are 
introduced and maintained as the probiotics industry continues to develop. The FAO/WHO 
report however, was only published as a guideline document and carries no legal weight. 
With many probiotic products, or ‘functional foods’ making health claims that were 
subjected to little regulation, the European Food Standards Authority (EFSA) introduced 
new legislation in 2007 that enforced stricter controls on these products. These regulations 
stipulate that all health claims need to be substantiated with scientific evidence, provided 
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in dossiers for approval by EFSA (Asp & Bryngelsson 2008). Key to the approval of a health 
claim would be evidence from human trials; a level of testing many products would not 
have been subjected to previously. It is worth noting that these regulations apply only to 
Europe, and that in other countries, regulations, if they exist at all are less stringent. This 
led to some consternation within the industry, with a feeling of unfair competition from 
global markets outside of the EU that are not subject to such regulations. An important 
distinction to make at this point is that the EFSA regulations apply to products being sold as 
foods, not as medicines. Medical science could benefit from these regulations if significant 
research is pursued by companies marketing probiotics. Intestinal dysbiosis caused by 
antibiotic treatment is a risk factor for development of CDI (Chang et al. 2008; Johnson 
2009), with disruption of the gut flora  also linked with other conditions such as chronic 
inflammatory disorders including IBD and Crohn’s disease (Round & Mazmanian 2009). 
Probiotic research represents an avenue to establish how managing the gut flora could 
provide a novel approach to managing GI tract conditions both at acute infection and 
chronic condition level.  
Specific use of probiotics as a medical intervention is still in experimental stages, despite 
the concept of probiotics being well established. There is a shortage of large scale clinical 
evidence regarding whether probiotic treatment can be successful and in which situations 
use of specific probiotics could be could be applied. Results from existing studies suffer as 
poor study design presents a challenge in obtaining significant results. There are however, 
numerous published studies covering the use of a variety of probiotics (Table 4.1). 
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 In order for probiotics to be considered seriously as treatment options, more research is 
required. This means defining what is expected from probiotic strains in specific situations; 
are they to be used as supplementary treatments to antibiotics, used in prophylactic 
treatments, or applied as a primary treatment option? Clear objectives are required in 
order to make results easily applicable to a specific medical problem. The most beneficial 
studies will, if possible, demonstrate the mechanisms behind positive results. Elucidating 
probiotic mechanisms will aid successful application to existing medical problems. In all 
studies, emphasis needs to be placed on specific findings and avoiding generalisations to all 
use of probiotics. Where meta-analysis of data is used in the absence of larger scale 
studies, differences between studies need to be highlighted to avoid misleading 
conclusions. 
Suggested mechanisms of action for probiotics in the GI tract include stabilisation of 
epithelial tight junctions, action of bacteriocins, immunomodulation and effects on immune 
cell signalling, displacement of pathogens from epithelial surfaces and alteration of the gut 
pH, among others (D’Souza 2002; McFarland 2009; Islam et al. 2012). Guidelines from the 
WHO (Araya et al. 2002) encourage strain specific information with regard to probiotic 
treatments in order to clarify findings as mechanisms will differ between probiotic strains. 
Ideally, studies should include identification of the product used to strain level so that 
available information is as accurate as possible. Generalisations between all types of 
probiotics do not present a valid argument for or against use of probiotics. Distinct strains 
and genera of microorganisms will behave differently and have unique properties. It 
therefore cannot be assumed that mechanisms of action or the successes of one strain or 
product can be applied to others without evidence from relevant studies. The makeup of 
the microflora of the human gut will vary with factors such as age, diet and ethnicity 
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(Woodmansey et al. 2004; Wu et al. 2011; Bäckhed et al. 2012), so the structure of study 
populations should also be addressed before applying data from studies to the general 
population.  
While efforts are being made to regulate and substantiate claims made around use of 
probiotics in food products, scientific literature presents conflicting opinions as to whether 
probiotics are a viable option for treatment of gastrointestinal disorders (Miller 2009; 
Rowland et al. 2010). Available data sets are often limited and a number of general 
improvements to studies could be made to improve available data.  
1. Study design needs to be consistent. Comparison of different probiotics and how 
successful they are is difficult when large differences exist between studies testing 
them. Outcomes and parameters of studies need to be clearly defined; using CDI as 
an example, does a study address the issue of antibiotic associated diarrhoea (AAD) 
or CDI in particular? How is CDI confirmed? How long does the study last and is 
long term assessment included? Specifics of the study should be clear; the strain, 
the dose regimen and quantity of bacteria used are all important factors in 
developing treatments.  
2. Study populations. Clinical studies relating to treatment of a certain condition 
should include at risk populations. Stringent exclusion criteria to control the study 
can mean that those most likely to develop CDI are not included in the studies. 
Ideally, studies need to be conducted including individuals from populations at risk 
of CDI for proper analysis of clinical efficacy. Size of the study also needs to be 
considered in order to ensure robust and significant results.  
3. Controls. Where specific treatments are being tested, placebo groups have to be 
included for the data to be significant.  
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Fulfilling all of these requirements is challenging, especially when human subjects are being 
used in studies. The health of individuals needs to be the foremost consideration. Use of 
alternative models for in vivo studies is not a perfect solution, but may enable more 
sophisticated preliminary work. Without well considered studies, debate about probiotic 
use will continue due to lack of conclusive evidence on either side. 
A recent study investigating use of a microbial preparation in prevention of AAD and CDI 
(Allen et al. 2013) demonstrates consideration of the scale involved in such research. A 
total of 2941 participants from five separate centres took part in this randomised, placebo 
controlled study. All participants were over 65 and had recently been exposed to antibiotic 
treatment, representing a specific population vulnerable to CDI. The microbial preparation 
used in treatments was shown to not reduce frequency of AAD or CDI between treatment 
and control groups. The scale of this study allows robust conclusions to be stated. 
However, a mix of strains was used in the microbial preparation, which prevents clarity. For 
example, a strain in the mix may have beneficial effects, but not at the levels used in the 
composition of the probiotic.  No beneficial effect attributable to the probiotic treatment 
was reported in this study, but if there were, use of a mix of microbes could have led to 
difficulty in elucidating a mechanism. If microbial therapies are to be considered as viable 
treatment options, more studies of this scale need to be carried out. Refinement of study 
protocols will produce superior data for consideration.  
Research into Saccharomyces boulardii is a good example of the debate surrounding 
probiotic use. S. boulardii has been shown to have efficacy in reducing episodes of C. 
difficile associated diarrhoea (Surawicz et al. 1989). Further work demonstrated that this 
yeast produces a protease that can cleave the toxins of C. difficile, rendering toxins 
ineffective at binding to receptors (Castagliuolo et al. 1996). These results led to work 
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combining the probiotic strain with antibiotic treatments to focus on reducing relapses of 
infection (Surawicz et al. 2000). However, more recent studies by a different investigator 
(Pozzoni et al. 2012) have shown that this yeast is not effective at reducing cases of AAD. A 
key difference here is the condition being assessed. AAD is a general condition whereas C. 
difficile is a specific cause of diarrhoea. It is distinctions such as this that are important in 
clarifying the role that probiotics can play in treatments. There is also concern over the use 
of S. boulardii in patients that are immunocompromised, with potential for opportunistic 
infections (Muñoz et al. 2005). When conflicting cases like this occur, it is not surprising 
that debate exists around the use of or potential of probiotics in medical therapies.  
This thesis will use a Bacillus subtilis strain to investigate its potential as a probiotic in 
treatment of C. difficile. Bacillus probiotics are of particular interest in this work as they 
have the ability to form spores. Spores are an incredibly resistant, stable form of the 
bacteria allowing for simple storage and dosing of the probiotics (Cutting 2011). 
Refrigeration of spores is unnecessary due to their heat stable nature. These spores can be 
administered in an oral dose, eliminating the need for trained medical professionals or 
needles for delivery of treatment. A key point of interest with B. subtilis spores is their 
ability to absorb proteins to their spore coat. In previous studies (Duc et al. 2007; Huang et 
al. 2010), this ability has been used to absorb antigens for use in vaccines. In the context of 
C. difficile treatment, this ability draws a parallel to use of toxin binding resins (Hinkson et 
al. 2008; Weiss 2009). In a 2011 study investigating the use of B. subtilis as a vaccine 
delivery system (Permpoonpattana et al. 2011a), it was shown that wild type B. subtilis 
PY79 spores, administered orally, could prolong survival of hamsters infected with C. 
difficile. These results raised the question of whether spores of B. subtilis could be used as 
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a probiotic treatment against C. difficile infection. The work of this thesis aims to address 
this question.  
 
4.1.3. Use of animal models 
One of the key issues surrounding use of probiotics is the lack of standardised studies and 
trials. Use of human trials often results in complex results that stem from the complex 
medical histories of the patients involved. It is difficult to arrange a standardised study for 
an opportunistic disease that presents with different stages of clinical manifestation in 
individual patients. Use of animal models would provide a controlled method for 
preliminary exploration of probiotic strains. This type of study could then be beneficial in 
identifying how probiotics may be used before use in humans. If animal studies can provide 
elucidation of mechanisms behind probiotic action, application to human use should be an 
easier, more successful step. 
In the study of C. difficile, two species of animal model are available: the hamster and the 
mouse (Sambol et al. 2001; Chen et al. 2008; Goulding et al. 2009). These can be used to 
represent different aspects of the disease, with benefits and limitations present in each 
model.  
Mice are less sensitive to C. difficile infection than hamsters, with the severity of induced 
infection dependant on the antibiotic regimen and the strain of C. difficile used. Hamsters 
however, will succumb to fatal disease within 48 hours of infection with a toxin producing 
strain. Clear signs of disease are evident in hamsters, including diarrhoea, pilo erection, 
hunched posture and lack of responsiveness. Presence of toxins and bacteria can be 
confirmed using faecal samples. Hamsters are held as the gold standard for studies in C. 
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difficile infection, as the symptoms are similar to those displayed in humans. The short time 
period that hamsters can survive with this infection imposes a limit on studies using this 
model. The short window of survival prevents study of manifestations of infection such as 
the carrier state (Riggs et al. 2007; Lawley et al. 2009a), where individuals can be infected 
with C. difficile but not display symptoms. Furthermore, human disease is only fatal in 
severe cases, which calls into question the comparability of the hamster model with the 
human CDI condition. 
In mice, doses of multiple antibiotics are required to induce susceptibility to fatal C. difficile 
infection. Manifestation of disease is seen in a strain and dose dependent manner, which 
adds a level of complexity to studies using this model and perhaps makes this model more 
comparable to the human clinical situation. Infections can be monitored over several days 
rather than hours, meaning that studies have more scope to collect data. Multiple aspects 
of disease can be studied in the murine model, from asymptomatic colonisation to fatal 
disease, providing a much wider range of possibilities for study. The murine model is also 
more accessible, with associated reagents commercially available for use. This probiotics 
study will use primarily the murine model of CDI described by Chen and colleagues (Chen et 
al. 2008), but also includes data from a hamster study to broaden the base of the study’s 
findings.  
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4.1.4. Experimental Objectives 
This study will address the hypothesis that B. subtilis spores can be used as a probiotic 
treatment for disease caused by C. difficile infection. The suitability of this strain will be 
assessed prior to use as treatment of disease, in terms of safety and ability to survive in the 
GI tract. If successful in alleviating symptoms, this work aims to then investigate the 
mechanism behind the probiotic action.   
Use of a murine model of infection will provide a controlled platform to carry out 
preliminary probiotic trials. Many of the criticisms surrounding probiotic use are due to the 
lack of clarity and control in research meant to provide evidence for or against probiotic 
usage. While it was not possible to address all the points raised in the WHO report (Araya 
et al. 2002) or indeed fulfil the requirements set out by ESFA this study aims to provide 
clear preliminary evidence for the suitability of this strain as a treatment of CDI.    
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4.2. Results 
 
4.2.1. Suitability of probiotic strain 
From a single oral dose of 1010 spores, spores of the probiotic strain B. subtilis PXN21 can 
still be detected in the faeces up to two weeks later (Figure 4.1). Elevated levels of spores 
in faecal samples over a two week period demonstrate evidence of transient colonisation. 
The plateau in numbers between days three and six represents the ability of the strain to 
maintain levels by establishing a growth cycle before faecal spore levels decrease. Numbers 
of B. subtilis spores recovered from faecal samples were generally lower in antibiotic 
treated individuals, but not significant at this sample size. 
  Figure 4.1. Detection of B. subtilis PXN21 spores in faecal samples from C57Bl/6 mice. 
Groups (n=4) received either antibiotic cocktail treatment or no treatment prior to 
receiving a single oral dose (10
10
) of B. subtilis PXN21 spores. Faecal samples were 
collected and treated with ethanol to leave only spores viable in samples. Spore content 
was measured by serial dilutions of samples plated on DSM agar and the PXN21 strain 
was identified by colony morphology. 
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The B. subtilis PXN21 strain was also tested against a panel of antibiotics to ensure 
conformity with EFSA guidelines for the species. Minimum inhibitory concentration (MIC) 
breakpoints were compared to guideline points from both EFSA and CLSI. Control B. subtilis 
strains PY79 (lab stock) and NCIMB strain 3610 were tested alongside the study strain for 
comparison. Ampicillin is the only antibiotic tested where the MIC was higher than the 
recommended breakpoints. This result was replicated in the control B. subtilis strains used, 
implying an intrinsic resistance rather than a transmissible property. Experimental MIC 
breakpoints show that the B. subtilis PXN21 strain has no resistances of concern, all being 
lower than guideline points, so conforms to current legislature for use as an oral probiotic. 
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4.2.2. Colonisation resistance 
Non-fatal colonisation of C. difficile was induced in a murine model of infection by 
antibiotic treatment followed by infection with C. difficile R20291 spores (Figure 4.2). 
Levels of C. difficile spores present in faecal samples demonstrated that oral delivery of B. 
subtilis PXN21 spores both prior to and post infection had no significant effect on reducing 
C. difficile colonisation. In all groups, peak levels of spores were detected on day two post-
infection, and although C. difficile levels were highest in mice receiving no probiotic 
treatment, this was not significant (p = 0.1).  
  
Figure 4.2. Colonisation resistance. Susceptible C57Bl/6 mice were infected with 10
4
 C. 
difficile R20291 spores. Groups (n= 6)  were given daily doses of B. subtilis PXN21 
spores pre infection (◊), during infection (□) or no treatment (Δ). Faecal samples were 
collected daily and ethanol treated samples were serially diluted then plated on BHISS 
agar for enumeration of C. difficile spores. 
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4.2.3. Attenuation of symptoms in a model of fatal disease 
A study model utilising C. difficile strain VPI 10463 to induce a fatal infection in mice was 
used to assess the ability of B. subtilis PXN21 to influence the clinical outcome of infection.  
This model of infection utilised pre-dosing with a cocktail of antibiotics including 
vancomycin that was designed to mimic the clinical situation of antibiotic therapy in 
humans (Chen et al. 2008). PXN21 spores were administered to mice before and after 
infection with VP1 10463 and both pre and post infection treatment increased survival 
compared to non-treated animals (Figure 4.4A). Pilot studies showed that administration of 
PXN21 spores did not reduce the efficacy of vancomycin in treatment of CDI in mice (Figure 
4.3). Delivery of PXN21 spores prior to infection resulted in a survival rate of 41.6% while 
66.6% survival was achieved in animals treated post C. difficile infection (Figure 4.4A), this 
compared to a survival rate of 16.6% in non-treated groups. Interestingly, weight profiles of 
infected animals added further complexity to these results (Figure 4.4B). Animals that 
survived infection having received probiotic treatment prior to infection displayed less 
weight loss than those treated with PXN21 spores post infection. Post infection treated 
animals displayed a similar weight profile to the non-treated group, despite having the 
highest rate of survival.  
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Figure 4.3. Effect of PXN spore treatment on antibiotic treatment. Susceptible C57Bl/6 
mice (n≥ 6) were infected with 10
4 
C. difficile VPI 10463 spores. Groups received daily 
doses of oral vancomycin (100μg/dose), oral vancomycin (100μg/dose) with B. subtilis 
PXN21 spores (10
9
/dose) or no treatment. A) Survival was monitored over 7 days post 
infection. Both vancomycin treatments at 100% survival over 7 days. B) % weight change 
was calculated based on recorded weight throughout infection monitoring period 
compared to weight at point of infection. Weights were recorded daily over 7 day 
infection period. 
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Figure 4.4. Pre and post infection probiotic treatment. Susceptible C57Bl/6 mice (n≥ 6) 
were infected with 10
4
C. difficile VPI 10463 spores. Groups received either daily doses of 
PXN21 spores pre infection, post infection, or no treatment. A) Kaplan-Meier survival plot 
over seven days post infection. B) % weight change was calculated based on recorded 
weight throughout infection monitoring period compared to weight at point of infection. 
Weights were recorded daily over the 7 day infection period. All probiotic doses 
contained 10
9
 spores and were delivered orally. 
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Treatment with B. subtilis PXN21 spores was also used in a hamster model (Figure 4.5), 
although the methodology was adapted to fit with the differences with the model. CDI is 
fatal in hamsters, and the probiotic treatment does not prevent infection, so results were 
based on survival time. Average length of survival was increased slightly in animals pre 
dosed with B. subtilis PXN21 spores. Increased survival times were not statistically 
significant (p=0.7) but a trend of increased survival in hamsters pre dosed with B. subtilis 
PXN21 spores supported data from the murine model that pre dosing probiotics (Figure 
4.4B) has links to a successful probiotic mechanism. 
  
Figure 4.5. Survival time of hamsters infected with 100 C. difficile 630 spores. Pre-
infection group (□) received daily oral doses of 10
9 
B. subtilis PXN21 spores in the 5 days 
prior to infection. Post infection group (Δ) received oral doses of B. subtilis PXN21 
spores at 12 hour intervals post infection. N=6, each point on scatter plot represents 1 
animal. Blue lines show mean average survival time. 
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To provide further information for optimisation of dose regimen, further aspects of dose 
were considered, including dose size. Two doses were tested; the original 109 dose, and a 
100 fold reduction in this, using 107 spores per dose (Figure 4.6). Survival rate in both the 
probiotic treated groups was 66.6% seven days after infection (Figure 4.6A). Reduction of 
the number of spores per dose gave no change in the rate of survival but the progression of 
disease appeared slower. Disease progression reached the fatal stage at day three of 
infection in the 109 dose treatment group; however the first fatality did not occur until day 
five in the 107 dose group. Weight profiles appear to reflect this observation from survival 
data (Figure 4.6B). Loss of body mass occurs in animals given doses of 107 spores, but at a 
reduced level and at a later stage of the experiment. The data indicates less severe 
symptoms in the 107 dose group.  
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Figure 4.6. Dose response probiotic treatment. Susceptible C57Bl/6 mice (n≥ 6) were 
infected with 10
4
C. difficile VPI 10463 spores. Groups received either daily PXN21 spore 
doses of 10
9
, 10
7
, or no treatment. A) Kaplan-Meier survival plot over seven days post 
infection.  B) % weight change was calculated based on recorded weight throughout 
infection monitoring period compared to weight at point of infection. Weights were 
recorded daily over 7 day infection period.  
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4.2.4. Live B. subtilis spores are required for suppression of infection  
Administering PXN21 spores post infection was more effective in preventing CDI than pre-
dosing. Since killed spores have been shown to have adjuvant properties and can enhance 
the immunity of prototype vaccines (Barnes et al. 2007; Huang et al. 2010), the effect of 
spore viability on survival rate in mice administered PXN21 spores post infection was 
assessed. As shown in Figure 4.7A dosing of mice post infection with killed spores showed 
almost no improvement in survival rate. By contrast, dosing with live spores markedly 
improved the survival rate. As shown earlier (Figure 4.4A) treatment post infection with 
live PXN21 spores increases survival rate but did not induce an improvement in the weight 
profile of infected animals. To further support the need for viable bacteria in this 
treatment, when vegetative cells of B. subtilis PXN21 were used (Figure 4.7A) survival rate 
increased to 83.3%.  Animals receiving vegetative probiotic doses displayed less weight loss 
over the course of infection (Figure 4.7B), demonstrating reduced severity of symptoms. 
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Figure 4.7. Viability of probiotics. Susceptible C57Bl/6 mice (n≥ 6) were infected with 
10
4
C. difficile VPI 10463 spores. Groups received either daily B. subtilis PXN21 doses of 
live spores, heat killed spores, vegetative cells or no treatment. A) Kaplan-Meier survival 
plot over seven days post infection. B) % weight change was calculated based on 
recorded weight throughout infection monitoring period compared to weight at point of 
infection. Weights were recorded daily over 7 day infection period. All probiotics doses 
contained 10
9
 spores or cells, and were delivered orally. 
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4.2.5. Histological sections 
H&E stained tissue sections were produced to assess pathology affecting gut tissues in 
groups receiving B. subtilis PXN21 spores. Images from tissue sections suggest that in 
animals given PXN21 spores the gut tissues display reduced pathology, with less damage to 
cell structure than in untreated animals (Figure 4.8).  Tissues from healthy, non-infected 
mice exhibited well defined tissue structure and cell integrity (Figure 4.8A). Toxin mediated 
damage is evident in the breakdown of tissue structure and disruption of epithelial cell 
membranes (Figure 4.8D). The level of damage in terms of cell structure and tissue integrity 
was reduced in groups receiving PXN21 spores both before (Figure 4.8B) and after infection 
(Figure 4.8C). However, PXN21 treatment did not completely protect tissues and some 
cellular damage was present in PXN21 treated animals, with minor disruption of cell 
membranes apparent.  
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  Figure 4.8. Hematoxylin and eosin stained sections of colon from C. difficile VPI 10463 
infected mice. (A) uninfected mice, displaying healthy tissue and intact epithelial lining 
to colon, (B) mice treated with PXN21 spores pre-infection with some damage to 
epithelial structure but with lining still intact although evidence of mild edema in 
submucosa, (C) mice treated with PXN21 spores post infection show slight damage to 
integrity of epithelial lining and some submucosal disruption and (D) untreated mice 
displaying extensive damage to colonic epithelial lining and erosion of the sub mucosa 
(shown by white arrows and stars). Scale bars = 25μm 
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4.2.6. Mechanisms of probiotic action 
The ability of spores to bind proteins has been demonstrated previously (Huang et al. 
2010), and was examined as a possible mechanism for protective action in CDI. In vitro 
experiments showed that the whole toxins, rather than protein fragments or antigens 
could be absorbed on to the spore coat of B. subtilis PXN21 spores (Figure 4.9). Incubation 
of spores with commercially purified toxin A and B was used to test absorption to spore 
coats. Western blots of extracted spore coats after incubation with the toxins showed the 
presence of both toxins A and B on the spore coat. In this experiment, toxin B was detected 
on the spore coat with greater efficacy than toxin A (Figure 4.9B). Due to the significant 
differences between an in vivo and in vitro situation, these in vitro results should be applied 
with caution to the in vivo situation. 
It was proposed that B. subtilis spores could replicate the in vitro scenario of absorbing 
toxins to the spore coat, binding free toxin in the gut to prevent causation of damage to 
cellular targets. However, on investigation, developing an assay to assess this was 
extremely difficult. A small amount of toxin is detectable via immunoblotting on spores 
isolated from caecal extracts (Figure 4.9C). However, the amount of free toxin also 
detected in the caecum of infected animals makes levels of absorbed toxin appear 
insignificant. Further study of toxin absorption may provide definitive evidence as to 
whether this mechanism actually contributes in vivo to the increase in survival seen in 
groups that have received B. subtilis PXN21 spore doses. 
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An alternative mechanism for how PXN21 spores might supress symptoms of CDI includes 
stimulation of the innate immune responses. In vitro assays were carried out to assess the 
ability of the B. subtilis PXN21 spores to interact with cellular receptors and produce 
measurable immune responses. Firstly, interaction with TLR2 was analysed. In this assay a 
response was detected when both vegetative cells and spores were incubated with 
macrophages. Interestingly, this reaction was reduced when heat killed spores were used 
(Figure 4.10). Live spores germinate over the time course of this experiment. The reaction 
stimulated by heat killed spores is solely attributable to spores rather than vegetative cells 
or germinating spores, showing that these spores are recognised by TLR2. 
Induction of pro inflammatory cytokines IL-6 and TNFα by macrophages incubated with B. 
subtilis PXN21 spores was also studied. Both cytokines were shown to be produced when 
incubated with live spores (Figure 4.11). Levels of IL-10 were also assessed, but no 
detectable levels were found in this assay. To control for germination of the spores during 
the assay, SC2376 gerD-cwlD, a strain congenic to B. subtilis PY79 that carries a severe 
defect in germination (Mauriello et al. 2007) was included. Heat killed spores were tested 
for induction of responses. Live cells were able to induce production of IL-6, but this effect 
was reduced with the use of germination deficient spores. Interestingly, heat killed spores 
failed to stimulate any detectable levels of IL-6, highlighting a difference between 
germination deficient and heat killed spores. TNFα production was limited to macrophages 
that were incubated with viable B. subtilis PXN21 spores (Figure 4.11B), linking production 
of this cytokine to germination and vegetative growth of the strain. Heat killed and SC2376 
gerD-cwlD B. subtilis spores failed to induce TNFα production in this assay. Production of 
cytokines demonstrates that the B. subtilis PXN21 strain is capable of interacting with 
receptors of the innate immune system. Differences between viable and inactive spores 
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imply that these interactions will strongly depend on the state of growth displayed by the 
strain. It is worth noting that these are simplistic in vitro assays and direct comparison to 
the extremely complex in vivo situation should be done with care. 
  
Figure 4.10. TLR2 expression in murine macrophages (RAW264.7) after incubation with 
B. subtilis PXN21. Vegetative cells, spores and heat killed spores were added to cells at 
a concentration of 10
7
/ml and incubated for 4hours. RNA was extracted from cells and 
TLR2 gene expression was calculated relative to β-actin expression, using qPCR. Results 
are from three individual experiments. 
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Figure 4.11. Cytokine production in murine macrophages (RAW264.7) after 
incubation with B. subtilis PXN21. Live and heat killed spores were added to 
cells at a concentration of 10
7
/ml and incubated for 24hours. Commercial ELISA 
kits (eBioscience) were used to quantify levels of A) IL-6 and B) TNFα in 
supernatants of cultured cells. Results are from three individual experiments. 
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4.3. Discussion 
This work demonstrates that oral administration of probiotic B. subtilis PXN21 spores is 
effective in reducing CDI symptoms in a murine model of disease. Variation displayed in 
survival rates between different treatment regimens highlights the need for optimisation of 
this probiotic treatment. Attempts to elucidate the mechanisms by which the probiotic 
effect is achieved and how the findings of this study can be applied to development of 
commercial treatments will be discussed.  
 
 Probiotic mechanisms 4.3.1.
B. subtilis PXN21 is a component of a commercial probiotic product and numerous other 
products also carry spores of B. subtilis as an active ingredient (Permpoonpattana et al. 
2012). Additionally, some traditional food such as Natto, a fermented soy bean based food 
stuff, contain live B. subtilis spores and have been recognised as having associated health 
benefits (Hosoi & Kiuchi 2004). There are also studies that show oral consumption of 
probiotic bacteria can have some effect in reducing symptoms or occurrence of CDI. As an 
adjunct to antibiotic therapy, species of Lactobacillus, Bifidobacteria and Saccharomyces 
boulardii appear to reduce the incidence of CDI in human studies although no study has yet 
shown full protection (Pochapin 2000; Surawicz et al. 2000; Wullt et al. 2003). In addition, 
no consensus has been reached as to how these bacterial supplements exert their effects. 
Several different mechanisms can be considered when explaining the ability of a strain such 
as B. subtilis PXN21 to reduce symptoms of CDI.  
Firstly, probiotic strains could influence the gut microbiota such that growth of C. difficile is 
inhibited, possibly by out-competing for available nutrients or by secretion of antimicrobial 
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factors. This is the basis of treatments that focus on supplementation of the gut flora in 
order to prevent C. difficile from maintaining a niche within the GI tract. Supplementation 
of the gut flora with a complex or even minimalist mix of microorganisms mimics the 
protection against colonisation by C. difficile that the normal healthy microflora of the gut 
provides. Single strains of bacteria are less likely to be able to successfully act as a 
substitute for the complex microflora of the gut. However, used alongside conventional 
antibiotics, particular strains could potentially exert enough influence in the gut 
environment to reduce the symptoms of infection and aid restoration of the gut flora. The 
PXN21 strain was shown to be able to transiently colonise the murine gut providing 
evidence for the strain being able to survive and exert an effect on the environment. The 
temporary nature of the colonisation shows that use of this strain is unlikely to 
permanently alter composition of the microflora, although further study would be required 
to confirm this. The state of the microflora is an important factor in susceptibility to CDI, 
therefore the long term impact on the microflora must be an important consideration of 
probiotic usage. 
 It is possible that the probiotic strain served as competition for C. difficile during the 
infection, but there is no direct evidence for this aside from the need for treatment with 
viable bacteria. It is possible however that competition between probiotic and pathogen 
was spatially defined with the probiotics filling the role of the commensal microflora by 
associating with the mucosa (O’Hara & Shanahan 2006). Histological sections from infected 
animals showed protection of the mucosal surface in probiotic treated animals, and a 
potential competition based mechanism behind this could be that presence of the probiotic 
strain prevents access to the tissue by C. difficile toxins. 
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A second potential probiotic mechanism is stimulation of a robust innate immune response 
in the gut associated lymphoid tissue (GALT). Immune regulation plays a large role in 
homeostasis in the GI tract with the commensal microflora influencing how the system 
responds. Probiotic bacteria will have a direct effect on immune regulation in a disrupted 
environment. In this work, both spores and vegetative cells of B. subtilis demonstrate the 
ability to interact with receptors of the immune system and stimulate responses. This was 
shown through basic in vitro assays, which are difficult to compare with the complex in vivo 
environment, but do provide indications of potential interactions for B. subtilis within the 
GI tract. The number of bacteria used in probiotic treatment also affects immune 
regulation within the gut. Spores of B. subtilis stimulated production of TNFα and IL-6 in a 
macrophage cell line, both of which are proinflammatory cytokines. IL-6 production in 
particular has been linked to stimulation of mucosal responses and IgA production (Ramsay 
et al. 1994; Mantis et al. 2011). Histological examination of tissue shows the least damage 
occurs in probiotic treated animals, implying a protective effect at the surface of the tissue. 
Presence of the B. subtilis strain could stimulate a mucosal immune response, contributing 
to protection of the mucosal surface. The normal gut flora acts to mediate intestinal 
immune responses, but when dysbiosis occurs this control is lost (Schiffrin & Blum 2002; 
Pils et al. 2011).  
The impact of interactions with the immune system is difficult to assess with data available 
from this study. In order to clarify the role of interaction with the immune system, immune 
deficient mice could be used in a similar study. Use of Myd88-/- mice in the study of C. 
difficile infection has been described previously (Lawley et al. 2009a). Mice with this 
mutation in innate immune signalling were more susceptible to disease. If use of probiotics 
in an infection model involving these mice resulted in increased survival as demonstrated in 
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this work, this further study would give an indication that the probiotic response was not 
due to interaction with the innate immune system in the gut, and so clarifying an aspect of 
the mechanism. Stimulation of an innate immune receptor, TLR5, has been used previously 
to prevent symptoms of CDI (Jarchum et al. 2011). Jarchum and colleagues used targeted 
TLR stimulation for successful treatment of CDI, thereby demonstrating how important 
specific interactions with the innate immune system could be in developing a treatment for 
CDI. 
Finally, it is possible that in toxin mediated disease, probiotics may moderate symptoms by 
reducing levels toxins present in the gut lumen. This is particularly relevant for probiotic 
spores since these entities have been shown able to efficiently absorb toxins onto the 
spore surface. This action draws a comparison to the novel treatment Tolevamer, a 
polymer that is able to bind toxins of C. difficile (Hinkson et al. 2008). While demonstrating 
the ability of PXN21 spores to bind toxin in vivo proved difficult, it is plausible that this 
mechanism could contribute to the probiotic effect. However, in this study, given the large 
amount of free toxin in the gut lumen it is unlikely that this is the sole mechanism by which 
the PXN21 strain produces a probiotic effect. 
The studies shown in this thesis support the role of innate immunity in the positive 
probiotic response, since PXN21 spores are shown to up regulate expression of TLR2. 
Peptidoglycan is one of many ligands associated with TLR2 induction and was used as a 
control for in vitro experiments. Spores carry peptidoglycan in their cortex, a layer lying 
beneath the spore coat, although when autoclaved spores were used induction of TLR2 was 
substantially reduced. Vegetative cells of PXN21 showed strong induction of TLR2, most 
likely due to peptidoglycan exposed on the cell envelope. This suggests that spore 
germination and release of the growing vegetative cell might be critical to induction of 
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TLR2. This assumption is based on the fact that when the spore is inactivated by 
autoclaving it is not broken but remains intact, so it is unlikely that peptidoglycan within 
the spore cortex is released in significant quantities. In other studies TLR2 was shown to be 
activated by live B. subtilis PY79 spores but not by heat-killed PY79 spores nor spores 
unable to germinate (Huang et al. 2008). Interestingly, in other work live spores of B. 
subtilis PY79 were shown to significantly delay symptoms of CDI in a hamster model of 
infection (Permpoonpattana et al. 2011a). Although hamsters did eventually die from CDI 
PY79 spores were clearly shown to delay fatalities and most likely this is due to germination 
and release of live B. subtilis vegetative cells. A clear result of TLR2 activation would be 
induction of pro-inflammatory cytokines and this study confirmed that i) both IL-6 and TNF-
α were induced and ii) induction did not occur with heat-killed PXN21 spores. Again, proof 
that this must arise from germination of live spores to the vegetative cell comes from 
indirect evidence using germinating and non-germinating spores of PY79. 
 
 Probiotic treatment regimen 4.3.2.
Survival rates of infected animals in this study depend on the dosing strategy employed. 
This highlights dose regimen as an important issue and also shows that optimisation studies 
are imperative to identify the most successful method and timing for use of treatments. 
The mechanism of probiotic action will have a significant impact on design of the treatment 
regimen. Evaluating how the probiotics increase survival rate in C. difficile infected mice is 
important to the application of the treatment.  
Factors to be considered in optimising use of the PXN21 strain in a CDI treatment include 
timing and size of doses and also viability of the probiotics.  
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The dose size is an important aspect of this treatment, linking with two potential 
mechanisms, impact on the microflora and stimulation of an innate immune response. 
Unlike other work where an increased dose resulted in an increased probiotic effect (Gao 
et al. 2010), use of  a smaller dose appears more efficacious with B. subtilis PXN21. The key 
to recovery from CDI is restoration of homeostasis within the GI tract, both in terms of 
normal microbiota reasserting itself and the return to normal immune regulation. Reducing 
the size of the probiotic dose suggests that commensal microflora have less competition for 
nutrients and space as they repopulate the gut. This would aid recovery of the system once 
the infection has cleared and therefore contribute to a faster improvement in health. 
Higher numbers of bacteria have the potential to increase immune responses, which may 
lead to over expression of inflammatory factors within the disrupted gut, as occurs in 
chronic conditions such as IBD (Duchmann et al. 1995; O’Hara & Shanahan 2006). The 
introduction of probiotics further alters the GI tract from its original state, even if the 
probiotics do produce the immediate benefit of attenuating effects of CDI. Reducing the 
dose of spores in probiotic doses limits stimulation of the immune system decreasing the 
risk of a damaging inflammatory response. This effect can be linked to results from pre 
infection treated groups, where surviving animals demonstrated an improved weight 
profile. In pre-infection dosing, the probiotic strain has time to adjust to the environment 
and find a niche to colonise, so numbers are limited to capacity of the system, avoiding 
overstimulation. Increased success with a reduced dose may however be a function of the 
physical size of the model used. 
Timing of treatment is also a significant factor in success of the probiotic treatment, with 
benefits that can be attributed to probiotic colonisation apparent in the comparison of 
dose regimens.  Probiotics delivered prior to infection did not increase survival rate as 
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effectively as post infection treatment. However, surviving individuals treated prior to 
infection demonstrated less weight loss than animals receiving probiotics post infection. 
This observation suggests that the mechanism behind protection depends on the dose 
regimen employed, hence the difference in survival rates. Probiotic doses delivered prior to 
infection provide time for the strain to colonise the gut. Colonisation allows the strain to 
establish itself within a niche and it is then able to play a role in a suitable response, 
tailored to the situation when infection occurs.  With probiotics dosed after infection, there 
is not sufficient time to adapt to the environment, so responses and interactions in the GI 
tract are not stabilised. The weight profile of the two groups reflects the difference in 
response to treatment; pre-treatment allows for a more stabilised environment, resulting 
in healthier animals. Post infection treatment acts acutely, preventing death, but does not 
support the recovery of microflora to a balanced, homeostatic state. 
The reduced rate of survival in the pre-treated group compared to the group receiving 
treatment after infection is likely due to some individual variation existing. That survival 
rate is increased compared with the non-treated group shows that at the very least, the 
dosing of probiotic spores prior to infection exerts a lasting beneficial effect. These results 
are supported by data from the hamster model both in this and previous work 
(Permpoonpattana et al. 2011a), where individuals given B. subtilis before infection 
showed an increase in survival time. 
A fundamental finding in this study is the importance of the viability of B. subtilis spores 
when used as a probiotic treatment, highlighting that it is not just when treatment is 
delivered but also what is delivered. Heat killed spores showed none of the beneficial 
effects demonstrated with the use of viable spores or vegetative cells. The probiotic effect 
can therefore be attributed to the ability of viable spores to germinate and establish 
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vegetative growth in the GI tract. This links to stimulation of innate immune responses 
through presence of peptidoglycan, amongst other ligands, from vegetative growth. In vitro 
data shows IL-6 production is reduced when non-germinating spores are used and is 
eradicated completely when heat killed spores are used to stimulate cells. TNFα is 
produced only when the cultured macrophages are incubated with live spores that 
germinate over course of the experiment. A similar effect is seen with study of TLR2 
expression where use of heat killed spores reduces the expression of TLR2 in comparison to 
use of live spores or vegetative cells. Increased responses due to vegetative growth and 
germinating spores may be due to the increase in bacterial number but can also be 
attributed to ligands produced by growing cells. Heat killed spores in this study 
demonstrated only a limited ability to stimulate expression of TLR2. Inactivated spores are 
unable to germinate and enter a vegetative growth phase. Lack of a vegetative phase 
prevents further interactions within the gut and limits the time period that spores will 
remain in the gut. Interaction with the immune system is important information in 
considering a probiotic treatment. It is plausible that presence of the non-commensal 
probiotic strain induces immune responses that contribute to a response against C. difficile, 
in effect priming the immune system to act against an infection. Based on results from this 
work, it is unlikely that B. subtilis spore specific interactions are responsible for the increase 
in survival when C. difficile infected mice are treated with probiotics. Vegetative growth of 
the strain carries more importance than the spores themselves.  In vivo studies show no 
improvement in condition when heat killed spores are used, so any interactions specific to 
spores with innate immune receptors have little impact. The strain itself proves beneficial; 
however spores as a dormant form do not contribute significantly to the probiotic effect.  
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The majority of studies on the use of probiotics use viable bacteria, as viability is inherent 
to the current definition of probiotics (Araya et al. 2002). However, there are studies that 
have reported beneficial effects with use of non-viable bacteria (Xiao et al. 2002; Ventola et 
al. 2012; Lahtinen 2012). Benefits are specific to strains and the method of inactivation 
used. The findings of this work however, show that B. subtilis PXN21 spores need to be 
viable to exert a beneficial effect. This highlights a key point in probiotic research; 
generalisations cannot be applied to the use of different strains, as properties of individual 
strains will vary. 
Occurrence of disease attributable to C. difficile has been assessed on several levels in this 
study. Despite this, no single defined mechanism can be linked to the increased survival of 
probiotic treated animals, although options for further study do exist to that could help 
clarify this. It is likely that several mechanisms contribute to the beneficial action of the 
probiotics. This is not surprising, as the G.I. tract itself is a complex environment. Gaining 
understanding of how the probiotic effect is achieved would enable more informed use of 
this treatment in terms of dosing regimens.  
 
 Application to a commercial product  4.3.3.
Results from this work show that the B. subtilis PXN21 strain can be used to attenuate the 
symptoms of disease in C. difficile infected mice. Following this success, application of this 
to a treatment for human disease is a possibility to be addressed.  
Factors to be considered in development of a product include not just the success of a 
treatment but also the ease of delivery, storage and overall cost.  
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Differences in survival rates of groups treated with either viable or non-viable bacteria 
make it clear that vegetative growth of the strain is essential for the probiotic effect. 
Survival rate was increased further when vegetative cells were used rather than spores in 
the probiotic dose. It is worth noting however, that these doses contained freshly grown 
cultures of cells, which would be difficult to replicate if this type of treatment was to be 
developed commercially. Logistics of probiotic treatment doses need to be considered. B. 
subtilis spores make a very attractive probiotic treatment; robust, dormant forms of the 
bacteria can be stored for long periods without loss of viability as would occur in vegetative 
cells. Also, spores can be delivered orally without risk of sensitivity to the extreme pH and 
digestive enzymes of the stomach and GI tract. If B. subtilis PXN21 as a probiotic treatment 
was to be used in a human, clinical situation, vegetative cells may well provide better 
protection against symptoms as demonstrated in this study. However, the ease of use that 
spores provide may outweigh the potential benefits of doses containing vegetative cells. 
Parallels can be drawn to an existing product Enterogermina™, which is a suspension of B. 
clausii spores. This product is marketed by Sanofi Aventis for the treatment of 
gastrointestinal disorders (Hong et al. 2005), and serves conveniently as a model for a 
spore based product. Two billion viable B. clausii spores are present either in a vial or 
capsule, for oral administration. Use of a pure suspension of spores avoids the need for 
dairy based matrices to support the probiotic strain, a model that is commonly used in 
probiotic products. This gives several advantages, firstly the creation of a simple product 
with no refrigeration required. Secondly, avoiding the use of an associated dairy based food 
product makes the product more accessible especially to those with lactose or dairy 
intolerances. A similar product could be developed using B. subtilis PXN21 spores that 
demonstrates the same ease of use. 
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Despite increasing survival rate in infected mice, treatment with B. subtilis PXN21 does not 
prevent infection so cannot be used as a standalone treatment. Antibiotics must still be 
relied upon to eliminate infections of C. difficile. B. subtilis PXN21 spores could therefore be 
considered for use as an adjunct therapy alongside or prior to antibiotic infection. Giving 
doses of these spores to individuals at risk of developing C. difficile infection could help 
reduce infections or bolster the gut against severe disease, as seen from the murine study 
results. The murine study represents a very simple controlled infection situation which 
allows basic research to be carried out before involvement with the clinically complex 
human situation. Evidence of a beneficial effect from the PXN21 strain in this model could 
feed into further study and potentially lead to design of a product that could also prove 
beneficial to human health. The murine model therefore is useful but only trial in human 
subjects would provide definitive results on the potential of the PXN21 strain for treatment 
of CDI.  
It is clear from the results in this study that the B. subtilis PXN21 strain alone will not 
prevent or cure C. difficile infection. However, use of the PXN21 strain to reduce symptoms 
of CDI is of significant interest and can be applied to further research into C. difficile 
treatments. Development of synthetic stool treatments uses a range of bacterial strains 
and species that in combination are able to treat infection. Identification of strains such as 
PXN21 that are able to reduce symptoms of disease caused by CDI could potentially be 
useful to production of such treatments, allowing further application of this work.   
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4.4. Conclusion 
B. subtilis PXN spores can be used as an oral treatment to reduce the severity of CDI 
symptoms in a murine model of infection. Success of this treatment is demonstrated 
through increased survival rates. Use of the murine model provides a good platform for this 
work, allowing in depth study of the disease progression in this model. A precise 
mechanism was not defined for the probiotic treatment, however it is likely that multiple 
mechanisms contribute to increased survival rates in probiotic treated groups. Complex 
interactions occur in the gut and as such unravelling the mechanics of interactions is 
challenging.  
A key observation was that B. subtilis spores must be viable in order to obtain the probiotic 
effect. This suggests that interaction with the immune system and ability to colonise a 
niche within the GI tract relies on vegetative growth of the probiotic strain. Results from 
use of a variety of treatment strategies highlighted the importance of optimising the dosing 
regimen.  The number of bacteria per dose, timing and regularity of treatment are all 
important factors for the successful use of this probiotic strain.  
Use of the B. subtilis PXN21 strain does not prevent infection and will not replace use of 
antibiotics. A single bacterial strain is unlikely to be able to exert a strong enough effect to 
inhibit C. difficile infection. Investigating the use of a single strain is still relevant however, 
as the complex interactions within the GI tract will only be understood once they have 
been stripped down to simple steps and then built back up again. This idea, however, 
represents a very large body of work. The study here reflects critical basic information 
about how infection can be managed. In order for C. difficile to be controlled, a more 
complex treatment has to be used, mimicking how the microflora could normally supress 
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invasive pathogens. A successful C. difficile treatment should address both restoration of 
homeostasis in the gut and prevention of toxin mediated disease. 
Spores of B. subtilis provide a stable, easy to store and easy to deliver probiotic treatment. 
Bacillus strains are already frequently used in probiotic applications and this history of use 
demonstrates their safety for human consumption. The findings from this work show the 
potential of the B. subtilis PXN21 strain in treating CDI. Application of these findings could 
result in production of a single strain probiotic supplement, or used in design of a complex 
probiotic mix.
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Chapter 5 
The Spore-Associated Protein 
BclA1 Affects the Susceptibility of 
Animals to Colonisation and 
Infection by Clostridium difficile  
This work has been published in part:  
The spore-associated protein BclA1 affects the susceptibility of animals to colonization and 
infection by Clostridium difficile. 
Phetcharaburanin, Hong and Colenutt et al. Molecular Microbiology, 92(5). 1025-1038 
I would like to acknowledge my co-authors for their contributions to planning and carrying 
out practical work, with specific reference to in vivo experiments. 
5.1. Introduction  
 
5.1.1. Clostridium difficile spores and infection  
The spore of C. difficile is the dormant state of this organism and is the primary agent of 
transmission (Gerding et al. 2008). This has been supported by recent studies where a 
mutant strain of C. difficile, unable to produce the Spo0A protein (a regulatory protein 
essential for spore formation) fails to persist and transmit the disease (Deakin et al. 2012). 
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The Spo0A protein has also been implicated to have role in biofilm formation, with a similar 
mutant strain unable to form biofilms as robustly as the wild type (Dawson et al. 2012). 
Interestingly, mice infected with C. difficile can exist in two physiological states, a carrier 
state, where low levels of C. difficile spores are shed in the faeces and a ‘supershedder’ 
state where large numbers of spores are shed (Lawley et al. 2009). This ‘supershedder’ 
state is induced following antibiotic treatment and most closely resembles the human 
clinical situation. Capable of withstanding heat, desiccation and noxious chemicals, spores 
facilitate transmission of C. difficile outside of the host and therefore present a major 
burden to hospitals in containment and disinfection (Vonberg et al. 2008). 
Although toxin A and toxin B are considered the two main virulence factors, others cannot 
be excluded; for example, it has been shown that hamsters challenged with spores of the 
non-toxigenic strain CD1342 showed mild caecal pathology characterised by local acute 
epithelial cell loss, haemorrhagic congestion and neutrophil infiltration (Buckley et al. 
2013). Similarly, hamsters colonised with non-toxigenic strains, M3 and T7, were protected 
against challenge with toxigenic B1 group strains (Nagaro et al. 2013). The mechanism for 
how these non-toxigenic strains confer protection remains both intriguing and unclear. 
 
Given the importance of spores in the transmission of C. difficile an effective treatment 
should address presence of the spores in the GI tract. Antibiotics will have no effect on 
spores, only vegetative growth of C. difficile. Current vaccination strategies are focused 
almost exclusively on parenteral delivery of toxoids and the generation of protective 
humoral (IgG) responses (Gerding 2012) based on a response against toxins, a feature of 
vegetative growth. Although it is possible that anti-toxin serum IgG could reach the mucosa 
by transudation (Woodrow et al. 2012) systemic delivery of toxoids will otherwise fail to 
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produce polymeric secretory IgA (sIgA), the predominant mucosal antibody that has been 
shown to neutralise toxins (Johnson et al. 1992; Kelly et al. 1992). An alternative strategy in 
developing a vaccine against CDI would be to investigate use of antigens from the surface 
of the bacterium rather than factors produced in vegetative growth. This would have the 
benefit of creating a response against the presence of the bacteria rather than waiting until 
toxins are produced. Addressing decolonisation with a vaccine is complex although if 
achieved would be beneficial in the case of C. difficile where recurrences of infection are 
common. Recurrences could be due to spores remaining in the gut post antibiotic 
treatment, so a vaccine that aims to produce sterile protection would provide an obvious 
benefit here. CDI is a complex infection with multiple levels of clinical manifestation; for 
example, it has been shown that strains of C. difficile show differences in pathology in the 
hamster model of infection (Goulding et al. 2009) and that some high toxin producing 
strains (such as NAP1/027) can produce mortality in hamsters but without diarrhoea (Razaq 
et al. 2007). A further complication is that C. difficile infection can recur in about 30% of 
infected patients (Gerding et al. 2008b). Interestingly, antibodies to the surface layer 
proteins of C. difficile vegetative cells have been found associated with reduced levels of 
recurrence implying that useful antigenic targets associated with the vegetative cell may 
exist (Drudy et al. 2004). 
 
5.1.2. Exosporium and BclA proteins 
The role of the spore in transmission of the disease suggests that this dormant life form 
may play a key role in colonisation, a process better divided into three stages; 
establishment of infection, maintenance of infection (persistence) and spore shedding. 
Spores of C. difficile resemble those of other Gram-positive spore-formers but differ 
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somewhat in the abundance of enzymes they carry on their surface layers, including three 
catalases and a bifunctional peroxiredoxin-chitinase (Permpoonpattana et al. 2011b; 
Permpoonpattana et al. 2013). Spores also carry a poorly defined surface layer known as an 
exosporium whose function has been linked to germination, adhesion and resistance 
properties of the spore (Henriques & Moran 2007; Lawley et al. 2009; Escobar-Cortés et al. 
2013). In some spore formers a major component of the exosporium is the BclA (bacillus 
collagen-like protein of anthracis) glycoprotein that carries collagen-like repeats of the 
amino-acid triplet GPT used for attachment to oligosaccharides and which forms a hair-like 
filament (Steichen et al. 2003; Sylvestre et al. 2002, 2003). A second collagen-like protein, 
BclB has also been identified in B. anthracis and has been linked to exosporium assembly 
(Waller et al. 2005; Thompson & Stewart 2008). 
 
The genome of C. difficile 630 carries three bclA genes (bclA1-3) (Sebaihia et al. 2006) 
although in a proteomic analysis of C. difficile 630 spores, only BclA1 was identified as 
present (Lawley et al. 2009b). The C. difficile exosporium has been visualised as a loose sac 
like material surrounding the spore, but the appearance of hair like structures formed by 
BclA in other species have not been reported in C. difficile strains. Recent research (Pizarro-
Guajardo et al. 2013) demonstrated that the BclA glycoproteins are located on the spore 
surface as part of the exosporium of C. difficile spores. The study also reports on the 
orientation of the glycoproteins, with the BclA N-terminal domain (NTD) buried inside the 
exosporium layer and the C terminal domain (CTD) angled to the surface of the 
exosporium. Parallels with work in B. anthracis can be drawn here, as similar orientation of 
the BclA proteins has been demonstrated (Boydston et al. 2005). Interest in the 
exosporium proteins of C. difficile has stemmed from studies in other species where 
Chapter 5                                                                   BclA is required for colonisation of C. difficile 
 
157 
 
specific properties have been attributed to the presence of an exosporium. As the outer 
layer of the spore, this proteinaceous layer is important as it represents the primary 
interactions the spore potentially has in an environment. In studies with B. cereus, the 
exosporium layer has been implicated in adherence and persistence of the spores on 
abiotic surfaces, although variation is demonstrated between different strains (Faille et al. 
2010). Adherence properties of spores are of interest in particular to the food 
manufacturing industry, where residual spores can be problematic in causing food 
poisoning cases. Decreased adherence reported after deletion of the BclA glycoprotein in B. 
cereus demonstrated the role this glycoprotein could play in the adherence of spores 
(Lequette et al. 2011). B. anthracis is another species that carries an exosporium, of which 
the BclA glycoprotein is a significant component (Sylvestre et al. 2002). The B. anthracis 
BclA protein was demonstrated to have immunogenic properties and has been trialled as a 
candidate antigen for use in a vaccine (Steichen et al. 2003; Brahmbhatt et al. 2007a). BclA 
is not necessary for virulence in B. anthracis, but has been shown to have an effect on 
adherence and germination characteristics of spores in this species (Brahmbhatt et al. 
2007b).  
 
5.1.3. ClosTron mutagenesis 
In the past, work with the Clostridia has been restricted due to difficulties in genetic 
manipulation. Extensive study and gains in knowledge of the Bacilli has been enabled by 
genetic studies and while parallels can be drawn between the Bacilli and the Clostridia, 
species specific information is far more valuable. The development of the ClosTron system 
(Heap et al. 2007) for targeted inactivation of genes has facilitated accessible functional 
genomic studies in the Clostridia. This system uses an intron based process to produce 
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stable mutations by insertional inactivation of genes. Further refinement of the technique 
(Heap et al. 2010) has broadened the scope of the system, with additional plasmids to 
address such issues as intrinsic antibiotic resistances and production of multiple mutations 
in a single strain.  
The ClosTron system is designed for use across the Clostridia, with research into C. difficile 
vastly benefitting from the availability of such a tool. A diverse range of studies have been 
undertaken using ClosTron with C. difficile, including characterisation of master regulator 
Spo0A (Underwood et al. 2009; Dawson et al. 2012; Deakin et al. 2012) and importance of 
toxins in disease (Lyras et al. 2009; Kuehne et al. 2010l). Functional genetic studies 
contribute significantly to understanding of this pathogen, enabling better treatments and 
control measures to be developed.  
In the work of this thesis, mutant strains of C. difficile created using the ClosTron system 
will be characterised. ClosTron inactivation of the bclA genes should result in the absence 
of the proteins from the surface of the spore allowing analysis of how removal of the BclA 
proteins can affect the spore properties. A recent characterisation of the C. difficile BclA 
proteins used enzyme digests to remove BclA from the spores (Pizarro-Guajardo et al. 
2013). This approach demonstrated that the proteins were present in the exosporial layer 
of the spore and allowed the orientation of the proteins to be determined. However, when 
defining the properties of the spores the collagenase treatment represents a deviation 
from wild type presentation of spores. In this thesis, spores will be purified using a 
Histodenz (Sigma) gradient to ensure that while a pure suspension of spores is obtained, 
they remain as similar to wild type as possible. The aim of the genetic approach to 
removing of the BclA proteins is to keep the rest of the spore structure as undisturbed as 
possible. 
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5.1.4. Experimental Objectives 
The genome of C. difficile 630 carries three bclA genes (bclA1-3) which in this work will be 
mutated and characterised. To define gene function insertional mutagenesis of each gene 
will be carried out. Mutated strains will be analysed for changes in properties that may 
affect infectivity. Strains will be tested to ensure maintenance of resistance properties and 
then in vitro germination and adhesion will be studied. Infectivity will be assessed through 
the use of two different animal models – mice and hamsters. These studies will be carried 
out based on the hypothesis that the BclA proteins have a significant effect on the 
properties of the C. difficile spore. 
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5.2. Results 
 
5.2.1. The C. difficile bclA genes 
Three genes encoding BclA-like proteins, annotated as bclA1, bclA2 and bclA3 are present 
on the genome of strain 630 (Figure 5.1) and encode proteins with predicted masses of 
67.8, 49.0 and 58.2 kDa respectively. Similar to the BclA proteins found in B. anthracis and 
B. cereus, all three C. difficile BclA proteins consist of a long, central, collagen-like region 
with multiple GXX repeats flanked by N- and C-terminal domains of varying length (Figure 
5.2A and 5.2B).  Most of the triplet repeats are GPT, with nearly all containing a threonine 
residue that could provide multiple potential sites for O-glycosylation as seen in B. 
anthracis (Daubenspeck et al. 2004) (Figure 5.3). Bioinformatic comparison of BclA protein 
sequences from B. anthracis, B. cereus and C. difficile revealed that most of the similarity 
between the proteins is limited to the collagen-like central region since both the C- and N-
terminal domains of the C. difficile BclA proteins seem to be distinct from those found in 
other species (Figure 5.4). In B. anthracis BclA these terminal regions are implicated in 
trimerisation of the BclA monomers and their attachment to the exosporial basal layer 
(Boydston et al. 2005; Thompson & Stewart 2008). Importantly, the C. difficile BclA proteins 
do not appear to carry a sequence at their N-termini that resembles the motif 
(LIGPTLPPIPP) that targets the BclA and BclB proteins of B. anthracis to the exosporium 
(Thompson et al. 2011a; Tan et al. 2011; Thompson et al. 2011b). 
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Figure 5.1. C. difficile bclA genes 
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5.2.2. Phenotypes of bclA mutant spores in vitro 
ClosTron mutagenesis was utilised to insertionally inactivate the three bclA genes creating 
the mutants, bclA1::CT1050a, bclA2::CT150a and bclA3::CT125s referred to hereafter as 
bclA1-, bclA2- and bclA3- (Table 5.1 and Figure 5.5). Mutants were examined for their 
growth and sporulation phenotypes in parallel with the isogenic Spo+ parent strain, 
630Δerm. Growth and sporulation of mutants in liquid medium was essentially identical 
between strains with approximately 104-105 spores/ml produced after 5 days (Figure 5.6).  
Transmission electron microscopy (TEM) was used to examine the structure of wild type 
and mutant spores (Figure 5.7). Compared to 630Δerm spores (Figure 5.7A) it was clear 
that for the bclA1- and bclA2- mutants there were substantial aberrations in the spore 
coats. In both cases sheets of coat-like material were present in the medium (Figure 5.7C 
and 5.7E) as well as angular projections of material at the spore surface (Figure 5.7B and 
5.7D). The bclA3- mutant did not present any apparent defect compared to wild type 
spores nor was any coat-like material shed into the medium (Figure 5.7F). 
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Table 5.1. Clostron insertional inactivation of bclA genes 
1
 as described in Sebaihia et al 
(2006) and schematically in Figure 5.1.  
2
 predicted mwt of full-length protein in brackets. 
3 
The mutant allele is shown with a) CT designing ClosTron insertion, b) the number 
showing the bp within the ORF immediately preceding the ClosTron insertion and c) letter 
a indicating insertion in the antisense strand. 
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  Figure 5.6. Growth of  wild type and isogenic mutant C. difficile strains grown in BHI 
medium at 37
o
C over 24h. 
A) OD
600
 
B) Total counts 
C) Heat-resistant (spore) counts. Heat resistance measured at 60
o
C 20 min. 
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Heat, ethanol and lysozyme treatments were used to determine the robustness of the 
mutant spores alongside the wild type strain. Histodenz-purified spores of all mutants 
showed no significant susceptibility to treatment with heat, ethanol and lysozyme (Table 
5.2).  
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Purified spores were used to assess their ability to germinate in BHI medium supplemented 
with 0.1% sodium taurocholate as a germinant (Table 5.3 and Figure 5.8). As controls spore 
germination experiments were conducted in parallel in the presence of the inhibitor 
sodium chenodeoxycholate. Germination correlates to a loss in OD600 as spores rehydrate 
and become phase dark. 630Δerm spores germinated relatively slowly with a 16% 
reduction in OD600 over a 30-minute period. All three mutants germinated faster than the 
wild type strain with the bclA1- and bclA2- mutants exhibiting the highest germination rates 
with 40% and 34% loss in OD respectively. In the presence of inhibitor though spores of 
wild type and mutant strains remained stable and all exhibited a maximum OD drop of 5-
6% over 30 minutes. Germination of sonicated spores of the wild type strain was also 
evaluated in parallel and had an OD drop of 29% indicating that disruption of the spore 
surface layers enhanced germination (Figure 5.8D).  
 
Table 5.3 Germination phenotypes.  
% drop in OD was determined as % loss in OD600 in the presence of inhibitor (0.1% sodium 
chenodeoxycholate) or germinant (0.1% sodium taurocholate). All samples had an initial 
OD of approximately 1.0. 
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The hydrophobicity of purified spores was measured and all three bclA mutants were 
significantly (p<0.035) less hydrophobic than spores of the wild type 630Δerm (Figure 5.9). 
It has been shown recently that sonication of C. difficile spores is efficient at removing the 
exosporium (Escobar-Cortés et al. 2013). For comparison, sonicated spores were used to 
demonstrate that sonication significantly (p<0.024) reduced the surface hydrophobicity of 
630Δerm and bclA mutant spores with the exception of the bclA3- mutant (p=0.185). 
Polyclonal antibodies raised against recombinant BclA1, BclA2 and BclA3 proteins were 
used to confirm that each protein was i) located on the surface of 630Δerm spores, ii) 
absent in vegetative cells and, iii) not present in spores of the corresponding isogenic 
mutant (Figure 5.10). 
  
Figure 5.9. Spore hydrophobicity. The SATH assay was used to calculate % 
hydrophobicity of Histodenz-purified spores of wild type and mutant spores with (white 
column) or without sonication (grey column). The analysis was performed three times. 
* indicates values significantly different between bclA mutants and 630Derm (bclA1
-
, 
0.036; bclA2
-
, 0.0064; bclA3
-
, 0.0006) and sonicated mutant and 630Derm spores (bclA1
-
, 0.02; bclA2
-
, 0.0243). 
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Figure 5.10. Surface display of BclA1, BclA2 and BclA3 proteins using immunofluorescence 
imaging of suspensions of 630Derm, bclA1
-
, bclA2
-
 and bclA3
-
 spores (7-day old cultures grown on 
solid medium) labeled with mouse serum (1:1,000 dilution) raised against each of the three BclA 
proteins. An anti-mouse IgG-TRITC conjugate was used for secondary labeling. BclA1, BclA2 and 
BclA3 proteins were detected on both purified and non-purified 630Derm spores whereas the 
bclA mutants showed negative signals. Controls included vegetative cells of wild type and 
mutants. 
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5.2.3. In vivo characterisation of BclA1- spores 
The recently described mouse model of cefoperazone pre-treatment to induce C. difficile 
infection (Theriot et al. 2011) was used to evaluate the progress of shedding of C. difficile 
spores. Animals were given a single dose (104) of mutant or wild type spores (Figure 5.11). 
Total counts (spores and vegetative cells) of C. difficile shed in the faeces ranged from 104 
to 106 per gram although somewhat lower counts were found for the bclA1- mutant (Figure 
5.11B). Mice body weights remained similar with no significant differences between groups 
(data not shown). Spore counts of 630Δerm-dosed mice declined over time (Figure 5.11A). 
Spores were not found in the faeces from mice dosed with the bclA3- mutant on day 1, 
despite substantial levels of spores being detected on days 3, 5 and 7. Spore counts of both 
the bclA2- and bclA3- mutants increased after day 1 and were substantially higher (>1-log) 
on days 3, 5 and 7 compared to that of wild-type infected animals (Figure 5.11A). 
Surprisingly no spores were detected for the bclA1- mutant in the faeces post-infection 
(Figure 5.11A) in all the time points. The experiment has been repeated with similar 
findings. 
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Figure 5.11. BclA
-
 strains colonisation in mice: Groups of mice (n=4) were administered 
a regimen of cefoperazone and then infected orally with a single dose (1 x 10
4
) of 
630Δerm spores or spores of one of the three bclA mutants. Freshly voided faecal 
samples were analysed for spore counts (A) and total counts (B) on days 1, 3, 5 and 7 
post-infection.  
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The colonisation ability of the bclA1- mutant was examined using a dose response assay. 
Mice were treated with clindamycin to induce susceptibility to infection, with animals given 
three doses (102, 103 or 104) of 630Δerm (Figure 5.12B) or bclA1- mutant (Figure 5.12C) 
spores. Levels of colonisation were determined by the number of ethanol-resistant spores 
present in fresh faecal samples. This model of infection was used since the erythromycin-
resistance cassette used in ClosTron mutants may not confer the same level of resistance 
to clindamycin as seen in the parental strain, depending upon its chromosomal location (N. 
Fairweather per. comm.). 
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Figure 5.12. Dose-response assays in mice. Mice (n = 4) were administered a single dose 
of clindamycin and five days later infected with A) R20291, B) 630Δerm or c) bclA1
-
 
spores, at three different dose levels (10
2
, 10
3
 and 10
4
). Fresh faeces were analysed for 
the presence of ethanol-resistant spore counts following infection. Results are shown as 
average counts. Where no symbols are displayed, counts were below detection limit 
(102/g) so classed as negative. 
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Analysis of the bclA1 genes in the genome sequences of two 027 ribotypes, R20291 and 
CD196 (Stabler et al. 2009) revealed a stop codon at position 48 in addition to an 
asparagine to lysine change at position three in the ORF (Figure 5.13). Independent 
sequencing of the bclA1 gene in R20291 confirmed that the stop codon is in place and not a 
sequencing error. As such, the 027 strains must each encode a BclA1 protein of approx. 6 
kDa and, being significantly smaller than the one found in strain 630, would presumably 
lack function. Using antibodies raised against BclA1 (from strain 630) BclA1 was identified 
on the surface of both R20291 and CD196 spores suggesting that the truncated protein can 
assemble into the exosporium in these 027 strains (data not shown). 
 
Results from this study suggest that bclA1 deletion would impair colonisation. Therefore, to 
determine the infectivity of a 027 strain carrying a truncated BclA1 protein, the ability of 
R20291 spores to colonise mice was analysed as previously described for 630Δerm and the 
bclA1 mutant (Table 5.4 and Figure 5.12). At an infective dose of 104 spores shedding was 
maintained till day ten, post-infection. By contrast, following the same dose of 630Δerm 
spores shed in the faeces steadily declined to zero by day six and then increased again. The 
bclA1- mutant however was not only shed at substantially lower levels but was cleared 
after four days compared to six days for its isogenic parent strain, 630Δerm (Figure 5.12). 
The ID50 for R20291 was 1 X 103 and therefore ten-times less infectious than 630 but more 
infectious than a strain completely devoid of BclA1, suggesting a correlation between the 
presence of an intact BclA1 protein and the susceptibility of mice to colonisation. This study 
indicated that i) spores lacking BclA1 are less competent at colonising the GI-tract resulting 
in reduced levels of faecal shedding and persistence, and ii) that at a low infective dose 
630Δerm was more competent at colonising the GI-tract, as evident from the lack of 
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shedding in animals infected with 102 spores of R20291 compared to those infected with 
the same dose of 630Δerm. Interestingly, in mice dosed with 630Δerm spores, following the 
sixth day there was a subsequent increase in counts in animals receiving the 103 and 104 
doses. This may be due to recolonisation of the GI-tract by 630Δerm spores shed in the 
faeces, as coprophagia was observed. This recolonisation was not observed for R20291-
infected mice most probably for a number of reasons. First, the maximum levels of spores 
shed in faeces, from experience with the murine model plateaus at between 106-107/g and 
so any increase would not be seen for mice dosed with 104 spores. Second, as shown from 
the ID50 values R20291 is less infectious than 630Δerm and may not be able to recolonise. 
Finally, for the bclA1- mutant, this strain clearly does not colonise efficiently so 
recolonisation of the GI tract would not be expected.  
  
Table 5.4. Infectivity of spores of different C. difficile strains in mice. Groups of mice 
were first treated with clindamycin followed by a 5-day interval before being given 
three doses (10
2
, 10
3
 or 10
4
) of spores followed by determination of ethanol-resistant 
spores counted in fresh fecal samples (cfu data are shown in Figure 5.11). Colonisation 
was defined as animals carrying >10
3
 spores/g feces at 48h post-infection. Using the 
Reed-Munch equation the dose of spores required to infect 50% of mice (ID
50
) was 
determined. 
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Hamsters provide a more sensitive model for C. difficile infection. Having demonstrated the 
difference in ability to colonise the GI tract between the parental 630Δerm strain and the 
bclA1- mutant, the hamster model was used to evaluate the infectivity of bclA1- mutant 
spores. In a preliminary study groups of three hamsters were dosed with 102, 103 or 104 
spores of 630Δerm or bclA1- spores (Figure 5.14A). Significant differences were observed in 
survival times between wild type and mutant (102, p=0.003; 103, p=0.008; 104, p= 0.0003) 
as well as a dose-dependent response. For example, using an infective dose of 100 
630Δerm spores the clinical end point was reached in approximately 40h while with the 
same dose of bclA1- mutant spores this was delayed till about 47h.  
  
Figure 5.14. Hamster colonisation. A) Survival time for hamsters infected with spores of 
strain 630Δerm or bclA1
-
. Doses of 10
2
, 10
3
 or 10
4
 spores were used to infect hamsters 
(n=3) by oral gavage. 630Δerm infected hamsters are represented by black symbols and 
bclA1
-
 infected hamsters with grey symbols. Mean survival time for each group shown 
by short black line. ** p value < 0.01; *** p value < 0.001. (Figure 5.14 continued 
overleaf)  
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The preliminary work was then expanded, using ten hamsters per group and two doses, 10 
and 102 spores, of both the 630Δerm and bclA1- mutant strain (Figure 5.14B). A dose of 102 
spores or 630Δerm resulted in no surviving infected animals while a lower dose of 10 
spores resulted in the survival of two animals. By contrast, the bclA1- mutant was clearly 
less infective with 50% survival following a dose of 10 spores and 20% survival using 100 
spores. The calculated ID50 for 630Δerm spores was 2.37 X 101 and for the bclA1- mutant 
2.56 X 102 demonstrating that the bclA1- mutant was ten-times less infective. Animals that 
were infected by either 630Δerm or bclA1- were shown to have similar levels of C. difficile 
spores in the caecum (Figure 5.14C) although levels were somewhat higher with bclA1- 
infected animals possibly reflecting the ability of this mutant to germinate more efficiently 
and proliferate. Toxin B levels in caecum samples were measured and levels were found to 
be similar in all groups of infected animals (Figure 5.14C). In surviving animals no viable 
counts of C. difficile or toxin B could be detected in caeca. This result supports the murine 
study demonstrating that bclA1- mutant strains although able to produce toxins are clearly 
less infectious than the wild type.  
 
It was possible that the low infectivity of the bclA1- mutant might have arisen if toxin 
production was reduced or delayed in vivo. Several pieces of evidence would suggest this 
unlikely: first, the bclA1 mutation was complemented in trans (Figure 5.15); second, based 
on the morphogenesis of the spore, it could be predicted that the bclA1 gene could be 
expressed in the late phase of spore formation, while toxin production is associated with 
the stationary phase of cell growth (Rupnik et al. 2009) and should occur before bclA1 
expression. Preliminary qPCR data (not shown) demonstrated that tcdA and tcdB are 
expressed during stationary phase and the early stages of spore formation, while the bclA1-
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3 genes are expressed at the terminal stages of sporulation (approx. 9h following the onset 
of development). To check if there was any relationship between bclA1 expression and 
toxin production, mice were infected eight days post clindamycin treatment with a high 
dose (105/mouse) of 630Δerm or bclA1- spores sufficient to cause infection in most of the 
mice (see Table 5.4). At 24 and 36 hours post infection the total CFU of C. difficile and toxin 
A and B levels were determined in caeca. As shown in Figure 5.16, the total CFU in mice 
infected with 630Δerm or bclA1- spores were equivalent at both time points, similarly no 
differences were observed between toxin A and B levels in the caeca and in the ratio 
between the two toxins. 
  
Figure 5.15. Complementation analysis of bclA mutants. A) pRPF185 plasmids carrying 
the complete bclA1, bclA2 or bclA3 genes were introduced into the bclA1, bclA2 or bclA3 
mutants by conjugation. Spores (purified or unpurified) were prepared and expression of 
the respective BclA proteins visualised by immunofluorescence microscopy using 
polyclonal antibodies as shown (right column) and compared to the mutants alone (left 
column). (Figure 5.15 continued overleaf) 
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Figure 5.15. (cont.) Complementation analysis of bclA mutants. B) Germination 
(measured through decrease of OD in spore suspensions) studies using Histodenz-
purified suspensions of spores (630Δerm), bclA mutants or complemented mutants 
(::CT1050a or CT125s) in the presence of germinant (ST) or inhibitor (SC).  
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5.3. Discussion 
 
The results from this work show that BclA proteins contribute significantly to the ability of 
C. difficile spores to colonise and persist within the mammalian gut. Removal of this protein 
also has substantial effects on the properties demonstrated in in vitro assays. The 
implications of these results with regard to the pathogenesis of C. difficile will be discussed. 
 
5.3.1. The role of the C. difficile exosporium  
The exosporium is poorly defined in C. difficile and images of this ‘sac-like’ outer layer vary 
from a well defined thick, electron dense laminated structure (Lawley et al. 2009b) to more 
diffuse layers that are easily removed from the underlying spore coat (Permpoonpattana et 
al. 2011b; Permpoonpattana et al. 2013; Escobar-Cortés et al. 2013). Most probably the 
exosporium of C. difficile is particularly fragile, at least under the conditions commonly 
used in the laboratory to prepare spores, during which the exosporial layer can easily be 
removed. This makes study of the exosporial proteins difficult, with the processes used to 
produce pure suspensions of spores also resulting in removal of the exosporium. Less harsh 
methods of purification such as use of Histodenz or a sucrose gradient allow the outer 
layers of the spores to remain more intact. The study of spores with more intact outer 
layers is beneficial to understanding the pathogenesis of this bacterium as a more accurate 
representation of the normal infectious cycle. Further analysis of other exosporial proteins 
is required to assign potential functions of the exosporium. A recent study analysed 
proteins from the outer layers of C. difficile spores in order to identify proteins that could 
be exploited for detection assays or control methods (Abhyankar et al. 2013). However 
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spores used in this analysis were purified using proteinase K and sarcosyl, so presence of 
exosporial proteins in the analysis is unlikely.  
One of the major immunodominant proteins found in the exosporium of B. anthracis and B. 
cereus is the BclA protein ( Sylvestre et al. 2002; Steichen et al. 2003; Todd et al. 2003; 
Redmond et al. 2004). Filaments of the BclA protein form the hairy nap which is 
characteristic of the exosporia of the Bacillus anthracis/thuringiensis family of spores 
(Kailas et al. 2011) but in the case of C. difficile these hair-like filaments have yet to be 
observed. C. difficile carries three bclA genes whose products share similarity with the BclA 
proteins of B. anthracis and B. cereus. However, the composition of these proteins differ 
significantly especially with regard to the absence of the N-terminal (targeting the 
exosporium) and C-terminal (oligomerisation) domains. Variability also exists between 
strains of C. difficile, highlighted by the observation that the BclA1 protein of C. difficile is 
severely truncated in two 027 strains. Evidence from antibody labelling showing that the C. 
difficile BclA proteins reside in the outermost layers of the spore and most probably the 
putative exosporium is supported by a recent paper also focusing on the BclA proteins of C. 
difficile (Pizarro-Guajardo et al. 2013). Whether the three BclA proteins form homo- or 
hetero-oligomers will need to be established. 
Insertional mutagenesis of the three genes also revealed noticeable defects in the spore 
coat. First, in two mutants, bclA1 and bclA2, aberrations in the spore coat were clearly 
evident and presumably assembly of the outer coat or exosporium is defective in these 
mutants emphasizing that both proteins are likely major exosporial proteins. Sheaths of 
ribbon like material are seen in association with spores in both bclA1- and bclA2- mutant 
strains. Empty sac-like structures of this material are also seen, raising the possibility that 
the BclA proteins act as an anchor for the exosporium. Therefore, in the absence of BclA, 
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the exosporium while remaining intact, is not as strongly associated with the spore.  
Second, spores of all three mutants had significantly reduced hydrophobicity. Reduced 
hydrophobicity was also apparent in spores that had been sonicated, an approach that has 
been shown elsewhere to remove the exosporium (Permpoonpattana et al. 2011b; 
Permpoonpattana et al. 2013; Escobar-Cortés et al. 2013). In B. anthracis, bclA mutants 
also have a much-reduced hydrophobicity where the exosporium is thought to provide a 
water repellent shield, reducing its ability to interact with the host matrix (Brahmbhatt et 
al. 2007b). Third, all three bclA mutants showed increased germination rates, a 
characteristic also found in the B. anthracis bclA mutant and presumably a result of a 
defective exosporium allowing access of germinants to receptors situated in the innermost 
spore membranes (Brahmbhatt et al. 2007b; Carr et al. 2010). Sonication of C. difficile 630 
spores also resulted in increased germination rates, highlighting the potential role of the 
exosporium in control of germination. As the outer layer of the spore, the exosporium 
serves to interact and control interactions with the environment. Preventing germination in 
hostile environments will be beneficial to the bacterium. The fragility of the exosporium 
when treated with purification enzymes could be replicated in passage through the 
stomach and GI tract, with removal of the exosporium allowing germination of the spore 
once in an environment in which it can survive.  
 
5.3.2. Effect on infectivity of spores 
In vivo infection studies in mice revealed that the bclA1 and bclA3 mutants had impaired 
colonisation efficiencies although this was most striking with the bclA1 mutant that 
completely failed to colonise the mouse GI-tract. This highlights that removal of the BclA 
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proteins in the 630 strain severely compromises the ability of spores to colonise the gut 
effectively. This is likely to be attributable to the effect on the exosporium of removing a 
significant component of the structure. The effect of a compromised exosporium has 
several facets. Firstly, properties that aid potential interactions with the host are altered. 
Hydrophobicity is reduced and although no host/spore specific interactions with specific 
receptors have been described, with a damaged exosporium the spores are at a significant 
disadvantage. Secondly, removal of the exosporium leaves the spore outer layers more 
exposed. Germinants have greater access to receptors on the spore, so germination can 
occur at a faster rate and in environments that may otherwise not encourage germination. 
Increased levels of germination could explain why few spores were detected in mice 
infected with BclA1- spores in the colonisation assay. 
In B. anthracis BclA has been shown to play no significant role in virulence, with a bclA 
mutant having no effect on pathogenicity in mice or in guinea pigs (Bozue et al. 2007a). 
Mutant and wild type strains also have similar LD50 values (Brahmbhatt et al. 2007b). This is 
in marked contrast to C. difficile where results from this chapter show at least one BclA 
protein, BclA1, to be involved in the initial stages of colonisation and infection. In mice and 
in hamster models of infection spores devoid of BclA1 were up to 2-logs less infective (i.e. 
by ID50) than isogenic wild-type spores. Hamsters that were colonised by the BclA1 mutant 
strain took longer to succumb to fatal disease, and fewer were colonised than in groups of 
hamsters infected with the wild type 630 strain. This suggests then that BclA1 could be 
involved in the initial stages of host colonisation and that this event must be mediated by 
the spore, an event occurring before spore germination. This also highlights the importance 
of the spore being able to colonise and persist in the GI tract environment, implying that 
without certain proteins, the spores are less effective at initial colonisation. 
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Even more intriguing was the observation that two 027 strains carried truncated BclA1 
proteins and that one of them,  R20291, a so-called ‘hypervirulent’ strain, was actually less 
infective in a mouse model of infection than the 630 strain. This observation is suggestive 
of a relationship between animal susceptibility and the presence of an intact BclA1 protein 
in the C. difficile spore. Spores of strains carrying a full length BclA1 protein (i.e. 630) 
appear able to colonise the murine GI tract better than those carrying a defective or 
truncated bclA1 gene. Interestingly there is already published work that supports this. For 
example, only 100 spores of 630 were required for 100% colonisation in hamsters but using 
the same dose lower levels of infection were found with a variety of B1 strains (Razaq et al. 
2007). Similarly, a larger dose of 104 spores of R20291 has been shown to produce 
complete infection in hamsters (Buckley et al. 2011). There is now evidence showing that 
hamsters are more susceptible to non-toxigenic strains of C. difficile than toxigenic strains 
(e.g. M68 and B1-7) (Buckley et al. 2013). The variation between strains is interesting and 
should be a key factor in studies looking further at spore proteins in particular. In 630, the 
BclA1 protein is clearly an important component of the exosporium, but as other strains of 
C. difficile lack this protein there must be alternative mechanisms that contribute to 
virulence. 
 
It has been proposed that hypervirulent 027 strains may have acquired additional virulence 
genes based on the considerable genetic differences between the epidemic and non-
epidemic strains (Stabler et al. 2009). However, data presented here suggests that in terms 
of initial colonisation the hypervirulent R20291 strain is actually less effective, that is, 
animals are less susceptible. This then raises some interesting and provocative questions. 
For example, whether animals including humans are actually less susceptible to 
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‘hypervirulent’ strains yet once colonisation occurs the severity of disease is much greater 
due to characteristics of the vegetative phase of this pathogen. In many ways this 
resembles the situation of influenza where seasonal flu strains are typically highly infective 
but of low severity compared to the low infectivity-high severity nature of H5N1 strains. If 
what happens in humans mirrors that in mice then the virulence of R20291 must arise not 
due to its infectivity but rather, due to some other factor affecting the severity of infection, 
e.g. levels of toxin production, increased persistence or faster germination. For the 027 
‘hypervirulent’ strains increased toxin production and biofilm formation (Dawson et al. 
2012; Dapa & Unnikrishnan 2013) have been identified as potential virulence factors. 
However, the presence of an intact BclA1 protein would correlate with the susceptibility of 
the host to infection and this implies that BclA1 may interact with a specific host target. 
Comparisons between diverse strains carry inherent risks and the presence of additional 
factors cannot be ruled out. A more detailed and extensive study of the bclA1 gene in 
clinically relevant strains coupled with analysis of infection stages will be required to 
address this but at this point it is clear that BclA1 plays a key role in the initial stages of 
infection and host susceptibility.  
 
Recent studies utilising genomic sequencing to track infections have shown that infections 
stem from diverse sources, not just transference between patients in hospitals as 
traditionally thought. The current thought is that C. difficile is acquired primarily from the 
environment but disease only manifests when colonic microflora is disrupted. The 
mechanisms that allow strains to persist in the GI tract until a niche is available for 
proliferation are unknown. Understanding this part of the infection cycle would provide 
valuable information in being able to prevent or treat infections before severe disease is 
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established. How persistence at low levels in the gut varies between strains will be of direct 
interest in understanding ‘hypervirulent’ strains. 
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5.4. Conclusion 
 
This work uses a genetic approach to removing the BclA proteins from C. difficile 630 
spores. Both in vitro and in vivo studies have been utilised to show that the three BclA 
proteins are integral components of the exosporium whose removal severely destabilises 
this outermost layer of the spore. The disruption to the exosporium layer allows increased 
access of germinants and reduces surface hydrophobicity. Infectivity of spores lacking 
BclA1 is also decreased, introducing this glycoprotein as a potential virulence factor in the 
630 strain. This encourages the hypothesis that initial colonisation is an important step in 
the infection cycle, and that colonisation is not a definite occurrence, especially considering 
the wide amount of variation that exists between strains of C. difficile. 
This work has led to the identification of the BclA1 protein as a potential colonisation factor 
in C. difficile infection. This presents this glycoprotein as a potentially important antigen 
that could be used in candidate vaccines that address colonisation as an issue. 
The results of this study encourage further work regarding variation in spore properties 
between strains and the make up of the exosporium. Identifying proteins of this layer will 
contribute to ascertaining an increased understanding of its role in the infection cycle. 
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Chapter 6 
General Discussion 
 
This thesis covered two main areas of study, the primary focus being the investigation of 
alternative treatments for CDI in order to reduce reliance on antibiotics. The secondary 
topic focused on the role of a specific spore associated protein BclA1. This protein was 
shown to play a role in initial colonisation of C. difficile, increasing knowledge with regard 
to the role of spores in this infection. As the mechanisms behind infection and persistence 
of this pathogen in the host are elucidated, more information is then available for design of 
novel treatments, linking to reducing antibiotic usage. 
 
6.1. Treatment for C. difficile 
Standard treatments for CDI rely on the use of specific antibiotics. Whilst treatment with 
either vancomycin or metronidazole can treat the infection, relapses will occur in around 
20% of cases (Barbut et al. 2000), highlighting a key problem with antibiotic treatment. The 
work of this thesis addressed two alternative approaches to treatment. Firstly, there is 
currently no licensed vaccine for prevention of CDI. In this thesis, a B. subtilis spore based 
vaccine (PP108) that was previously demonstrated to provide protection from fatal disease 
in a hamster model (Permpoonpattana et al. 2011a) was used in further study with a 
murine model. In the previous study, this vaccine was delivered orally in order to induce a 
mucosal response. In this thesis sublingual delivery was investigated as an alternative 
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method of immunisation and proved to be successful in both production of an immune 
response and protection from symptoms of disease. Secondly, the use of a B. subtilis strain 
was investigated as a potential probiotic treatment for CDI. Pure suspensions of B. subtilis 
spores given as an oral treatment were able to increase survival rates in a murine model of 
infection.  
 
6.1.1. Vaccines 
Development of a vaccine that would protect against C. difficile infection is important as it 
would provide an extra tool with which this infection could be controlled. Previous research 
has shown that a spore based vaccine (PP108) expressing a toxin A antigen provided 
protection against challenge in a hamster model of CDI, also protecting against relapse of 
infection. This work demonstrated, in agreement with other studies (Kim et al. 1987; Kyne 
et al. 2001), that antibodies against toxin A are sufficient to protect against a strain that 
produces both toxin A and toxin B, as antibodies against toxin A cross reacts with toxin B 
(Permpoonpattana et al. 2011a). This vaccine was delivered orally with a focus on 
producing a mucosal immune response. Both mucosal and systemic responses were 
elicited, with antigen specific IgA detected in faeces and antigen specific IgG detected in 
sera. This approach represents a deviation from the norm in C. difficile vaccine research, 
where a distinct focus is placed on parenteral vaccines and production of a systemic 
response. The PP108 vaccine was developed based on the idea that inducing a mucosal 
response will be a significant factor in successful protection against CDI. This hypothesis is 
based on several factors, firstly that IgA produced at mucosal surfaces in the colon have 
been shown to prevent binding of toxin A (Kelly et al. 1992). Secondly, producing a local 
response as well as a systemic response provides two levels of protection against the 
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disease.  The hypotheses of the original PP108 study were further investigated in this 
thesis, with alternative methods of delivering the vaccine and a new challenge model 
utilised. Sublingual delivery was used as a novel method for immunisation, this route of 
interest for several reasons: Oral routes of delivery tend to use high levels of antigens due 
to inaccurate delivery to mucosal surfaces and the risk of enzymes and pH damaging 
antigens. Oral immunisations are also associated with development of tolerance to the 
antigen. Sublingual dosing potentially avoids the issue of oral tolerance and reduces the 
amount of antigen required to generate an immune response. Use of the sublingual route 
allows the antigen direct contact with the oral mucosa where the antigen can be absorbed 
(Harris & Robinson 1992). Use of this route also reduces exposure of the antigen to 
potentially damaging conditions such as the low pH of the stomach. This thesis showed that 
in the murine model, both oral and sublingual routes for vaccine delivery demonstrated 
protection against severe symptoms of CDI.  
Research in this thesis showed that a spore based vaccine delivered via mucosal routes can 
initiate an immune response at both local and systemic level. This outcome demonstrates 
that both delivery route and the antigen used are successful and effective. The novel 
sublingual route was the most successful in terms of level of response and also protection 
rate in challenge studies. Mucosal routes for immunisations represent an easier approach 
to vaccination than use of parenteral routes. Eliminating the use of needles is a key 
advantage of the sublingual and oral dosing routes (Levine & Sztein 2004). This factor alone 
makes the spore based vaccine platform a promising step in vaccine development. Use of 
sublingual dosing addresses the issue of dysphagia, so even patients with difficulties 
swallowing can receive this vaccine.   
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Coupled with the ease of dosing, the PP108 vaccine candidate also provides a flexible 
platform for vaccine delivery, allowing adaptations to be introduced through the use of 
alternative or multiple antigens delivered in the same inoculum. Multivalent approaches to 
inducing protection are used in other diseases, such as seasonal influenza vaccinations 
(CDC 2013b) and experimental anthrax treatments (Hahn et al. 2006). The nature of the 
PP108 vaccine means that the antigen is expressed by the bacterium on the spore surface, 
thereby giving the benefit of reduced costs associated with protein production. The 
amount of antigen required for use in the vaccination is also reduced when using sublingual 
dosing, further increasing the economic benefits of this vaccine strategy.  
The protection shown in the murine model of CDI was not as clear cut as previously 
demonstrated in the hamster model. It should also be noted that in order to induce disease 
in the murine model, a different strain was employed from the original study. The strain 
used for murine infections was C. difficile R20291, a 027 ‘hypervirulent’ strain. In the 
murine model utilised in this work, the R20291 strain will cause obvious symptoms of 
disease, but not fatal infection as the 630 strain does in hamsters. This difference between 
the models highlights two important factors in C. difficile research. Firstly, differences 
between animal models are significant. There are several variations of the murine model 
for C. difficile infection (Chen et al. 2008; Theriot et al. 2011; Lawley & Young 2013) and it 
should be considered that variations in the study model also contribute to variations in 
results. The difference in strains used is also important given variation in virulence, ideally 
treatments should be tested against multiple strains to represent the real life situation 
where strains from multiple ribotypes can cause disease (Bauer et al. 2011). A successful C. 
difficile vaccine should protect against multiple strains, especially clinically relevant and 
‘hypervirulent’ strains. Use of cultured lab strains such as 630 provides a solid basis for 
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information, but as further study of virulence factors increases awareness of variation 
between strains (Lanis et al. 2013), vaccine protocols should also reflect this. Use of 
antigens common and homologous between strains of C. difficile is key to producing 
complete protection against this infection. Genetic analysis tools are useful for this and also 
in demonstrating the potential of this pathogen. The potential in C. difficile for evolution of 
virulence was seen clearly in the prevalence of the 027 ribotype in outbreaks of the early 
2000’s across North America and Europe (Pépin et al. 2004). Genome sequencing of the C. 
difficile strain 630 revealed a high proportion of mobile genetic elements across the 
genome demonstrating the capability of this organism to acquire traits by genetic transfer 
which could add to virulence properties (Sebaihia et al. 2006). Potential vaccine candidates 
using specific toxin antigens are effective at neutralising toxins, but if virulence of strains 
increases then use of alternative antigens may need to be addressed. A study using 
CD1342, a PaLoc negative strain of C. difficile, reported signs of pathology in the hamster 
gut despite lack of production of toxins (Buckley et al. 2013). This appearance of pathology 
in the absence of major virulence factors highlights the complexity of this disease and the 
challenge behind development of a successful vaccine. 
A significant consideration in the production of vaccines is the antigen used in producing a 
protective response. Toxin fragments or toxoids, representing the major virulence factors 
of C. difficile, are the favoured antigens for inducing protection against CDI. A key finding 
from the study in this thesis was that in groups showing protection from the symptoms of 
CDI, there were still high levels of C. difficile detectable in faecal samples. A reduction in 
severity of infection is a positive result in a potential treatment for CDI, but does not 
address the issue of this infection in its entirety. Understanding transmission and spread of 
cases is essential in developing better control strategies for this disease, something that is 
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complicated by limited knowledge surrounding reservoirs of infection and asymptomatic 
carriers. A vaccine that protects against symptoms without inhibiting the spread of the 
disease through asymptomatic carriers may have diminished efficacy in reducing cases of 
disease. Without a factor preventing spread and controlling prevalence of this pathogen, 
evolution of virulence factors could increase the virulence of this pathogen beyond the 
protection of the vaccination. Evolution of virulence has already been seen in certain clades 
of C. difficile, with the appearance of the 027 ribotype that caused severe outbreaks across 
North America and Europe in the early 2000s. Strains from the 027 ribotype have been 
reported as having increased virulence compared to historic strains. Factors that contribute 
to increased virulence are under debate, although increased virulence has been linked to 
higher toxin production and increased sporulation ability (Merrigan et al. 2010). As C. 
difficile remains prevalent in the environment it will be subjected to evolutionary pressure 
that could drive further developments in virulence. Therefore in order to address this issue 
the PP108 vaccine could be improved significantly by use of an antigen that prevents 
colonisation of the pathogen, providing a higher level of protection against infection than 
just neutralisation of toxins. Preventing colonisation by C. difficile has a twofold advantage. 
Firstly, this opportunistic pathogen cannot cause disease if it cannot colonise the gut. 
Secondly, by preventing colonisation by a non-commensal organism, the normal gut flora 
has an increased chance of returning to a healthy state without the GI tract environment 
being significantly altered by the colonisation of this pathogen. To protect against 
colonisation, an antigen from the spore or vegetative cell is required for the basis of the 
immune response.  
Studies in the literature have shown various surface layer proteins (SLPs) are able to elicit 
immune responses, with potential key proteins identified as Cwp66, FliD and FliC (Drudy et 
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al. 2004; Péchiné et al. 2005; Wright et al. 2008). Immunisations using these as antigens 
has shown no real success, with one such study using anti-SLP sera to passively immunise 
hamsters against disease (O’Brien et al. 2005). This approach extended the survival time of 
the animals, but failed to protect from fatal outcome of infection. Another study, this time 
using the flagella cap protein FliD to immunise mice, reported decreases but not prevention 
of colonisation in immunised mice, also concluding that a mucosal response was likely 
necessary for an effective immune response (Pechine et al. 2007). The observation that 
levels of colonisation can be reduced suggests that use of cell associated antigens is a 
feasible strategy for vaccination. It is possible that a multivalent approach is needed, 
incorporating both toxin and colonisation factors into a vaccine to produce several levels of 
protection. Multivalent vaccines are also used in influenza vaccines to protect against 
multiple strains, whereas this approach would target different stages of the infection. In 
vitro assays have been used to show the ability of spores to bind to epithelial cells 
(Paredes-Sabja & Sarker 2012) and it is generally accepted that spores are the primary 
mode of transmission for this infection (Deakin et al. 2012). Therefore a spore based 
antigen could show more potential for protecting against colonisation than a cellular 
antigen. With some proteins of the spore showing enzymatic activity (Permpoonpattana et 
al. 2013), they also have the potential to cause inflammatory responses, and as such could 
make ideal candidates as drug or vaccine targets. 
The advanced progress of Sanofi Adventis’ candidate C. difficile vaccine in clinical trials 
means that a vaccine for C. difficile should be available in the near future. However, this 
does not render all other investigations into vaccination strategies redundant. The work in 
this thesis demonstrates use of alternative methods for delivering a vaccine to a broader 
market and the successful generation of protection from disease symptoms. The 
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mechanism which allows generation of both systemic and mucosal immune responses is 
highly advantageous. The platform technology could also be applied to other infections, so 
contributing to the wider field of infection control, as well as C. difficile. 
 
6.1.2. Probiotics 
Probiotics are poorly described as a medical treatment for C. difficile and other GI tract 
conditions. Perception of probiotic use is greatly overshadowed by simplified marketing 
campaigns aimed at the general public which feature terms such as ‘good’ and ‘bad’ 
bacteria without any focus on the science behind a product. The potential for use of 
probiotics in clinical situations does attract attention however, especially with increased 
interest into the role the microflora plays in health and development. This is especially 
relevant to treatment of C. difficile where the state of the gut microflora is directly linked to 
risk of developing symptoms of C. difficile infection. Only a limited number of studies have 
produced findings powerful enough to provide definitive data on the efficacy of probiotics 
in the treatment or prevention of C. difficile. The issue is further complicated by the wide 
range of strains and products used in studies, often without clear definition of the strain. 
Recent changes in legislation have provided an incentive for investment in producing 
scientific evidence for probiotic based health claims rather than relying on anecdotal 
evidence (Saxelin 2008). Information from probiotic studies can also contribute to our 
understanding of how the microbiome can contribute to disease and how manipulation of 
the microbiome can be exploited for treatments.  
Commonly used probiotics in association with GI tract disorders are Lactobacilli spp. and 
the yeast Saccharomyces boulardii. The work of this thesis took a new approach, using a 
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Bacillus subtilis strain, novel due to the spore forming ability of the species. The use of 
spores in a probiotic product has several benefits. Spores are heat stable and resistant to 
environmental extremes so packing and storage requirements of the product are simpler 
than products using vegetative forms of probiotic strains. Additionally, the resistance 
properties of spores mean that bacteria are less susceptible to damage when in transit 
through the GI tract. B. subtilis spores are able to germinate in the gut so spores act as a 
transit vehicle for delivery of the vegetative forms. Heat inactivated spores demonstrate no 
beneficial effect in the murine model tested, implying that germination of spores and 
ability for vegetative growth is essential for the success of this strain. The B. subtilis PXN21 
strain was also shown to transiently colonise the murine gut with presence diminishing as 
normal microflora restored balance. Recovery of the normal microflora is an important 
factor when using treatments that could affect the structure or make-up of the flora. An 
issue not addressed by this study was the lasting effects of probiotic use and whether any 
shifts in the flora occurred that could be attributed to use of the probiotics. How the gut 
flora is affected by probiotic use in the long term is important as the state and structure of 
the microflora is reported to have implications for many conditions, not just in 
susceptibility to CDI.   
 
In this current research, a study was performed demonstrating the benefits of the B. 
subtilis PXN21 strain in mice, which provides a useful preliminary model for infection 
studies. However, for clinical application these probiotics would be used in humans. Human 
subjects do not have uniform genetics, microflora or medical case histories, introducing a 
level of complexity that our study model cannot address. Trials in humans would show the 
real effectiveness of this treatment. The murine model used in this work allows controlled 
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preliminary work to be carried out, appraising the potential of a bacterial strain. Limitations 
are common in existing probiotic studies, which is understandable given the complex 
nature of CDI, the range of patients that are potentially vulnerable and general regulations 
in the use of human subjects. If potentially useful bacterial strains and mechanisms of 
probiotic action can be elucidated using models and studies as shown in this thesis, human 
trials could be planned according to information about the strain. This would enable 
studies in humans that carry more weight and significance, furthering our ability to use 
microbes to manipulate health status.   
 
The basis of the protection given by probiotics doses of B. subtilis spores is difficult to 
attribute to one specific mechanism. Results from this thesis suggest that interactions of 
the probiotics aid defence of the mucosal barrier that protects the cells lining the gut. It is 
clear that this treatment prevents disease by protecting against toxin mediated damage 
rather than acting by preventing colonisation of this pathogen. Suppression of symptoms is 
a clear benefit in a potential treatment although an ideal treatment would also eliminate 
the infection. The B. subtilis PXN21 strain has the potential for use as a supplement to 
traditional antibiotic treatments, attenuating symptoms while antibiotics are used to 
resolve the infection. Eradication of the infection has to be a priority alongside reducing the 
symptoms of disease. Use of a probiotic strain as bacterial therapy during the course of 
antibiotic treatment could also contribute to repopulation of the gut and accelerated 
recovery of the microflora after infection. It should be noted that use of a single strain will 
not provide the benefits of a healthy, complex microflora, emphasising the case for 
reducing and monitoring antibiotic usage and effects. 
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Epidemiological evidence, numbers of relapsing cases and severe infections contribute to 
the complexities of managing C. difficile for healthcare providers. Treatments cannot rely 
exclusively on antibiotics, as currently available antibiotics do not produce adequate 
results; the relapse figures are a clear example of this (Barbut et al. 2000). One of the most 
successful treatment options for prevention of relapses is the use of faecal transplant 
therapy (Rohlke & Surawicz 2010; Brandt et al. 2012), this approach treats the disrupted 
microflora as a cause of susceptibility to infection rather than treating just the infection. 
Antibiotics that can eradicate infection from the gut are important, but are also principal 
risk factors for CDI. Bacteriotherapy addresses the risk associated with antibiotics by 
replacing microflora and preventing proliferation of C. difficile in the GI tract. ‘Synthetic 
stools’ which give the benfits of faecal transplants without the drawbacks, are being 
developed (Lawley et al. 2012; Petrof et al. 2013). This approach fits into the definition of 
probiotics: ‘Live microorganisms which when administered in adequate amounts confer a 
health benefit on the host’ (Araya et al. 2002). Whilst on a small scale, studies like the work 
in this thesis that assess the potential of individual bacterial strains are useful. 
Identification of strains with particular attributes is necessary to create mixtures of 
bacterial strains that can be used to replace or modify the gut microflora. Treatments 
targeting repopulation of the gut could have wide ranging applications. Restoration of gut 
homeostasis and a healthy condition would prove beneficial to not just infections of C. 
difficile but also other conditions related to dysbiosis such as colitis and IBD.  
 
This work has presented a method of probiotic treatment that reduces symptoms of CDI 
through use of B. subtilis PXN21 spores. The strain is one used in a commercial probiotic 
mix, with no reported safety issues. Regulations on probiotic constituents have become 
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more stringent over the past few years, so more than anecdotal evidence of safety is 
required. However, the use of the B. subtilis PXN21 strain in attenuation of CDI symptoms 
has been demonstrated, highlighting the potential of this strain.  
 
Understanding the role that the microbiome plays in susceptibility to C. difficile will 
facilitate the use of bacteriotherapy and of particular bacterial strains as probiotics. 
Research associated with the Human Microbiome Project (Turnbaugh et al. 2007) will be 
particularly useful in elucidating the interactions and complex communities required for 
particular gut functions. Through information gathered in the study of probiotics, key 
bacterial strains can be identified that hold potential for the manipulation of the gut 
microflora to re-establish healthy conditions.  
 
6.2. Role of the BclA spore coat protein 
The second aspect of this thesis evaluated the role that the BclA spore associated protein 
plays in infection. The data that resulted from this study is of interest for several reasons. 
Firstly, the BclA1 protein is identified as an important protein for colonisation of the 
pathogen in the infection cycle. Secondly, the state of the spore coat alters properties of 
spores. This is important for studies that utilise purified spores in experimental work as the 
method used to produce the spores could potentially affect results.  
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The formation of spores is a key process in the survival and infection process for this 
bacterium, allowing persistence of the infection both in the gut and in the environment. 
Producing consistent data about spores and understanding the role they play is important. 
In this work, a non-ionic density gradient medium (Histodenz, Sigma) was used in spore 
purification in order to keep surface layers of the spore as intact as possible. Use of 
enzymes and sonication for purification of spores is well established for Bacillus spores 
(Harwood & Cutting 1990) and adaptations of these methods have been successful in 
generating pure suspensions of C. difficile spores (Lawley et al. 2009b).  Use of these 
methods degrades proteins and structures associated with the spore however, reducing 
the similarity between wild type and laboratory produced purified spores. C. difficile is 
described as having an exosporium layer, which is removed by harsh purification methods 
(Escobar-Cortés et al. 2013). This layer is likely to play an important role in how the spore 
can interact with the surrounding environment, so it is important that studies of spores 
take this into account when designing spore purification protocols. The number of 
predicted spore coat genes in the sequenced genomes far exceeds those that have been 
identified and studied (Sebaihia et al. 2006; Permpoonpattana et al. 2013). However, it is 
important that when the surface layers of spores are studied, they represent as close as 
possible the wild type form of the spore.  
The work of this thesis addressed the importance of the BclA proteins and previous work 
from the Cutting group at Royal Holloway has also investigated enzymatic properties of 
some spore coat proteins (Permpoonpattana et al. 2013). The spore coat however, is a 
complex structure made up of at least 50 proteins (Abhyankar et al. 2013). The analysis of 
the spore coat by Abhyankar and colleagues uses spores purified using proteinase K, so 
does not address the composition of the exosporium. Further study is required before our 
 
Chapter 6  General discussion 
 
 
210 
 
working knowledge of the spore surface layers is complete. Genetic and molecular tools 
give us the ability to identify and work with individual proteins but ideally, the spore as a 
complete structure needs to be assessed, as it is unlikely that infection will depend on a 
single protein. Variation between strains belonging to the same ribotype has been 
demonstrated in other characteristics such as germination studies (Heeg et al. 2012). The 
potential for significant variation in spore coat layers between different strains should also 
be considered therefore. 
 
The state of the spore coat has also been demonstrated to be important for transmission. 
Work on a transmission model of C. difficile showed that spores from faecal samples were 
more effective at transmitting disease than purified spores (Lawley et al. 2010). This has 
implications for all studies assessing the properties of spores, as the purification methods 
used will affect how much of the spore coat is present and in what state. The potential for 
differences between strains should also be considered here. The results of this thesis show 
clear differences in germination rate, hydrophobicity and the colonisation ability of spores 
lacking BclA proteins. EM images showed aberrations to the spore surface and empty 
structures in suspensions of BclA mutant spores. These images and alteration of properties 
suggest that BclA plays a role in attachment of the exosporium. Removal of this layer 
results in increased germination rates and a reduced ability to colonise an animal host. The 
role of the BclA proteins has also been assessed in a recent study (Pizarro-Guajardo et al. 
2013) but a different approach was taken. Pizarro-Guajardo and colleagues used wild type 
spores that were treated with collagenase to remove the BclA proteins instead of using 
mutants in these particular genes. This variation in methodology can account for 
differences in conclusions and again highlights how different approaches can result in 
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conflicting results. Clearly the outer layers of the spore structure are important and further 
study of spores will enable additional properties to be elucidated.  
 
 The interest in the BclA protein is due to parallels drawn to work with B. anthracis where 
this protein is a key component of the exosporium (Sylvestre et al. 2002). The BclA protein 
of B. anthracis was reported as an immunodominant antigen on the spore surface 
(Steichen et al. 2003). Earlier, discussion focused on the need for successful vaccines to 
express more than just an immune response against toxins, but also address the need for 
preventing colonisation. Based on studies from B. anthracis, the BclA proteins identified in 
C. difficile become interesting candidates for antigens to be used in a vaccine that could 
potentially prevent colonisation of C. difficile. There is little information in the literature 
about immunogenicity of C. difficile spore associated proteins, although the BclA protein 
has been reported as having limited immunogenicity (Pizarro-Guajardo et al. 2013). This 
however should not rule out the possibility of spore associated proteins being useful in this 
context.  
 
Colonisation of individuals with C. difficile should be an important consideration in any 
control measures for this pathogen. Recent research shows that spread of infection in 
hospitals is actually overestimated, with only around a quarter of cases that can be 
attributed to contraction within hospitals (Walker et al. 2012). This study raises several 
issues, the main question being if infections are not passed between patients in hospitals, 
where do they indeed come from? The study did not investigate colonisation of 
asymptomatic individuals, which ignores a potential source of infection. Screening of all 
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patients and visitors would be a huge undertaking, but could identify currently undetected 
sources of infections. For example, nurses, doctors and visitors all have contact with 
patients and could all potentially be carriers of C. difficile. The transmission study 
encourages a fresh view on C. difficile infection and its transmission, with infections not just 
spread between symptomatic individuals or on inanimate objects and surfaces, but 
disseminating through less obvious routes of transmission. It is also feasible that patients 
who develop symptoms of CDI in hospital were already colonised before entry to hospital. 
 
 The increase in community associated cases of CDI highlights an aspect of C. difficile 
epidemiology that would benefit from further study. With little known about reservoirs of 
infection, it is difficult to design comprehensive control measures. A vaccine that focuses 
on reduction or prevention of colonisation would reduce the issue of asymptomatic 
carriers, as this reservoir of infection would be reduced if the vaccine was widely used. The 
work of this thesis has demonstrated an effective, easily applicable method for mucosal 
delivery of antigens, inducing a protective response local to the site of infection. Coupled 
with the finding that the BclA1 protein is important for initial colonisation and persistence 
of C difficile infection, a new strategy for vaccination is apparent. The spore based vaccine 
delivery platform could be engineered to deliver both toxin and spore coat protein antigens 
to the relevant surfaces in a multivalent strategy. This would protect against symptoms of 
the disease mediated by toxins, but also produce an immune response against initial 
colonisation of this pathogen. A similar approach has been investigated previously, using a 
cell associated antigen (Pechine et al. 2007) that resulted in reduced colonisation of C. 
difficile. This is a promising result and strengthens the plausibility of the approach. Spores 
of C. difficile are identified as persistence factors, so it is proposed that use of a spore 
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rather than cell associated antigen will be a more successful approach to preventing 
colonisation by vaccination. 
The role of spores in C. difficile infection is important. With further study regarding the role 
spores play in transmitting and persistence of the infection, this information can be 
exploited for development of new treatments and control programs.  
The BclA protein of C. difficile 630 spores is demonstrated to be of importance for 
colonisation in animal models. The exosporium and spore coat of C. difficile contain many 
other proteins that could be investigated for similar properties. As comprehensive study of 
the toxins of C. difficile has contributed to elucidating virulence mechanisms, continued 
study of the spore surface layers will contribute to understanding the ability for persistence 
of this organism.   
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6.3. Conclusions 
Clostridium difficile, whilst only emerging as a significant pathogen in the last 30 years, is a 
serious problem in developed countries, not just as a nosocomial infection but also 
increasingly within communities. The results of this thesis contribute to the development of 
potential treatment strategies for CDI that could reduce reliance on antibiotics, as well as 
addressing the role of the BclA spore protein in infection. An increased understanding of 
the complex infection process of C. difficile enhances our ability to produce effective 
treatments against CDI. Alternative treatment strategies such as vaccination and use of 
bacteriotherapy could reduce reliance on antibiotics and bring infections under control. 
A key example of how investigating the processes used by C. difficile for infectious 
capability can benefit development of treatments is demonstrated in the work of this 
thesis. The BclA1 protein of C. difficile 630 was identified as a potential colonisation factor. 
Coupled with research also carried out into alternative methods for delivery a candidate 
vaccine, this presents an interesting avenue for future work. The vaccine platform is 
adaptable and could be used to develop a vaccine with BclA as an antigen that has 
potential to prevent colonisation of C. difficile; an approach that is currently not employed 
in potential vaccines for C. difficile. This approach would address issues such as reservoirs 
of infection where little is currently understood, enabling enhanced control of disease to be 
established. 
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Summary
The BclA protein is a major component of the outer-
most layer of spores of a number of bacterial species
and Clostridium difficile carries three bclA genes.
Using insertional mutagenesis each gene was char-
acterized and spores devoid of these proteins had
surface aberrations, reduced hydrophobicity and ger-
minated faster than wild-type spores. Therefore the
BclA proteins were likely major components of the
spore surface and when absent impaired the protec-
tive shield effect of this outermost layer. Analysis of
infection and colonization in mice and hamsters
revealed that the 50% infectious dose (ID50) of spores
was significantly higher (2-logs) in the bclA1− mutant
compared to the isogenic wild-type control, but that
levels of toxins (A and B) were indistinguishable from
animals dosed with wild-type spores. bclA1− spores
germinated faster than wild-type spores yet mice
were less susceptible to infection suggesting that
BclA1 must play a key role in the initial (i.e. pre-spore
germination) stages of infection. We also show that
the ID50 was higher in mice infected with R20291, a
‘hypervirulent’ 027 strain, that carries a truncated
BclA1 protein.
Introduction
Clostridium difficile is a leading cause of nosocomial
antibiotic-associated diarrhoea in industrialized countries
(Rupnik et al., 2009). This spore forming bacterium is able
to colonize the gastro-intestinal (GI) tract of infected
patients and, during antibiotic therapy, the resulting distur-
bance to the natural gut microflora promotes germination
of C. difficile spores, outgrowth and proliferation of live cells
(Songer and Anderson, 2006) followed by shedding of
large numbers of spores in the faeces (Lawley et al.,
2009a). Disease is caused mainly by the production of two
toxins,A(TcdA) and B (TcdB), which leads to diarrhoea and
in more severe cases, pseudomembrane colitis (Rupnik
et al., 2009). The spore of C. difficile is the dormant state of
this organism and the primary agent of transmission
(Gerding et al., 2008). This has been supported by recent
studies where a mutant strain of C. difficile, unable to
produce the Spo0A protein (a transcriptional regulatory
protein essential for the initiation of sporulation) fails to
persist and transmit the disease (Deakin et al., 2012).
Interestingly, mice infected with C. difficile can exist in two
physiological states, a carrier state, where low levels of C.
difficile spores are shed in the faeces and a ‘supershedder’
state where large numbers of spores are shed (Lawley
et al., 2009a). This ‘supershedder’ state is induced follow-
ing antibiotic treatment and most closely resembles the
clinical situation where patients contract C. difficile infec-
tion. Capable of withstanding heat, desiccation and
noxious chemicals, spores transmit C. difficile outside of
the host and therefore present a major burden to hospitals
in containment and disinfection (Gerding et al., 2008).
Strains producing neither toxin are completely attenu-
ated in the hamster model of infection (Kuehne et al.,
2010) yet non-toxigenic strains have been found to be
endowed with vaccine-strain attributes. Although toxin A
and toxin B are considered the two main virulence factors,
others cannot be excluded; for example, it has been
shown that hamsters challenged with spores of the non-
toxigenic strain CD1342 showed mild caecal pathology
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characterized by local acute epithelial cell loss, haemor-
rhagic congestion and neutrophil infiltration (Buckley
et al., 2013). Hamsters colonized with non-toxigenic
strains, M3 and T7, were protected against challenge with
toxigenic B1 group strains (Nagaro et al., 2013), suggest-
ing non-toxic strains can exclude toxigenic strains from
colonization. However, the mechanism for how these non-
toxigenic strains confer protection remains both intriguing
and unclear.
The role of the spore in transmission of the disease
suggests that this dormant life form may play a key role in
colonization, a process better divided into three stages:
establishment of infection, maintenance of infection (per-
sistence) and spore shedding. Spores of C. difficile resem-
ble those of other Gram-positive spore-formers but differ
somewhat in the abundance of enzymes they carry on their
surface layers including three catalases and a bifunctional
peroxiredoxin-chitinase (Permpoonpattana et al., 2011b;
2013). C. difficile spores also carry a poorly defined outer
surface layer whose function has been linked to germina-
tion, adhesion and resistance properties of the spore
(Henriques and Moran, 2007; Lawley et al., 2009b;
Escobar-Cortes et al., 2013). This outermost layer of C.
difficile spores has similarities to the exosporium of
some spore formers but conflicting published data have
delayed a definitive assignment. The BclA (bacillus
collagen-like protein of anthracis) glycoprotein is a major
component of the exosporium in some spore formers that
can form hair-like filaments and carries collagen-like
repeats of the amino-acid triplet GPT used for attachment
to oligosaccharides (Sylvestre et al., 2002; 2003; Steichen
et al., 2003). A second collagen-like protein, BclB has also
been identified in Bacillus anthracis and has been linked to
exosporium assembly (Waller et al., 2005; Thompson and
Stewart, 2008).
The genome of C. difficile 630 carries three bclA genes
(bclA1–3) which, other than a recent paper (Pizarro-
Guajardo et al., 2014) showing that BclA1 is located on the
spore surface, have not been characterized in any detail.
To define gene function we have used insertional mutage-
nesis to disrupt each gene coupled with analysis of infec-
tivity of mutants in two different animal models, mice and
hamsters. We conclude first that BclA1 appears to be a
critical factor in the initial stages of colonization, and
second that truncation of BclA1 in some 027 strains may
account in part for a reduced infectivity of these strains.
Results
The C. difficile bclA genes
Three genes encoding BclA-like proteins, annotated as
bclA1, bclA2 and bclA3 are present on the genome of strain
630 (Fig. S1) and encode proteins with predicted masses
of 67.8, 49.0 and 58.2 kDa respectively. Similar to the BclA
proteins found in B. anthracis and B. cereus, all three C.
difficile BclA proteins consist of an extensive, central,
collagen-like region with multiple GXX repeats flanked by
N- and C-terminal domains of variable length (Fig. 1A and
B). Most of the triplet repeats are GPT with nearly all
Fig. 1. A. Schematic representation of the domain structure of BclA proteins from B. anthracis Sterne (AY995120.1) and C. difficile 630
(BclA1, CAJ67154.1; BclA2, CAJ70128.1; BclA3, CAJ70248.1). The central, collagen-like region (purple) contains multiple GXX repeats and is
flanked by the N-terminal (green/blue) and C-terminal (orange/red) domains. In B. anthracis the C-terminal domain mediates trimerization of
the BclA monomers while the N-terminal domain is implicated in anchoring the proteins to the exosporial basal layer. The function of these
domains in C. difficile remains to be confirmed.
B. Pair-wise alignment of the same BclA protein sequences from B. anthracis Sterne and C. difficile 630. Most sequence similarity is limited to
the central, collagen-like region. Key: black, 100% similarity; dark grey, 80–100%; light grey, 60–80; white, < 60%. Pair-wise identity was
generated using CLUSTALW and a Blosum62 scoring matrix and between all four proteins was 39.1%.
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containing a threonine residue, which could provide multi-
ple potential sites for O-glycosylation as seen in B. anthra-
cis (Daubenspeck et al., 2004) (Fig. S2). Bioinformatic
comparison of BclA protein sequences from B. anthracis,
B. cereus and C. difficile revealed that most of the similarity
between the proteins is limited to the collagen-like central
region since both the C- and N-terminal domains of the C.
difficile BclA proteins seem to be distinct from those found
in other species (Fig. S3). In B. anthracis BclA these ter-
minal regions are implicated in trimerization of the BclA
monomers and their attachment to the exosporial basal
layer (Boydston et al., 2005; Thompson and Stewart,
2008). Notably, the C. difficile BclA proteins do not appear
to carry at their N-termini a sequence resembling the motif
(LIGPTLPPIPP) that targets the BclA and BclB proteins of
B. anthracis to the exosporium (Tan and Turnbough, 2010;
Thompson et al., 2011a,b).
Phenotypes of bclA mutant spores
ClosTron mutagenesis can be used to inactivate genes by
using a group II intron to insert an erythromycin resistance
allele within a target gene (Heap et al., 2009). Using this
technique, the three bclA genes were inactivated in strain
630Δerm creating the mutants bclA1−, bclA2− and bclA3−
(Table 1). In bclA1 and bclA2, the erythromycin resistance
cassette was inserted in the anti-sense direction, while in
bclA3, it was in the sense direction. Mutants were exam-
ined for their sporulation and germination phenotypes in
parallel with the isogenic Spo+ parent strain, 630Δerm.
Growth and sporulation of mutants in liquid medium was
essentially identical between strains with approximately
104–105 spores ml−1 produced after 5 days (Fig. S4).
Histodenz-purified spores of all mutants showed no sus-
ceptibility to treatment with heat, ethanol and lysozyme
(Table S1). Transmission electron microscopy (TEM) was
used to examine the structure of wild-type and mutant
spores (Fig. 2). Compared to 630Δerm spores (Fig. 2A) it
was clear that for the bclA1− and bclA2− mutants they
carried substantial aberrations in the spore coats. In both
cases sheets of coat-like material were present in the
medium (Fig. 2C and E) as well as angular projections of
material at the spore surface (Fig. 2B and D). The bclA3−
mutant did not present any apparent defect compared to
wild-type spores nor was any coat-like material shed into
the culture medium (Fig. 2F). The hydrophobicity of spores
was assessed by measurement of the optical density of the
aqueous layer after mixing with hexadecane. All three bclA
mutants were found to be significantly (P < 0.035) less
hydrophobic than spores of the wild-type 630Δerm (Fig. 3).
It has been shown recently that sonication of C. difficile
spores is efficient at removing the putative exosporium
(Escobar-Cortes et al., 2013) and for comparison we dem-
onstrated here that sonication of spores significantly
(P < 0.024) reduced the surface hydrophobicity of
630Δerm, bclA1 and bclA2 mutant spores. Polyclonal anti-
bodies raised against recombinant BclA1, BclA2 and
BclA3 proteins were used to confirm that each protein was
(i) located on the surface of 630Δerm spores, (ii) absent in
vegetative cells and (iii) not present in spores of the corre-
sponding isogenic mutant (Fig. 4).
Purified spores were assessed for their ability to germi-
nate in BHI medium supplemented with 0.1% sodium
taurocholate as a germinant (Table 2 and Fig. S5). Ger-
mination correlates to a loss in OD600 as spores rehydrate
and become phase dark. 630Δerm spores germinated
relatively slowly with a 16% reduction in OD600 over a 30
min period. All three mutants germinated faster than the
wild-type strain with the bclA1− and bclA2− mutants exhib-
iting the highest germination rates with 40% and 34% loss
in OD600, respectively, over 30 min. As a control, spore
germination was conducted in parallel in the presence of
the inhibitor sodium chenodeoxycholate. In the presence
of this inhibitor, spores of wild-type and all bclA mutant
strains remained stable and exhibited a maximum OD600
drop of 5–6% over 30 min. Germination of sonicated
Table 1. C. difficile bclA genes and mutations.
Gene Locus taga Encoded proteinb Mutant allelec Retargeted sequenced
bclA1 CD0332 Putative exosporium
glycoprotein (83 kDa)
bclA1::CT1050a ACTCCTGTCGCTCCTGTTGGACCTGTTGCT<intron>CCTGTTGGTCCTATA
bclA2 CD3230 Putative exosporium
glycoprotein (67 kDa)
bclA2::CT150a GCTCCATTTGCTCCTGTTGCTCCTGTCGCC<intron>CCTGTTGCTCCTGTC
bclA3 CD3349 Putative exosporium
glycoprotein (79 kDa)
bclA3::CT125s GTCGTGATGATTATAATAGCTGTGATTGC<intron>CATCATTGCTGTCCAC
a. As described in Sebaihia et al. (2006) and schematically in Fig. S1.
b. Predicted MW of full-length protein in brackets.
c. The mutant allele is shown with (a) CT designing ClosTron insertion, (b) the number showing the bp within the ORF immediately preceding the
ClosTron insertion and (c) letter a indicating insertion in the antisense strand.
d. The 45 bp targeting sequence produced using the http://www.clostron.com algorithm and used for mutant construction. The intron insertion site
within the 45-mer target sequence is shown.
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Fig. 2. Ultrastructure analysis by TEM.
A. High-magnification image showing purified 630Δerm spores with a normal morphology. Bar: 100 nm.
B and C. bclA1− purified mutant spores showing clear defects including sheet-like material on the outermost layer (arrows indicated). Bars:
100 nm (panel B) and 0.5 μm (panel C).
D and E. Ill-formed bclA2− purified mutant spores with sheet-like material (arrows indicated). Bars: 200 nm (panel D) and 0.2 μm (panel E).
F. A bclA3− mutant spore showing normal morphology. Bar: 100 nm.
Fig. 3. Spore hydrophobicity. The SATH
assay was used to calculate % hydrophobicity
of Histodenz-purified spores of wild-type and
mutant spores with (open column) or without
sonication (grey column). The analysis was
performed three times. The asterisk (*)
indicates values significantly different between
bclA mutants and 630Δerm (bclA1−, 0.036;
bclA2−, 0.0064; bclA3−, 0.0006) and sonicated
mutant and 630Δerm spores (bclA1−, 0.02;
bclA2−, 0.0243).
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spores of the wild-type strain, evaluated in parallel,
revealed an OD600 drop of 29%, indicating that disruption
of the spore surface layers enhanced germination
(Fig. S5).
Infectivity of bclA mutants in the mouse model
of infection
The recently described mouse model of cefoperazone
pre-treatment to induce C. difficile infection (Theriot et al.,
2011) was used to evaluate the progress of shedding of C.
difficile spores. Animals were given a single dose (104) of
mutant or wild-type spores (Fig. 5). Total counts (spores
and vegetative cells) of C. difficile shed in the faeces
ranged from 104 to 106 per gram although somewhat
lower counts were found for the bclA1− mutant (Fig. 5B).
Mice body weights remained similar with no significant
differences between groups (data not shown). Heat-
resistant spore counts of 630Δerm-dosed mice declined
over time (Fig. 5A). Spores were not found in the faeces
from mice dosed with the bclA3− mutant on day 1, even if
substantial levels of spores were detected on days 3, 5
and 7. Spore counts of both the bclA2− and bclA3−
mutants increased after day 1 and were substantially
higher (> 1-log) on days 3, 5 and 7 if compared to that of
wild-type infected animals (Fig. 5A). Surprisingly no heat-
resistant spores were detected for the bclA1− mutant in
the faeces post infection (Fig. 5A) in all the time points.
The experiment has been repeated with similar findings.
However, using a dose–response assay (Table 3 and
Fig. S6) where counts were detected following ethanol
treatment spores of the bclA1− mutant were clearly
detected in the faeces albeit at lower levels than in mice
infected with wild-type 630 spores. This suggested that
the bclA1− mutant spores in faecal samples were suscep-
tible to heat treatment but not to ethanol. One explanation
might be that the bclA1− mutant, being more germination
proficient than the isogenic parent strain 630 was more
susceptible to heat treatment, or more likely, that heat was
producing premature germination of bclA1− mutant
spores. For this reason, in subsequent analysis we used
ethanol for measurement of wild-type and mutant spores.
Fig. 4. Surface display of BclA proteins.
Surface display of BclA1, BclA2 and BclA3
using immunofluorescence imaging of
suspensions of 630Δerm, bclA1−, bclA2− and
bclA3− spores (7-day-old cultures grown on
solid medium) labelled with mouse serum
(1:1000 dilution) raised against each of the
three BclA proteins. An anti-mouse
IgG-TRITC conjugate was used for secondary
labelling. BclA1, BclA2 and BclA3 proteins
were detected on both purified and
non-purified 630Δerm spores whereas the
bclA mutants showed negative signals.
Controls included vegetative cells of wild-type
and mutants.
Table 2. Germination phenotypes.
Spores
% germinationa
+ Inhibitor + Germinant
630Δerm 5.6 ± 3.3 15.6 ± 4.3
bclA1− 6.2 ± 2.2 40.2 ± 0.7
bclA2− 5.9 ± 2.0 34.4 ± 1.3
bclA3− 5.3 ± 2.5 20.5 ± 1.8
630Δerm (sonicated) 5.6 ± 0.6 29.1 ± 0.9
a. Per cent germination was determined as % loss in OD600 in the
presence of inhibitor (0.1% sodium chenodeoxycholate) or germinant
(0.1% sodium taurocholate).
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Returning to the dose response assay this showed that
the number of spores required to infect 50% of mice (ID50)
was 2-logs higher in the bclA1− mutant compared to the
wild-type control. In contrast to 630, spores of the bclA1−
mutant were not detectable 3 and 4 days post infection
(Fig. S6). Together these data show that bclA1− mutants
are less infective than wild-type strains.
Reduced colonization by a ‘hypervirulent’ 027 strain
Analysis of the bclA1 genes in the genome sequences of
two ribotype 027 strains, R20291 and CD196 (Stabler
et al., 2009) revealed a stop codon at position 48 in addi-
tion to an asparagine to lysine change at position 3 in the
ORF (Fig. S7). We have independently sequenced the
bclA1 gene in R20291 and confirm that the stop codon is
present and is not a sequencing error. As such, the 027
strains must each encode a BclA1 protein of approximately
6 kDa and, being significantly smaller than the one found in
strain 630, would presumably lack function. Using antibod-
ies raised against BclA1 (from strain 630) we have been
able to identify BclA1 on the surface of both R20291 and
CD196 spores suggesting that the truncated protein can
assemble into the exosporium in these 027 strains
(Fig. S8).
R20291 is a so-called ‘hypervirulent’ strain (Stabler
et al., 2009; Buckley et al., 2011), is clinically relevant and
would, prima facie, be considered more virulent than the
630 strain. Our studies suggest that bclA1 deletion would
impair colonization. Therefore, to determine the infectivity
of a 027 strain carrying a truncated BclA1 protein, the
ability of R20291 spores to colonize mice was analysed as
previously described for 630Δerm and the bclA1 mutant
(Table 3 and Fig. S6). The ID50 for R20291 was 1 × 103 and
therefore ten-times less infectious than 630 but more infec-
tious than a strain completely devoid of BclA1, suggesting
a correlation between the presence of an intact BclA1
protein and the susceptibility of mice to colonization. Inter-
estingly, compared to the 630Δerm spores, R20291 spores
(i.e. at doses ≥ 103) were able to persist longer in the
GI-tract and were maintained at higher levels.
BclA1 is a virulence determinant in hamsters
Hamsters provide a more acute model of C. difficile infec-
tion (Sambol et al., 2001; Goulding et al., 2009) with wild-
type strains causing a rapid fulminant infection most likely
due to the sensitivity of these animals to C. difficile toxins.
Accordingly, this model was used to evaluate the infectivity
of bclA1− mutant spores. In a preliminary study, groups of
Fig. 5. Colonization of mice with C. difficile
bclA mutants. Groups of mice (n = 4) were
orally administered a regimen of
cefoperazone and then infected orally with a
single dose (1 × 104) of 630Δerm spores or
spores of one of the three bclA mutants.
Freshly voided faeces was analysed for
heat-resistant spore counts (panel A) and total
counts (spores plus vegetative cells) (panel B)
on days 1, 3, 5 and 7 post infection.
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three hamsters were dosed with 102, 103 or 104 of 630Δerm
or bclA1− spores (Fig. 6A). Significant differences were
observed in survival times between wild-type and mutant
(102, P = 0.003; 103, P = 0.008; 104, P = 0.0003) as well as
in the dose-dependent response. Using an infective dose
of 102 630Δerm spores the clinical end-point was reached
in approximately 40 h while this was delayed until approxi-
mately 47 h with the same dose of bclA1− mutant spores.
This study was repeated using 10 hamsters per group and
two doses, 10 and 102 spores, of either 630Δerm or the
bclA1− mutant.As shown in Fig. 6B, a dose of 102 spores of
630Δerm resulted in no survival of infected animals while a
lower dose of 10 spores resulted in the survival of two
animals. By contrast, the bclA1− mutant was clearly less
infective with 50% survival following a dose of 10 spores
and 20% survival using 102 spores. The calculated ID50 for
630Δerm spores was 2.37 × 101 and for the bclA1− mutant
2 × 102, indicating that the bclA1− mutant was ten-times
less infective. Animals infected with either 630Δerm or
bclA1− had similar levels of C. difficile spores in the caecum
(Fig. 6C), although levels were somewhat higher in bclA1−
infected animals, possibly reflecting the ability of this
Fig. 6. Infection of hamsters with bclA mutants. The hamster model of infection was used to assess the virulence of the bclA1 mutant.
Animals were pre-treated by oral gavage with clindamycin followed by C. difficile spores.
A. Survival time for hamsters infected with spores of strain 630Δerm or bclA1−. Doses of 102, 103 or 104 spores were used to infect hamsters
(n = 3) by oral gavage. 630Δerm black symbols and bclA1− grey symbols. **P value < 0.01; ***P value < 0.001.
B. Kaplan Meier survival plot of hamsters (n = 10) infected with doses of 10 or 102 spores of 630Δerm (black lines) or bclA1− spores.
C. Caecum tissue excised from infected hamsters (from panel A) was evaluated for average counts of ethanol-resistant spores (columns; cfu
g−1) and toxin B (ng g−1; internal black squares). All samples were taken from caecum post death at the clinical end-point of infection.
Table 3. Infectivity of spores of different C. difficile strains in mice.a
Strain ID50b
630Δerm 1 × 102
R20291 1 × 103
bclA1− >1 × 104
a. Groups of mice were first treated with clindamycin followed by a
5-day interval before being given three doses (102, 103 or 104) of
spores followed by determination of ethanol-resistant spores counted
in fresh faecal samples (cfu data are shown in Fig. S6). Colonization
was defined as animals carrying > 103 spores per gram of faeces at
48 h post infection.
b. Using the Reed-Munch equation (Ozanne, 1984) the dose of
spores required to infect 50% of mice (ID50) was determined.
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mutant to germinate more efficiently and proliferate. The
levels of toxin B in caecum samples were measured and
found to be similar in all samples, showing no significant
differences (Fig. 6C). In surviving animals no viable C.
difficile or toxin B could be detected in caeca. These data
support the murine study demonstrating that bclA1− mutant
strains, although able to produce toxins, are clearly less
infectious than the wild-type.
It was possible that the low infectivity of the bclA1−
mutant might have arisen if toxin production was reduced
or delayed in vivo. This is unlikely though since based on
the morphogenesis of the spore, we would predict that the
bclA1 gene would be expressed in the late phase of spore
formation, while toxin production is associated with the
stationary phase of vegetative cell growth (Rupnik et al.,
2009) and should occur before bclA1 expression. Prelimi-
nary qPCR data (not shown) demonstrated that tcdA and
tcdB are expressed during stationary phase and the early
stages of spore formation, while the bclA1–3 genes are
expressed at the terminal stages of sporulation (approxi-
mately 9 h following the onset of development). To rule out
differences in production of toxins in vivo between
630Δerm and the bclA1 mutant, we infected mice 8 days
post clindamycin treatment with a high dose (105 per
mouse) of 630Δerm or bclA1− spores sufficient to cause
infection in most of the mice (see Table 3). At 24 and 36 h
post infection the total cfu of C. difficile and toxin A and B
levels were determined in caeca. As shown in Fig. 7, the
total cfu in mice infected with 630Δerm or bclA1− spores
were equivalent at both time points and no differences
were observed between toxin A and B levels in the caeca
and in the ratio between the two toxins.
Discussion
The exosporium is poorly defined in C. difficile and images
of this ‘sac-like’ outer layer vary from a well-defined thick,
electron dense laminated structure (Lawley et al., 2009b)
to more diffuse layers that are easily removed from the
underlying spore coat (Permpoonpattana et al., 2011b;
2013; Escobar-Cortes et al., 2013). Most probably the
exosporium of C. difficile is particularly fragile at least under
the conditions commonly used in the laboratory to prepare
spores so defining this structure in C. difficile remains
elusive. One of the major immunodominant proteins found
in the exosporium of B. anthracis and B. cereus is the BclA
protein (Sylvestre et al., 2002; Steichen et al., 2003; Todd
et al., 2003; Redmond et al., 2004). Filaments of the BclA
Fig. 7. Toxins A and B in vivo kinetics.
A and B. Levels of toxins A (panel A) and B (panel B) at different time points (24 or 36 h) in the caeca of mice infected with 1 × 105 spores per
mouse of C. difficile 630Δerm wild-type strain or bclA1− mutant.
C. Ratio between toxin A and toxin B levels in infected mice.
D. Total C. difficile cfu counts (cfu g−1) in caecum tissues excised from infected mice.
1032 J. Phetcharaburanin et al. ■
© 2014 John Wiley & Sons Ltd, Molecular Microbiology, 92, 1025–1038
protein form the hairy nap which is characteristic of the
exosporia of the Bacillus anthracis/thuringiensis family of
spores (Kailas et al., 2011) but in the case of C. difficile
these hair-like filaments have yet to be observed. C. diffi-
cile carries three bclA genes whose products share simi-
larity with the BclA proteins of B. anthracis and B. cereus.
However, the composition of these proteins differ signifi-
cantly especially with regard to the absence of the
N-terminal (targeting the exosporium) and C-terminal (oli-
gomerization) domains. Our evidence suggests that the C.
difficile BclA proteins reside in the outermost layers of the
spore and most probably the putative exosporium. Anti-
bodies against all three BclA proteins confirmed expres-
sion on the spore surface and mutagenesis of the three
genes also revealed noticeable defects in the spore coat.
First, in two mutants, bclA1 and bclA2, aberrations in the
spore coat were clearly evident and presumably assembly
of the outer coat or exosporium is defective in these
mutants emphasizing that both proteins are likely major
exosporial proteins. Second, spores of all three mutants
had significantly reduced hydrophobicity. Reduced hydro-
phobicity was also apparent in spores that had been soni-
cated, an approach that has been shown elsewhere to
remove the exosporium (Permpoonpattana et al., 2011b;
2013; Escobar-Cortes et al., 2013). In B. anthracis, bclA
mutants also have a much-reduced hydrophobicity where
the exosporium is thought to provide a water repellant
shield reducing its ability to interact with the host matrix
(Brahmbhatt et al., 2007). Third, all three bclA mutants
showed increased germination rates, a characteristic also
found in the B. anthracis bclA mutant and presumably a
result of a defective exosporium allowing access of germi-
nants to receptors situated in the innermost spore mem-
branes (Brahmbhatt et al., 2007; Carr et al., 2010). Finally,
in vivo infection studies in mice revealed that the bclA1 and
bclA3 mutants had impaired colonization efficiencies
although this was most striking with the bclA1 mutant that
completely failed to colonize the mouse GI-tract. Thus, the
three BclA proteins are integral components of the outer-
most layers of the spore (and most probably the
exosporium) and whose removal severely destabilizes this
outermost layer allowing access of germinants and reduc-
ing surface hydrophobicity.
In B. anthracis BclA has not been shown to play a
significant role in virulence with a bclA mutant having no
effect on pathogenicity in mice or in guinea pigs (Bozue
et al., 2007) and with mutant and wild-type strains having
similar LD50 values (Brahmbhatt et al., 2007). This is in
marked contrast to our study where we show that in C.
difficile at least one BclA protein, BclA1, is involved in the
initial stages of colonization and infection. In mice and in
hamster models of infection spores devoid of BclA1 were
up to 2-logs less infective (i.e. by ID50) than isogenic
wild-type spores and showed increased times to death in
hamsters. This suggests that BclA1 could be involved in
the initial stages of host colonization and that this event
must be mediated by the spore, an event occurring before
spore germination. Even more intriguing was the obser-
vation that two 027 strains carried truncated BclA1 pro-
teins and that one of them, R20291, a so-called
‘hypervirulent’ strain, was actually less infective in a
mouse model of infection than its counterpart 630 sug-
gesting a relationship of animal susceptibility to the pres-
ence of an intact BclA1 protein in the C. difficile spore.
Spores of strains carrying a full-length BclA1 protein (i.e.
630) were more infectious than those carrying a defective
or truncated bclA1 gene. Interestingly there is already
published work that would support this. For example, only
102 spores of 630 were required for 100% colonization in
hamsters but using the same dose lower levels of infec-
tion were found with a variety of B1 strains (Razaq et al.,
2007). Similarly, 104 spores of R20291 have been shown
to produce complete infection in hamsters (Buckley et al.,
2011). Finally there is now evidence showing that ham-
sters are more susceptible to colonization with non-
toxigenic strains of C. difficile than with toxigenic strains
(e.g. M68 and B1–7) (Buckley et al., 2013).
It has been proposed that hypervirulent 027 strains may
have acquired additional virulence genes based on the
considerable genetic differences between the epidemic
and non-epidemic strains (Stabler et al., 2009). However,
we suggest that in terms of initial colonization the hyper-
virulent R20291 strain is actually less effective, that is,
animals are less susceptible. This then raises some inter-
esting and provocative questions. We wonder whether
animals including humans are actually less susceptible to
‘hypervirulent’ strains yet once colonization occurs the
severity of disease is much greater. In many ways this
resembles the situation of influenza where seasonal flu
strains are typically highly infective but of low severity
compared to the low infectivity-high severity nature of
H5N1 strains. If what happens in humans mirrors that in
mice then the virulence of R20291 must arise not due to its
infectivity but rather, due to some other factor affecting the
severity of infection, e.g. levels of toxin production,
increased persistence or faster germination. For the 027
‘hypervirulent strains increased toxin production and
biofilm formation (Dawson et al., 2012; Dapa and
Unnikrishnan, 2013) have been identified as potential viru-
lence factors. However, the presence of an intact BclA1
protein would correlate with the susceptibility of the host to
infection and we assume that BclA1 may interact with a
specific host target. We acknowledge that comparisons
between diverse and non-isogenic strains carry inherent
risks and of course we cannot rule out the presence of
additional factors. A more detailed and extensive study of
the bclA1 gene in clinically relevant strains coupled with
analysis of infection will be required to address this but at
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this stage it is clear that BclA1 plays a key role in the initial
stages of infection and host susceptibility. Current thought
is that C. difficile is acquired primarily from the environment
but is it possible for hypervirulent strains to remain as latent
members of the gut flora and to be rendered infectious only
after their numbers reach a critical level resulting from
antibiotic disturbance?
In B. anthracis it has recently been shown that BclA
interacts with the integrin Mac-1 leading to uptake by
professional phagocytes. Rhamnose residues within BclA
have been shown to interact directly with CD14 molecules
(Oliva et al., 2009). If C. difficile BclA1 also recognizes a
specific target then it is a prime candidate for inclusion in
a more robust vaccine to C. difficile infection. In prelimi-
nary trials we have expressed the 48-amino-acid
N-terminus of BclA1 on the surface of Bacillus subtilis
spores. This segment is that which is present in the 027
strain R20291 (Fig. S7). When combined, 50:50, with B.
subtilis recombinant spores expressing the C-terminus
of toxin A [strain PP108 as described elsewhere
(Permpoonpattana et al., 2011a)] they were able to
provide significantly greater levels of protection than
PP108 alone when administered orally (data not shown).
This is encouraging and suggests that BclA1 can act as a
decolonization factor and could be combined with an anti-
toxin-based vaccine to prevent C. difficile infection.
Experimental procedures
Strains
630 is a toxigenic (tcdA+ tcdB+) strain of C. difficile isolated
from a patient with pseudomembranous colitis during an out-
break of C. difficile infection (CDI) (Wust et al., 1982). For
ClosTron mutagenesis and mutant analysis an erythromycin-
sensitive derivative 630Δerm (Hussain et al., 2005) was used
(provided by N. Minton, Univ. Nottingham, UK). R20291 is an
epidemic strain of ribotype 027 isolated from Stoke Man-
deville Hospital in 2006 (Stabler et al., 2009) and was
obtained from T. Lawley (Wellcome Trust Sanger Institute,
UK).
Growth of C. difficile and preparation of spores
Clostridium difficile was routinely grown in vegetative culture
by overnight growth in TGY- medium (Paredes-Sabja et al.,
2008). Spores of C. difficile were prepared by growth on SMC
agar plates using an anaerobic incubator (Don Whitley, UK)
as described previously (Permpoonpattana et al., 2011a).
After growth for 7 days at 37oC spores were harvested and
either washed three times with water or purified using His-
toDenz as follows. Crude spore suspensions were washed
five times with ice-cold sterile water, re-suspended in 500 μl
of 20% HistoDenz (Sigma) and layered over 1ml of 50%
HistoDenz in a 1.5 ml tube. Tubes were centrifuged at 10 000
g for 15 min. The spore pellet was recovered and washed
three times with ice-cold sterile water. Spore purity was
assessed by phase-contrast microscopy and spore yields in
individual preparations were estimated by counting colony-
forming units (cfu) of heat-treated (60°C, 20 min) aliquots on
BHIS agar plates (Brain heart infusion supplemented with
0.1% L-cysteine and 5 mg ml−1 yeast extract) supplemented
with 0.1% sodium taurocholate (BHISS).
ClosTron mutagenesis
Insertional mutations in the bclA genes were made using the
ClosTron system developed at the University of Nottingham
(Heap et al., 2007; 2009; 2010). The Perutka algorithm
(Perutka et al., 2004) available at http://www.clostron.com
was used to design 45 bp retargeting sequences for each
gene (Table 1). Derivatives of plasmid pMTL007C-E2 carry-
ing these retargeting sequences were obtained from DNA2.0
(DNA20.com, Menlo Park, USA). Using the protocols pro-
vided by Heap et al. (2007; 2009; 2010) plasmids were first
introduced into Escherichia coli and then conjugated with C.
difficile 630Δerm. For each mutant five erythromycin-resistant
(ErmR) transconjugants were checked by PCR for ClosTron
insertion. Genomic DNA was prepared as described
(Antunes et al., 2011) and then three PCR reactions were
performed (Fig. S9). First, PCR using the ErmRAM primers
resulted in a 900 bp product confirming that the ErmR pheno-
type was due to splicing of the group I intron from the group
II intron following integration. Second, primers targeting the
gene left and right ends of the insertion site were used to
check the site of insertion. If insertion occurred a PCR
product 1800bp greater than that obtained in the wild-type
strain would be found. Third, PCR was made using primers
flanking the gene and intron (EBS-universal) to confirm the
insertion site where no product would be expected in the
wild-type strain.
Complementation of bclA mutants
All three bclA mutants were complemented with wild-type
copies of the respective genes using pRPF185 (Fagan and
Fairweather, 2011). Briefly, a DNA fragment including the
entire coding sequence of each gene and Shine–Dalgarno
sequence was PCR amplified using KOD Hot Start polymer-
ase (Merck) and primers listed in Table S2. The resulting
fragments were cloned using SacI and BamHI sites into
pRPF185 under the control of the inducible Ptet promoter.
Plasmids were transferred into the corresponding bclA
mutant strains by conjugation. Gene expression was induced
using anhydrous tetracycline (ATc) at 500 ng ml−1. To confirm
that the bclA mutants were due to a single insertional muta-
tion we used in trans complementation analysis to demon-
strate that the wild-type phenotype could be restored using
two methods: (i) immunofluorescence microscopy of spores
to demonstrate surface expression of the BclA protein on
spores of the complemented strain, and (ii) restoration of
wild-type levels of germination (Fig. S10).
Germination assays
Spore germination was carried out in a 96-well plate (Greiner
Bio-One) and germination of spores was measured by the
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percentage change in OD600. HistoDenz-purified spores at an
OD600 of ∼ 0.8–1.0 (∼ 1 × 108 ml−1) were pelleted by centrifu-
gation (10 000 g, 1 min) and suspended in 1 ml of BHIS
supplemented with 0.1% sodium taurocholate (germinant) or
0.1% sodium chenodeoxycholate (inhibitor). The initial OD600
was recorded and then measured at 1 min intervals over 30
min using a microplate reader (Molecular Devices, Spec-
tramax plus). Per cent germination was determined as
recorded OD600 at time interval/initial OD600) × 100. The
experiment was performed three times. For preparations of
sonicated spores 10 cycles of sonication were used as
described elsewhere (Permpoonpattana et al., 2011b).
SATH (spore adhesion to hydrocarbon) assay
As described elsewhere (Huang et al., 2010) HistoDenz-
purified spores were washed in 1 M NaCl and then sus-
pended in 0.1 M NaCl for assay. Five hundred microlitres of
spore suspension was added to 800 μl n-hexadecane
(Sigma) and vortexed for 1 min. Samples were then incu-
bated for 10 min at 37°C with mild agitation, vortexed (30 s)
and absorbance (OD600) read. Per cent hydrophobicity was
determined from the absorbance of the original spore sus-
pension (A1) and the absorbance of the aqueous phase after
incubation with hydrocarbon (A2) using the equation:
%H = [(A1 − A2)/A1].
Recombinant proteins and antibody production
Escherichia coli pET28b expression vectors carrying the
bclA1, bclA2 and bclA3 ORFs were used to express rBclA
proteins. The segments of BclA used for expression were
rBclA1 (Met-1 to Pro-393), rBclA2 (Met-1 to Gly-302) and
rBclA3 (Thr-489 to Ala-645). High levels of expression were
obtained upon IPTG induction and purification of proteins
made by passage of the cell lysate through a HiTrap chelating
HP column on a Pharmacia AKTA liquid chromatography
system. Polyclonal antibodies were raised in BALB/c mice
immunized by the intra-peritoneal route with 2 μg of purified
recombinant proteins on days 1, 14 and 28. Antibodies were
first purified using a Protein G HP Spin-Trap column (GE
Healthcare).
Transmission electron microscopy (TEM)
Spores were processed for ultra-microtomy according to
standard procedures (Hong et al., 2009). Briefly, spore sus-
pensions were diluted 10× in dH2O and washed twice by
centrifugation (10 000 g for 10 min) to eliminate residual
debris. Spore pellets were fixed for 12 h at 4°C in a mixture of
2.5% glutaraldehyde and 4% paraformaldehyde in 0.2 M
cacodylate buffer (pH 7.4), then post-fixed for 1 h at RT with
1% osmium tetroxide in the same buffer. Sample pellets were
dehydrated with ethanol and embedded in Epon-Araldite.
Thin sections were stained successively with 5% uranyl
acetate and 1% lead citrate. TEM observation was performed
with a FEI CM120 operated at 120 kV.
Immunofluorescence microscopy
The procedure followed was as described in Duc et al. (2003)
with minor modifications. Microscope coverslips were first
treated with 0.01% poly-L-lysine overnight. Spores (1 × 107)
were added to the slide and dried for 1 h at RT. After three
washes with PBS (pH 7.4) and blocking in PBS + 2% BSA
+ 0.05% Tween-20 for 1.5 h, the first antibody was added
(1:1000). Spores were incubated for 30 min at RT followed by
three washes with PBS + 0.05% Tween-20 after which anti-
mouse-TTFC sera (1:1000) was added and incubated for 30
min at RT. After six more washes the slide was viewed under
a Nikon Eclipse Ti-S fluorescence microscope.
Colonization experiments
(a) Infection of mice using cefoperazone pre-treatment. The
cefoperazone murine model was initially used since the
erythromycin-resistance cassette used in ClosTron mutants
may not confer the same level of resistance to clindamycin as
seen in the parental strain, depending upon its chromosomal
location although this was found in this work to be unfounded
(N. Fairweather, pers. comm.). Groups (n = 4) of C57BL/6
mice (6–8 weeks old; female, Charles River) were adminis-
tered with five doses of cefoperazone (MP Biomedicals), LLC
(100 mg kg−1; by intra-gastric gavage) on day 1, 3, 5, 7 and 9
using a procedure previously described (Theriot et al., 2011).
Animals were kept in IVCs (independently ventilated cages)
under sterile conditions. On day 10, mice were orogastrically
(o.g.) infected with C. difficile 1 × 104 spores per mouse of the
wild-type 630Δerm strain or one of the three bclA mutants
(one group/mutant). Fresh faeces from individually infected
mice were collected on day 1, 3, 5 and 7 post challenge.
Samples were reconstituted in PBS supplemented with pro-
tease inhibitor (Thermo Scientific) using a ratio of 1:5 [weight
faeces (g): volume (ml)]. Total counts and spore counts of C.
difficile were performed by plating serial dilutions on BHIS
and BHISS respectively, media was supplemented with
cefoxitin and cycloserine (Bioconnections, Knypersley, UK).
Spore counts were determined after heat-treating (60oC, 30
min) samples, serial dilution and plating for cfu ml−1.
(b) Infection of mice using clindamycin pre-treatment. On
days 1 and 3 animals received a single dose of clindamycin
(30 mg kg−1) as described above for cefoperazone (a) and
they were kept in IVCs under sterile conditions. On day 8,
animals were o.g. infected with different doses (ranging from
102 to 104 spores per mouse) of C. difficile strains R20291,
630Δerm or bclA1− mutant (n.b., the 630Δerm and bclA1−
mutant are sensitive to clindamycin). Spore counts in freshly
voided faeces were determined after ethanol treatment
(100% ethanol, 20 min) by plating as described above (a).
(c) Analysis in mice of in vivo toxin levels and spore kinet-
ics. Groups of 9–10 mice were administered with clindamy-
cin as described above (b) and housed in IVCs. On day 8,
mice were o.g. infected with spores of C. difficile wild-type
630Δerm and bclA1 mutant strains at the dose of 1 × 105
spores per mouse. Caeca from infected mice were asepti-
cally removed 24 or 36 h post challenge. Samples were
processed as described above (a). For detection of levels of
toxin A and toxin B in caecum, samples were centrifuged for
10 min (10 000 g; 4°C) and supernatants sterilized using 0.2
μm filters. An ELISA assay was performed following the
method described below (toxin detection, e).
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(d) Hamster infections. Golden Syrian Hamsters (female,
aged 10 months; ∼ 100 g; Charles River) housed in IVCs
were dosed o.g. with clindamycin (30 mg kg−1) and infected 5
days later with C. difficile spores of the wild-type 630Δerm
strain or bclA1− mutant at doses of either 102, 103 or 104
spores per hamster. Hamsters were then monitored for signs
of disease progression and, based on severity of symptoms,
culled upon reaching the clinical end-point. Caecum samples
were examined for toxin B by ELISA as described below.
Toxin cytotoxicity assays using HT29 cells was assessed as
described previously (Permpoonpattana et al., 2011a). Spore
counts in caeca was performed as described above (b). Sta-
tistical significance between groups was calculated using a
Student’s t-test.
(e) Toxin detection. Toxins were extracted using a protease
inhibitor buffer as described previously (Permpoonpattana
et al., 2011a) and detected by a capture ELISA method.
ELISA plates (Greiner, high binding) were coated with rabbit
polyclonal antibodies against toxin A or toxin B (Meridian Life
Science; 1 μg ml−1 in PBS buffer). Plates were blocked with
2% BSA (1 h, 30oC), 10 μl of samples and 2 μl of reference
toxin A or toxin B (Ab Serotec) were added to plates and
incubated at 30oC for 3 h. Monoclonal antibodies against
toxin A (1/500) and toxin B (1/500) were used for detection (1
h, 30oC). HRP-conjugated anti-mouse IgG was added as
secondary antibody (1 h, RT). Plates were developed with
TMB (Sigma). The sensitivity of the assays for both toxin A
and B is 7 ng ml−1.
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Abstract
Clostridium difficile is the primary cause of nosocomial diarrhoea in healthcare
centres of the developed world. Only a few antibiotics are available for treat-
ment, and relapses are common in patients undergoing antibiotic therapy. New
approaches are required to reduce reliance on antibiotics, the use of which rep-
resents a primary risk factor for development of C. difficile infections. Supple-
mentation of the gut flora with probiotics represents a key area for producing
more successful treatment options for C. difficile infection (CDI). In this study,
spores of B. subtilis have been evaluated as a potential probiotic treatment
against CDI. Using a murine model of infection, we demonstrate that oral
administration of B. subtilis spores can attenuate the symptoms of infection.
We further show that (1) suppression of symptoms was better if spores were
administered post infection, and (2) germination of the spore to a vegetative
cell may be an integral part of how CDI is suppressed. The results of this study
highlight the potential of this bacterium as a probiotic treatment for CDI.
Introduction
Clostridium difficile is the primary aetiological agent of
nosocomial diarrhoea in developed countries. Disease
occurs when the normal colonic flora is disrupted, typi-
cally associated with antibiotic treatment. Dysbiosis of the
microbiota of the gastro-intestinal (GI) tract allows
ingested spores of C. difficile to germinate and proliferate.
Clinical symptoms are mediated by production of two
major exotoxins, toxin A and toxin B. Infection results in
a variety of manifestations ranging from a nonsymptom-
atic carrier state to diarrhoea and inflammation of the
gut. Severe infections can lead to development of pseudo-
membranous colitis and toxic megacolon which is poten-
tially fatal (Rupnik et al., 2009). Hospitalised elderly
individuals receiving antibiotic treatment are the primary
group at risk for developing this infection, although inci-
dence in other groups such as pregnant woman (Roupha-
el et al., 2008) and younger individuals is increasing
(Wilcox et al., 2008). Production of highly resistant
spores during the infection cycle presents a major chal-
lenge to the control of infection, as spores play a signifi-
cant role in the spread and persistence of disease
(Dawson et al., 2012; Deakin et al., 2012).
The implementation of mandatory reporting across the
UK in 2007 has resulted in a decrease in the number of
cases as awareness of C. difficile has increased (HPA,
2009). However, the emergence of ‘hypervirulent’ strains
and high relapse rates of infection have contributed to
the persistence of this infection. A limited number of
antibiotics are available for use in the treatment of C. dif-
ficile infection (CDI), and around 20% of treated cases
will experience a recurrence of infection following treat-
ment, representing a key challenge for treatment of CDI.
Use of antibiotics is also a principle risk factor for devel-
opment of infection. Due to these limitations in the use
of antibiotics, alternative treatment strategies are being
investigated. Most promising is faecal transplantation
therapy consisting of an extract prepared from homogen-
ised stool sample which is administered to the patient via
a nasogastric tube (MacConnachie et al., 2009). A second
approach is that of the use of probiotics and/or prebiotics
which have shown some effect in reducing symptoms of
CDI. As an adjunct to antibiotic therapy, species of Lacto-
bacillus, Bifidobacteria and Saccharomyces boulardii appear
to reduce the incidence of CDI in human studies
although none has shown full protection (Pochapin,
2000; Surawicz et al., 2000; Wullt et al., 2003). No
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consensus has been reached as to how these bacterial sup-
plements exert their effect, but one likely mechanism is
by influencing the gut microbiota such that growth of
C. difficile is inhibited. A number of human trials are in
progress.
In this work, we used spores of Bacillus subtilis, a bac-
terial species already widely associated with probiotic use,
to suppress symptoms of C. difficile CDI. Our objective
was to assess the capacity of this bacterium, as a probiot-
ic, to protect against disease.
Methods
Strains
(1) B. subtilis: PXN21 is one of fourteen strains in the
commercial product Bio-Kult (Probiotics International
Ltd, Lopen Head, UK) and was obtained from NCIMB
where it is registered as NCIMB strain 30223. PY79 is a
laboratory strain and derived from the type strain 168
(Youngman et al., 1984). SC2376 gerD-cwlD is congenic
to strain PY79 and carries a severe germination defect
(Mauriello et al., 2007).
(2) Clostridium difficile: R20291 is an epidemic strain of
ribotype 027 and was obtained from T. Lawley (Wellcome
Trust Sanger Institute, UK). Clostridium difficile VPI
10463 (provided by B. Wren, London School of Hygiene
and Tropical Medicine, UK) was originally isolated in the
USA in 1980 and has since been used as a reference
strain.
General methods
Spores of B. subtilis strains were prepared in liquid med-
ium by the exhaustion method as described previously
(Harwood & Cutting, 1990). Heat-killed spores were pre-
pared by autoclaving suspensions of spores at 120 °C for
20 min. Spores of C. difficile were prepared by growth on
SMC agar plates using an anaerobic incubator (Don
Whitley, UK) as described previously (Permpoonpattana
et al., 2011).
Animal models of infection
Female C57BL/6 mice (Charles River, UK) aged
6–8 weeks were used in all experiments, with animals
housed in IVC units (Tecniplast, Italy). Sterile bedding
was used in cages, and animals had ad libitum access to
sterile water and food.
Two animal models were used to evaluate CDI: (1) a
nonfatal colonisation model modified from that of Lawley
(Lawley et al., 2009) and (2) the fatal, severe, disease
model of Chen et al. (Chen et al., 2008).
(1) Nonfatal colonisation model: a single oro-gastric
(o.g.) dose of clindamycin (30 mg kg!1) was used 1 day
prior to o.g. delivery of 1 9 104 R20291 spores. Faecal
samples were collected daily. Faecal samples were homog-
enised and then incubated with 70% ethanol for 20 min
at RT. Samples were pelleted and ethanol removed before
suspension in sterile water for serial dilution on brain
heart infusion agar (BHI) supplemented with 0.1% cyste-
ine and 0.1% sodium taurocholate for enumeration of
ethanol-resistant spore counts.
(2) Fatal model: An antibiotic cocktail containing kana-
mycin (40 mg kg!1), gentamicin (3.5 mg kg!1), colistin
(4.2 mg kg!1), metronidazole (21.5 mg kg!1) and vanco-
mycin (4.5 mg kg!1) was delivered via the o.g. route in a
final volume of 200 lL per dose. Mice received three
doses of the cocktail on consecutive days (D1, D2 and
D3). On D5, mice were given a single o.g. dose of clinda-
mycin (30 mg kg!1). Animals were then infected with
1 9 104 of VPI 10463 spores on D6. Animals were moni-
tored for appearance of symptoms, with faecal samples
and weights recorded daily. Animals were culled at the
clinical end point of disease, which was considered when
animals lost 20% of original body weight.
Probiotic treatment
Doses of 1 9 109 spores in 200 lL of sterile H2O were
delivered by o.g. gavage. Animals received treatment daily:
preinfection doses commenced on day 7 (where day 0
was the point of infection with C. difficile) with a total of
seven doses received, and postinfection doses started on
day 1, and administered until day 7 of study.
Haematoxylin and eosin (H & E) staining
C57Bl/6 mice (Charles River) were culled 3 days post
infection with C. difficile. Colon and caecum were removed
from animals that had received probiotic treatment either
pre- or post infection, using nontreated and noninfected
animals as controls. Tissue contents were carefully washed
out and tissues fixed using 4% paraformaldehyde. Tissues
were then sectioned, fixed on slides and stained with H&E
(TUPI Manufacturing, Woodbridge, UK). Appearance of
tissue was assessed microscopically once stained and
images were taken using associated camera and software
(GT Vision, Haverhill, UK).
In vitro innate immunity tests
RAW264.7 macrophage cells were seeded to six-well
plates (3 9 105) in antibiotic-free growth medium
(DMEM with 10% foetal bovine serum) and incubated
for 2 days to develop confluency. Cells were washed two
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times with fresh growth medium then infected with
media containing bacteria (spores or vegetative cells of
B. subtilis PXN21 at a CFU of 1 9 107 mL!1).
For the Toll-like receptor 2 (TLR2) expression assay, a
protocol previously used to study immunostimulatory
properties of B. subtilis (Huang et al., 2008a, b) was
adapted for the assay. Cells were incubated for 4 h before
washing two further times with sterile PBS. Macrophages
were then lysed in situ and total RNAs extracted using an
RNeasy Kit (Qiagen, the Netherlands) as per manufac-
turer’s instructions. cDNA was produced using a Preci-
sion qScript Reverse Transcriptase Kit (PrimerDesign,
Southampton, UK). qPCR used primers targeted at the
TLR2 gene (forward: AAGAGGAAGCCCAAGAAAGC
reverse: CAATGGGAATCCTGCTCACT), with b-actin
(forward: AGAGGCAAATCGTGCCTGAC reverse: CA-
ATAGTGATCATCACCTGGCCCT) as a reference gene. A
three-step PCR cycle was run 50 times with the following
conditions: 95 °C 15 s, 55 °C 30 s and 72 °C 10 s. Data
were analysed using ROTORGENE 3000 software (Qiagen, the
Netherlands).
For detection of cytokines, macrophages were incu-
bated with antibiotic-free growth medium (DMEM with
10% foetal bovine serum) containing spores or vegetative
cells of B. subtilis PXN21 at a CFU of 1 9 107 mL!1 bac-
teria for 24 h. Lipopolysaccharide, (Sigma, MO) was used
as a positive control for activation of macrophages in
vitro. Supernatants were then removed, and detection of
cytokines in the medium was carried out using commer-
cial ELISA Kits (eBioscience, Hatfield, UK). Plates were
read at 450 nm using a Spectramax microplate reader
(Molecular Devices, CA).
Results
Colonisation resistance
Nonfatal colonisation of C. difficile was induced in a mur-
ine model of infection by antibiotic treatment followed by
infection with C. difficile R20291 spores (Fig. 1). Levels of
C. difficile spores present in faecal samples demonstrated
that oral delivery of B. subtilis PXN21 spores both prior to
and post infection had no significant effect on reducing
C. difficile colonisation. In all groups, peak levels of spores
were detected on day two post infection, and although
C. difficile levels were highest in mice receiving no probiot-
ic treatment, this was not significant (P = 0.1).
Attenuation of symptoms in a model of fatal
disease
A study model utilising C. difficile strain VPI 10463 to
induce a fatal infection in mice was used to assess the
ability of B. subtilis PXN21 to influence the clinical out-
come of infection. This model of infection utilised pre-
dosing with a cocktail of different antibiotics including
vancomycin that was designed to mimic the clinical situa-
tion of antibiotic therapy in humans (Chen et al., 2008).
PXN21 spores were administered to mice before and after
infection with VP1 10463, and both pre- and post infec-
tion with C. difficile increased survival compared with
nontreated animals (Fig. 2a). In pilot studies, we showed
that administration of PXN21 spores did not reduce the
efficacy of vancomycin in treatment of CDI in mice (data
not shown). Delivery of PXN21 spores prior to infection
resulted in a survival rate of 41.6% while 66.6% survival
was achieved in animals treated post-CDI (Fig. 2a); this
compared to a survival rate of 16.6% in nontreated
groups. Interestingly, weight profiles of infected animals
added further complexity to our results (Fig. 2b). Ani-
mals that survived infection having received probiotic
treatment prior to infection displayed less weight loss
than those infected with PXN21 spores post infection.
Post infection-treated animals displayed a similar weight
profile to the nontreated group, despite having the high-
est rate of survival.
Live B. subtilis spores are required for
suppression of infection
Administering PXN21 spores post infection was more
effective in preventing CDI than predosing. As killed
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Fig. 1. Suppression of colonisation. Three groups of mice (n = 6)
were treated as follows. (1) Preinfection, animals received seven daily
o.g. doses of PXN21 spores (109) and were then infected with a
single dose of Clostridium difficile R20291 spores (104) (◊); (2)
postinfection, animals were infected with a single dose of R20291
spores (104) and then dosed o.g. for 7-days thereafter with PXN21
spores (109) (□); (3) no treatment, animals were infected with a single
dose of R20291 spores (104) (D). In each treatment programme, the
number of ethanol-resistant spores of C. difficile R20291 shed in the
faeces was enumerated by plating serial dilutions of treated faecal
samples on BHISS agar containing 0.1% sodium taurocholate.
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spores have been shown to have adjuvant properties and
can enhance the immunity of prototype vaccines (Barnes
et al., 2007; Huang et al., 2010), we addressed whether
spore viability might affect survival in mice administered
PXN21 spores post infection. As shown in Fig. 3, a dos-
ing of mice post infection with killed spores showed
almost no improvement on survival. By contrast, dosing
with live spores markedly improved survival. As shown
earlier (Fig. 2a), treatment post infection with live PXN21
spores increases survival rate but did not induce an
improvement in the weight profile of infected animals.
Histopathology
H&E-stained tissue sections were produced to assess
pathology affecting gut tissues in groups receiving B. sub-
tilis PXN21 spores. Images from tissue sections suggest
that in animals given PXN21 spores, the gut tissues dis-
play reduced pathology, with less damage to cell structure
than in untreated animals (Fig. 4). Tissues from healthy,
noninfected mice exhibited well-defined tissue structure
and cell integrity (Fig. 4a). Toxin-mediated damage is
evident in the breakdown of tissue structure and disrup-
tion of epithelial cell membranes (Fig. 4d). The level of
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Fig. 2. Suppression of CDI using PXN21 spores. Groups (n ≥ 6) of
mice received daily o.g. doses of 109 Bacillus subtilis PXN21 spores
either preinfection with Clostridium difficile VP1 10463 spores (104)
or postinfection. The preinfection groups received 7 doses of PXN21
spores and postinfection seven doses of PXN21 after infection. (a)
Kaplan–Meier survival plot for pre- and postinfection treatment
groups. (b)% weight change for groups receiving either daily doses of
PXN21 spores preinfection (◊), post infection (□) or no treatment (D).
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Fig. 3. Live PXN21 spores are required for suppression of CDI.
Groups of mice were infected with Clostridium difficile VPI 10463 as
described in Fig. 2 but in this case dosed post infection with live
PXN21 spores (109) or heat-killed PXN21 spores. (a) Kaplan–Meier
survival plot for pre- and postinfection treatment groups. (b) %
weight change for groups receiving either daily doses of PXN21
spores preinfection (◊), postinfection (□) or no treatment (D).
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damage in terms of cell structure and tissue integrity was
reduced in groups receiving PXN21 spores both before
(Fig. 4b) and after infection (Fig. 4c). However, PXN21
treatment did not completely protect tissues, and some
cellular damage was present in PXN21 treated animals,
with minor disruption of cell membranes apparent.
Mechanisms of probiotic action
One mechanism for how PXN21 spores might suppress
symptoms of CDI includes stimulation of the innate
immune responses. To address this, first we examined
stimulation of the Toll-like receptor 2 gene (TLR2) and,
second, induction of two proinflammatory cytokines, IL-6
and TNF-a. Using an in vitro assay, expression of the
TLR2 gene was measured using real-time PCR (RT-PCR)
in RAW264.7 macrophages infected with PXN21 spores
(live or killed) and PXN21 vegetative cells. This approach
has been used previously to show potential TLR2 stimu-
lants as TLR2 agonists can upregulate the TLR2 gene (Liu
et al., 2001). As shown in Fig. 5, vegetative cells and live
spores of PXN21 efficiently stimulated expression of the
TLR2 gene implying an interaction with the TLR2 recep-
tor. Levels of expression were consistent with that of
purified peptidoglycan which is a known TLR2 agonist
(Liu et al., 2001). By contrast heat-killed PXN21 spores
showed a marked (four- to fivefold) reduction in TLR2
expression. Induction of the proinflammatory cytokines
IL-6 and TNF-a was only apparent in macrophages
infected with live PXN21 spores, and virtually no activity
was present in cells infected with heat-killed spores
(Fig. 6).
Discussion
This study shows that oral administration of B. subtilis
PXN21 spores can reduce symptoms of CDI in a murine
model of disease. PXN21 is a component of a commercial
probiotic product and of course numerous products carry
spores of B. subtilis as their active ingredient (Permpoon-
pattana et al., 2012). In addition, some traditional foods
such as natto contain live spores of B. subtilis and have
(a) (b)
(c) (d)
Fig. 4. H&E-stained sections of colon from
Clostridium difficile VPI 10463 infected mice.
(a) Uninfected mice, displaying healthy tissue
and intact epithelial lining to colon; (b) mice
treated with PXN21 spores preinfection with
some damage to epithelial structure but with
lining still intact although evidence of mild
oedema in the submucosa; (c) mice treated
with PXN21 spores post infection showed
some damage to the integrity of the epithelial
lining and some submucosal disruption; and
(d) untreated mice displaying extensive
damage to the colonic epithelial lining and
erosion of the submucosa (shown by white
arrows and stars). Scale bars 25 lm.
FEMS Microbiol Lett && (2014) 1–8 ª 2014 Federation of European Microbiological Societies.
Published by John Wiley & Sons Ltd. All rights reserved
Spore-mediated suppression of C. difficile infection 5
been recognised as carrying health benefits (Hosoi &
Kiuchi, 2004). There is also good data showing that oral
consumption of probiotic bacteria or prebiotics can have
some effect in reducing the symptoms or occurrence of
CDI. As an adjunct to antibiotic therapy, species of Lacto-
bacillus, Bifidobacteria and S. boulardii appear to reduce
the incidence of CDI in human studies although no study
has yet shown full protection (Pochapin, 2000; Surawicz
et al., 2000; Wullt et al., 2003). Moreover, no consensus
has been reached as to how these bacterial supplements
exert their effect. A number of mechanisms can be con-
sidered. First, by influencing the gut microbiota such that
growth of C. difficile is inhibited possibly by out-compet-
ing for available nutrients or possibly by secretion of anti-
microbials. This is the basis of treatments that focuses on
supplementation of the gut flora to prevent C. difficile
from maintaining a niche within the GI tract. Faecal
transplants, for example, while unpleasant, have been
demonstrated to have a high success rate in resolving per-
sistent infection (Gough et al., 2011) although carry risk
of further infections unless samples are heavily screened
prior to use. More recently, ‘synthetic stools’ have been
developed (Lawley et al., 2012; Petrof et al., 2013), select-
ing particular microorganisms that are able to resolve
infections through rebuilding the microbial communities
in the gut without the unpleasant and uncertain aspect of
faecal transplants. Supplementation of the gut flora with
a complex or even minimalist mix of microorganisms
mimics the protection against colonisation by C. difficile
that the normal healthy microbial community of the gut
provides. Single strains of bacteria are less likely to be
able to successfully act as a substitute for the complex
microbial communities of the gut. However, used along-
side conventional antibiotics, particular strains could pro-
vide enough influence in the gut environment to reduce
the symptoms of infection and aid restoration of the gut
flora. A second mechanism would be by stimulation of a
robust innate immune response in the gut-associated
lymphoid tissue (GALT). The importance of the innate
immune response in CDI has been demonstrated previ-
ously, with mice carrying deficiencies in immune signal-
ling (Lawley et al., 2009) more vulnerable to infection.
Direct stimulation of the innate immune receptor TLR5
has also been demonstrated to successfully protect against
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
Unstimulated Live PXN21 
spores 
Heat killed 
PXN21 
spores 
Live PY79 
spores  
IL
-6
 (p
g m
L–
1 )
SC2376
Ger-
spores 
0
50
100
150
200
250
300
350
Unstimulated Live PXN21 
spores
Heat killed 
PXN21 
spores
PY79 spores lipopolysaccharide
0.1 µg mL–1
lipopolysaccharide
0.1 µg mL–1
TN
Fα
 (p
g/m
L–
1 )
SC2376
Ger-
spores
(a)
(b)
Fig. 6. Cytokine production. Production of the pro-inflammatory
cytokines IL-6 (a) and TNFa (b) in murine macrophages (RAW264.7)
after incubation with Bacillus subtilis PXN21. Live and heat-killed
spores were added to cells at a concentration of 1 9 107 mL!1 and
incubated for 24 h. Lipopolysaccharide was used as a control for
induction of cytokines. Commercial ELISA kits (eBioscience) were used
to quantify levels of IL-6 and TNFa in supernatants of cultured cells.
Data are from three individual experiments.
0
100
200
300
400
500
600
Unstimulated Vegetative 
cells
Live spores Heat killed 
spores
Peptidoglycan 
1 μg mL−1
R
el
at
iv
e 
TL
R
2 
ex
pr
es
sio
n 
(%
)
Fig. 5. In vitro analysis. TLR2 expression in murine macrophages
(RAW264.7) after incubation with Bacillus subtilis PXN21. Vegetative
cells, spores or heat-killed PXN21 spores were added to cells at a
concentration of 107 mL!1 and incubated for 4 h. RNA was extracted
from cells, and TLR2 gene expression was calculated relative to b-
actin expression, using qPCR. Data are from three individual
experiments.
FEMS Microbiol Lett && (2014) 1–8ª 2014 Federation of European Microbiological Societies.
Published by John Wiley & Sons Ltd. All rights reserved
6 C. Colenutt & S.M. Cutting
disease in infected mice (Jarchum et al., 2011). Finally,
for toxin producing pathogens, it is possible that probiot-
ic bacteria might subtract toxins produced in the gut
lumen. This is particularly true for probiotic spores as
these entities have been shown able to efficiently adsorb
toxins onto the surface of the spore (Huang et al., 2010).
Our studies shown here support the role of innate
immunity as we have shown that PXN21 spores can upre-
gulate expression of TLR2. Peptidoglycan is one of many
ligands associated with TLR2 induction and was used as a
control in our in vitro experiments. Spores carry peptido-
glycan in their cortex, a layer lying beneath the spore
coat; however, when autoclaved spores were used, induc-
tion of TLR2 was substantially reduced. Vegetative cells
of PXN21 showed strong induction of TLR2, so we assign
this to peptidoglycan exposed on the cell envelope. This
suggests that spore germination and release of the grow-
ing vegetative cell might be critical to induction of TLR2.
We base this assumption on the fact that when the spore
is inactivated by autoclaving, it is not broken but remains
intact, so it is unlikely that peptidoglycan within the
spore cortex is released in significant quantities. In other
studies, TLR2 was shown to be activated by live B. subtilis
PY79 spores but not by heat-killed PY79 spores or spores
unable to germinate (Huang et al., 2008a, b). Interest-
ingly, in other work, we have shown that live spores of
B. subtilis PY79 were shown to significantly delay symp-
toms of CDI in a hamster model of infection (Permpoon-
pattana et al., 2011). Although hamsters did eventually
die from CDI, PY79 spores were clearly shown to delay
fatalities and most likely this is due to germination and
release of live B. subtilis vegetative cells. A clear result of
TLR2 activation would be induction of pro-inflammatory
cytokines, and we have confirmed here that (1) both IL-6
and TNF-a were induced and (2) induction did not
occur with heat-killed PXN21 spores. Again, proof that
this must arise from germination of live spores to the
vegetative cell comes from indirect evidence using germi-
nating and nongerminating spores of PY79.
It is not clear why dosing of spores beginning at the
onset of CDI (post dosing) was superior to pre dosing.
Innate immunity is normally short-lived and would be
induced pre- and post dosing and should not really affect
the outcome. One possibility, spores might have some
ability to adsorb and subtract toxins produced by C. diffi-
cile, and this process might be more effective if spores are
dosed at the time infection begins. We have found that
PXN21 spores can adsorb C. difficile toxin A in vitro but
have not yet addressed whether this might occur in vivo.
One problem with this explanation is practicalities of
adsorption in the GI tract due to the interference of the
gut microbiota. We are essentially sceptical but cannot
completely exclude the possibility that with regular doses
of spores, some level of adsorption could occur in the
intestine.
Alternatively, prior dosing of probiotics could allow the
probiotic strain to colonise the gut of the animal prior to
infection allowing for some level of protection through
supplementation of the gut flora. Bacillus subtilis can sur-
vive and reproduce in the murine gut (Hoa et al., 2001;
Tam et al., 2006), and in the case of PXN21, this strain
has been shown to persist in the GI tract of mice for
18 days following a single oral dose of spores (Permpoon-
pattana et al., 2012). Although often considered a soil-
based organism, it is likely that B. subtilis has adapted for
at least transient colonisation of the animal GI tract
(Hong et al., 2009; Schyns et al., 2014). Reduced success
of predosing could therefore be due to individual varia-
tion in animals in terms of successful colonisation.
Clearly, suppression was not complete and animals suc-
cumbed to CDI. We are not necessarily alarmed by this,
and it is quite possible that the dose of PXN21 spores
used was not at an optimal level. It is also possible that
the dosing regimen might need adjustment, and we can-
not rule out that excessive dosing might induce some
level of tolerance. PXN21 spores as a treatment for CDI
might have some value, and we state only that symptoms
are significantly suppressed. If translated to humans,
spores might have some utility possibly as an adjunct
therapy with no apparent side effects.
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